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ABSTRACT
Streptococcus pyogenes is a Gram-positive, human-specific bacterial pathogen with the
ability to cause a wide range of diseases from strep throat to necrotizing fasciitis and toxic
shock syndrome. In addition, S. pyogenes may also induce post-streptococcal sequelae
including rheumatic fever, acute glomerulonephritis, and reactive arthritis. Although
primarily recognized as a pathogen, S. pyogenes also colonizes the skin and throat often
without causing disease, and while numerous surface adhesions are important to attach to
these surfaces, additional factors important for colonization and persistence by S.
pyogenes are poorly understood. In addition to host defence mechanisms, the upper
respiratory tract also contains other endogenous microorganisms that compete for the
same niche. In order to gain a more complete understanding as to how S. pyogenes is able
to adapt within the nasopharyngeal environment, a recombinase-based in vivo expression
technology (RIVET) system was developed to identify genes activated in the
nasopharyngeal niche using a humanized murine model. Using RIVET, 82 unique clones
were recovered revealing 22 ‘cryptic’, 9 ‘typical’, and 30 ‘antisense’ in vivo induced
promoters with single inserts. One ‘typical’ promoter (Pblp) that controlled a putative
class IIb bacteriocin operon was further characterized. Testing this promoter as a single
clone in the RIVET system confirmed its activation in vivo. However, in vitro testing
failed to activate this bacteriocin, despite continued addition of the characterized
pheromone, SilCR.

A blp operon deletion was out-competed by the wild-type S.

pyogenes in vivo, but not in vitro. Activation of the bacteriocin in vivo provides a further
explanation for the ability of S. pyogenes to occupy the nasopharyngeal niche and begin
the process of colonization. This work provides a new molecular tool for the in vivo
analysis of S. pyogenes, and demonstrates a novel bacteriocin system important for niche
adaptation by S. pyogenes.
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CHAPTER 1: INTRODUCTION
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1.1 Streptococcus pyogenes
Streptococcus pyogenes (also commonly referred to as Group A Streptococcus) is a
Gram-positive, human-specific bacterial pathogen. S. pyogenes is an aerotolerant
anaerobic coccus that forms long chains of cells when actively dividing. A characteristic
of S. pyogenes is the formation of zones of β-haemolysis around colonies when grown on
blood agar plates (1). The genome of S. pyogenes is a single circular chromosome of
~1.9 Mbp with a low G+C content of ~39% and is well known for the abundance of
exogenous genetic elements including prophage and prophage-like elements, and
integrated conjugative elements. These elements occupy ~10% of the chromosome and
provide the greatest amount of genetic difference between strains (2). Virulence factors
are commonly found on these elements including the well-known superantigens (SAgs).
Using the Lancefield classification of serologic typing that is based on surface
carbohydrate production, S. pyogenes is the only member of the Group A streptococci.
Serotyping is based on the surface expressed M protein, of which more than 100
serotypes exist (1, 3). More recently, this serotyping system has been replaced with the
nucleotide sequence of the 5´ end of the emm gene, producing over 223 serotypes to date
(4).
1.2 Global burden of disease caused by S. pyogenes
S. pyogenes has the ability to cause a wide spectrum of diseases and contributes to an
immense burden of human illness on a global scale (5). These diseases can range from
mild, non-invasive pharyngitis (strep throat) and impetigo, to far more severe invasive
diseases such as necrotizing fasciitis and toxic shock syndrome. Further post-infection
complications can also result from non-invasive diseases in the development of acute
post-streptococcal glomerulonephritis (APSGN) and acute rheumatic fever (ARF), which
may lead to rheumatic heart disease (RHD) and reactive arthritis (1).
Mild diseases by S. pyogenes cause the most number of cases, with pharyngitis
contributing to more than 616 million cases per year and impetigo estimated to be at an
incidence of 111 million people. Furthermore, approximately 1.78 million new severe
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cases per year have been estimated at 663 000 invasive infections, 472 000 cases of
APSGN, and 282 000 of RHD. The remaining 366 000 include stroke, endocarditis, or
requiring prophylaxis due to RHD. Combined diseases lead to over 517 000 deaths per
year world-wide. When broken down, APSGN causes the fewest number of deaths at
5000 per year, followed by invasive disease at 163 000. It is RHD that causes the most
deaths at 233 000 per year, with the remaining 116 000 due to complications arising from
diseases caused by RHD. There are an estimated 15.6 million current cases of RHD and
this continues to be the greatest cause of death caused by S. pyogenes in the world (5).
Antibiotics have been routinely used to treat S. pyogenes infections for decades and, to
date, there have been no documented strains of S. pyogenes that have developed
resistance to β-lactam antibiotics (6). Unfortunately, resistance to second line antibiotics,
such as macrolides, tetracyclines, and fluoroquinolones, seems to be on the rise, creating
difficulties treating patients with allergies to penicillin and other β-lactams (6, 7). To
combat this, development of an effective vaccine is ongoing, and as humans remain the
only reservoir for S. pyogenes, it creates the possibility of severely reducing S. pyogenes
disease (8).
1.3 Dissemination of S. pyogenes throughout the globe
Disease caused by S. pyogenes is not evenly distributed around the world. In developing
countries, due to the lack of sanitary conditions and access to appropriate treatment, the
rate of invasive disease and RHD is much higher than in developed countries (5). The
dissemination of different strains also likely contributes to this imbalance. Different emm
types are more prevalent in contrasting geographical areas, and specific emm serotypes
are often more commonly associated with different types of disease (9). Accumulating
over 100 data sets (38 081 S. pyogenes isolates), Steer et al. demonstrated the varying
emm types occurring in Africa, Asia, Latin America, Middle East, Pacific Island
countries/Indigenous Australians, and Established Market Economy countries (such as
Canada, US, most of Europe, Japan, Australia, New Zealand) (9).
The top three emm types for each region divided by pharyngeal, skin, invasive, and
combined diseases are shown in Table 1.1. These data, where available, demonstrate the

emm11
emm1

emm55
emm12

Pharyngeal
emm75 emm12
emm44 emm12
emm1
emm12
nonemm1
typable

emm4

emm1

emm12

emm3
emm75
emm3

emm53

nontypeable

-

Skin
emm80
emm1
emm83

Disease and corresponding emm types

Data from Steer et al., 2009 (9)

Pacific Island/
Indigenous Australians
Established Market
Economy Countries

Middle East

Africa
Asia
Latin America

Region

emm81

emm55

-

emm100
emm2
emm53

emm28

emm70

-

st62
emm44
emm33

emm1

emm18

emm3

emm28

emm80

emm28

Invasive
emm1
emm12
emm1
emm12

Table 1.1: Top emm types of the world divided by region and disease

emm3

emm114

emm8
emm75
nontypeable

emm1

emm12

Combined
emm12
emm75
emm1
emm12
emm1
emm12
nonemm12
typeable
nonemm55
typeable

emm28

emm11

emm1

st62
emm4
emm2

5

19

5

18
3
6

50% of
isolates

4
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diverse emm types between regions and disease, as well as the common strains that are
important worldwide. Overall diversity of S. pyogenes can be demonstrated by the
number of emm types that account for the first 50% of the total population. From the data
accumulated by Steer et al., Africa and the Pacific Island counties/Indigenous Australians
showed the greatest variability with the top 50% represented by 18 and 19 emm types
isolated, respectively.

On the other hand, Asia, Latin America, Middle East, and

Established Economy Market Countries have a similar but much lower diversity with the
top 50% representing only 3, 6, 5, and 5 emm types, respectively (Table 1.1) (9). The
smaller proportions and therefore greater number of isolates represented, gives Africa and
the Pacific Island counties/Indigenous Australians a far greater diversity compared to the
other regions.
When looking at a global scale, emm1 and emm12 play an important role in causing
disease world-wide. However, outbreaks of disease caused by emm types that are not
typical to the area can also occur. For example, isolates from patients during an acute
APSGN outbreak in the south province of Guizhou, China demonstrated that emm60 and
emm63 predominated at 43.5% and 30.4%, respectively, with four other emm types
present, all under 9% (10). ARF outbreaks have also occurred in Salt Lake City, Utah,
United States in 1985 and 1998. In 1985, emm18 dominated while in 1998 the most
prominent were emm4 and emm12 (11). Thus, individual emm serotypes may dominate
across large geographical regions, yet specific disease states and outbreaks can be linked
to different serotypes.
1.4 Clinical diseases
1.4.1 Pharyngitis
Pharyngitis is an inflammatory response due to infection of the pharynx. S. pyogenes is
the most common cause of bacterial pharyngitis and primarily affects school-age children
ranging from 5-15 years of age (12, 13). Inflammation specifically involves the pharynx
and the tonsils, often with the presence of pus, and includes symptoms such as fever,
headache, nausea, and other flu-like symptoms. While normally associated with school-
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age children, it can also be linked to all ages in crowded areas such as military facilities
(1, 14). In addition to this, episodes become recurrent in a small percentage of people
(15). Several theories exist to explain this phenomenon including antibiotic failure due to
poor patience compliance, antibiotic degradation from nearby β-lactamase producing
bacteria, tolerance, invasion of cells, and reinfection by S. pyogenes from repeated
exposure or as a consequence from the eradication of competing bacteria (7, 16, 17).
Tonsillectomy has shown to decrease infections caused by S. pyogenes with those
suffering from recurrent pharyngitis (18, 19).

Although pharyngitis caused by S.

pyogenes is usually acute, uncomplicated, and self-limiting, if untreated it may lead to
other consequences as described below (20).
1.4.2 Impetigo
Impetigo, or pyoderma, is a localized purulent infection of the skin that can occur in the
bullous and nonbullous forms. While both forms can be caused by Staphylococcus
aureus, only the more common nonbullous form can be caused by S. pyogenes.
Nonbullous impetigo is most prevalent in warm, humid climates among children below
school-age in economically disadvantaged families (21). Starting as a single red macule,
nonbullous impetigo can rapidly become vesicles that rupture and dry, forming honeycoloured crusts. Although often spread by autoinoculation, it is self-limiting after several
weeks if left untreated (22). While both S. aureus and S. pyogenes are sometimes found
within the same skin lesions, typically S. aureus dominates the moderate climate cases
and S. pyogenes predominates humid and warmer climates (23, 24). Interestingly, S.
pyogenes strains that cause impetigo are not known to cause pharyngitis or ARF, but can
be nephritic (these last two discussed below) (21). This implies a varying disease tropism
for different strains of S. pyogenes, which is discussed in more detail in subsequent
sections.
1.4.3 Scarlet fever
Typically occurring in children between the ages 4 and 7, scarlet fever is associated with
pharyngitis, fever, a bright tongue with a strawberry appearance, and a sandpaper-like
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rash starting on the face and neck and spreading to the trunk and other parts of the body
(25). Scarlet fever used to be a major cause of child morbidity and mortality in the 19th
and early 20th centuries. However, due to improved living conditions in industrialized
nations and the discovery of antibiotics, incidents decreased and it became more of a mild
disease (26, 27).
1.4.4 Necrotizing fasciitis
Necrotizing fasciitis, previously called Streptococcus gangrene, is a rare deep bacterial
infection of the subcutaneous tissue, resulting in the destruction of the surrounding fascia
and fat (28). This deep penetration can occur following a break in the epithelial layer
caused by some form of trauma such as cuts, burns or even surgical procedures, but many
incidences occur in the absence any known portal of entry (29, 30). Within the first day,
flu-like symptoms appear as well as pain that is disproportionate to the injury. At a more
advanced stage, swelling and dark patches will appear, eventually filling with fluid. The
area will ultimately become necrotic, with separation of the dead tissue.

It is also

possible for patients to development streptococcal toxic shock syndrome, described below
(29). Treatment of necrotizing fasciitis involves immediate surgical debridement of the
affected tissues as well as antibiotic treatment and supportive therapy.

Surgical

debridement is performed until all dead tissue is removed, potentially leading to
amputation (30).
1.4.5 Streptococcal toxic shock syndrome
Streptococcal toxic shock syndrome (STSS) is caused by a hyperactive immune system
triggered by potent immunostimulatory toxins called superantigens (SAgs), leading to a
massive cytokine response. In contrast to toxic shock syndrome caused by S. aureus
where the infecting organism often remains localized, STSS typically occurs during the
context of an invasive infection by S. pyogenes (31). Early symptoms may be flu-like and
include fever, sore throat, swollen glands, rash, diarrhea, and vomiting. After 3-4 days,
the fever remains persistent and hypotension and shock develop, which can lead to
tachycardia and multi-organ failure. Coagulation can also occur leading to gangrene or
also the development of necrotizing fasciitis from the invasive infection (32). Treatment
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includes the use of antibiotics and fluids to maintain blood pressure, and may include
additional developmental therapies such as the administration of intravenous
immunoglobulin (IVIG) and activated protein C. IVIG would potentially contain antiSAg antibodies, effectively neutralizing the SAgs, while activated protein C can help
prevent coagulation from occurring (33-35).
1.4.6 Acute post-streptococcal glomerulonephritis
APSGN is a renal disorder first reported by von Plenciz over 200 years ago, and was a
feared consequence following scarlet fever (36). Caused only by certain ‘nephritogenic’
S. pyogenes strains, APSGN typically affects children between the age of 2 and 12
following pharyngitis or a skin infection (37). Depending on the original infection, the
latent period for APSGN is 1 to 4 weeks from a skin infection and 1 to 2 weeks for
pharyngitis (1). Symptoms include edema, hypertension, and dark coloured urine from
blood due to the impaired filtering properties of the glomerulus (1, 38). APSGN patients
show spontaneous recovery over 95% of the time and generally only supportive therapy
maintaining blood pressure and fluids is required. Very rarely are any long term effects
seen after recovery in children; however, adults seem more likely to develop chronic
symptoms afterward (1, 39).
1.4.7 Acute rheumatic fever and rheumatic heart disease
ARF is an autoimmune disease caused by the cross reaction of antibodies directed against
S. pyogenes with human tissues (40). ARF most commonly involves inflammation of the
joints, central nervous system, or the heart, typically arising 2 to 5 weeks after non-treated
pharyngitis. Along with one of the major areas of swelling, additional symptoms include
fever, malaise, tachycardia, and anemia (6, 41). Inflammation of the joints (arthritis) is
the most common symptom and occurs in 75% of ARF patients. Affecting the large
joints, painful episodes can last from a number of days to weeks, and treatment includes
pain medication and anti-inflammatory drugs (41, 42). Occurring in approximately 10%
of patients is a neurological manifestation of ARF known as Sydenham’s chorea. The
characteristic of the disease is the presence of involuntary, purposeless, and jerky
movements of the face and extremities that disappear while sleeping, typically lasting 8 to
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15 weeks (41, 42). Lastly, while not the most common, inflammation of the heart tissue
is the most serious as permanent, long-term damage to the heart can occur. This damage
is given the term rheumatic heart disease (RDH) and occurs most frequently to the mitral
valve (41, 42). Healing of the valves results in scarring and fibrosis preventing proper
function. Damaged valves show narrower openings and allow blood to leak back, which
can lead to congestive heart failure. Treatment of RHD involves the use of antiinflammatory and diuretic drugs with valve replacement in severe cases (42, 43).
1.5 Molecular mechanisms of colonization and disease
1.5.1 Barriers of the human host
The major recognized sites of colonization by S. pyogenes on the human host include the
skin and the nasopharynx (44, 45). In order to attach and colonize, group A streptococci
have to bypass or subvert a number of mechanical, chemical, and biological barriers.
Healthy skin creates an intact barrier that microorganisms cannot penetrate, as well as the
process of desquamation that must be overcome (46, 47). Along with this, skin has a low
moisture content, low pH, and produces antimicrobial compounds such as fatty acids,
lysozymes, and defensins (48, 49). Finally, S. pyogenes must compete with other bacteria
for the same space, with Staphylococcus epidermidis a prime example, as it creates
peptides toxic to S. pyogenes (47).
The oral cavity maintains the same physical barriers as the skin, and bacterial
competition, but also contains saliva (50). Saliva has many different functions involved
with eating, maintaining healthy teeth, and also has many antimicrobial properties (51).
Saliva contains many components, including those of the innate and acquired immune
system, that interact with the oral microbiota, controlling the composition of the
microorganisms within the oral cavity (51). These include immunoglobulins, defensins,
lysozyme, as well as cysteine and serine proteinase inhibitors (51, 52). For example,
immunoglobulin A (IgA) from human saliva showed both interference with binding and
opsonisation of S. pyogenes in vitro (53-55). Agglutinins have shown to cause coaggregation with some strains, and subsequently these strains would be swallowed (56,
57). Additionally, the commensal bacteria S. salivarius produces a bacteriocin that is
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known to be toxic to S. pyogenes (58).
The innate immune system also provides a significant barrier that S. pyogenes must
overcome in order to colonize the host. Innate immunity utilizes a pattern recognition
strategy based on a set of conserved molecular patterns, referred to as pathogenassociated molecular patterns (PAMPs) (59). Unique to microbes, PAMPs are recognized
by pattern recognition receptors (PRRs), such as Toll-like receptors (TLR), on immune
cells (60). These targets are generally indispensable to the organism and therefore rarely
become modified due to mutation (61). With varying numbers between species, TLRs
can detect multiple PAMPs with TLRs 1, 2, 4, 5, and 6 recognizing bacterial products
exclusively (62). After recognition, PRRs signal to the host via signalling cascades,
which ultimately results in the activation of gene expression and the production of a wide
range of molecules such as cytokines, chemokines, cell adhesion molecules, and
immunoreceptors (60).
TLRs are present on numerous innate cell types such as macrophages, neutrophils, and
dendritic cells (DC). Distributed throughout the body in morphologically diverse forms,
macrophages are capable of engulfing invading microbes, causing the release of
cytokines. This in turn diverts blood flow to the affected tissue in order to attract cells
capable of killing microbes including more macrophages as well as neutrophils and DCs
(60-62). DCs, like macrophages, are also found in most parts of the body and kill
microbes via phagocytosis. Coming into contact with pathogens causes these cells to
activate, starting the production of cytokines (63). One important feature of both DCs
and macrophages is the ability to present foreign antigen to naïve T cells, creating the
bridge between the innate to the adaptive immune systems (61, 64). Neutrophils likewise
combat invading microbes using phagocytosis, but also possess granules made up of
proteolytic enzymes and antimicrobial proteins that combine with phagosomes in a
process called degranulation (65, 66).

Activated neutrophils also create neutrophil

extracellular traps, generated by the release of DNA and granule components, to trap and
destroy invading microbes (66).
The last major component of the innate immune system discussed here is the complement
system, which can recognize invading pathogens through the classical, alternate, or lectin
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pathway (67). Activated in different manners, the complement pathways begin a highly
regulated cascade of enzymatic reactions that generate effector compounds able to
intercept invading pathogens and induce a pro-inflammatory response (68, 69). Classical
and lectin pathways are activated via bound antibodies and microbial carbohydrates,
respectively.

The alternate pathway, on the other hand, is autoactivated, with the

hydrolyzation that begins the cascade always occurring at a slow rate (68, 70). These
effector compounds bind to self and non-self carbohydrates, lipids, and proteins
indiscriminately. Self-cells block further activation through the presence of specific
regulatory proteins. Pathogens, lacking these proteins, further activate the complement
system (68, 70). This leads to the production of C3b, an opsonin that coats the cell,
inducing phagocytosis, and the assembly of the membrane attack complex, which causes
pore formation and lysis (68).
1.5.2 Mechanisms of adhesion
Once the initial barriers have been crossed, S. pyogenes must adhere to host cells to begin
colonization. To accomplish this, S. pyogenes utilize surface components called adhesins,
which bind in a stereochemical manner to complementary molecules on the tissue surface
called ligands or receptors (71). The process of adhesion and colonization has been
studied for decades, but it still has not been completely characterized at the molecular
level due to its complexity.

S. pyogenes uses a multi-adhesin approach, which

complicates research since removing a single adhesin may have little to no effect (50).
While many different adhesins have been discovered, not all are present on each strain,
and different adhesins have been found to be important depending on the tissue. Some of
the best-characterized adhesins are described below.
1.5.2.1 Fibronectin binding proteins
Fibronectin (Fn) was first shown as a ligand by Simpson et al. with the adherence of S.
pyogenes to polymorphonuclear leukocytes and oral epithelial cells (72, 73). Fn is a large
glycoprotein dimer of two ~250 kDa fragments, each covalently linked near the Cterminus. Each monomer is made of 12 type I repeats, two type II repeats, and 15 to 17
type III repeats (74). Found as two forms, the soluble form occurs in various body fluids
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such as plasma and the insoluble form occurs on cell surfaces and interstitial connective
tissues (50, 75). Numerous adhesins have been found to bind Fn and have been grouped
together as the Fn binding proteins.
First, the Fn binding protein F1 (PrtF1, also called SfbI) was found separately by Talay et
al. and Hanski et al. (76, 77). Not present in all strains of S. pyogenes, complementation
of PrtF1/SfbI to strains without it, and unable to adhere to Fn, were then able to bind Fn
(76-78). Interestingly, Hanski et al. also showed that while adherence to epithelial cells
was affected by the loss of PrtF1/SfbI, the loss of M protein had no effect (77).
PrtF1/SfbI binds to Fn from two distinct regions; the upstream Fn-binding domain
(UFBD) immediately followed by a region of 2 to 6 repeats of repeat domain 2 (RD2)
(79-81). UFBD attaches to the N-terminal region of Fn composing of both the fibrin and
collagen binding domains (70 kDa), while just the fibrin domain (30 kDa) binds most
efficiently to RD2 and does not interact with the collagen domain (45 kDa) (79, 81).
Serum opacity factor (SOF, also called SfbII) was discovered based on its ability to turn
human serum opaque. It was not until much later that it was found that SOF had Fn
binding domain repeats located at the C-terminus. SOF was found on ~50% of S.
pyogenes isolates, with 30% to 60% homology between serotypes (82-84).

Unlike

PrtF1/SbfI, SOF binds to the 30 kDa portion of Fn, utilizing the C-terminus repeats, with
adherence maintained by as little as one repeat (85, 86). Knockout studies of the SOF
gene showed that strains retained ~10% of the wild-type ability to bind Fn, and pretreatment with anti-SOF antibodies reduced adherence to human epithelial HEp-2 cells by
50% (86, 87). SOF has also been shown to bind fibulin-1, a secreted glycoprotein
associated with the extracellular matrix, through a domain different then that of Fn. It is
hypothesized that SOF binds to Fn, fibulin-1, and gelatin forming a quaternary complex,
but further research is required for confirmation (88).
Protein F2 (PrtF2) is a Fn-binding protein comprised of two distinct variants; S. pyogenes
Fn-binding protein (PFBP) and Fn-binding protein of group A streptococci type B
(FbaB). PFBP consists of a UFBD followed by three different repeat domains. Whole
Fn, as well as the 70 kDa and 30 kDa N-terminal fragments, can bind to the PFBD
domain (89-92). FbaB is shorter than PFBP due to a shortened central region, causing the
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first half of the UFBD to be missing, followed by two to four different repeat domains
(89, 92, 93). It remains unknown if the shorter UFBD domain affects Fn binding,
however, a knockout of both variants showed a significant decrease in the ability to
adhere to epithelial cells (91, 93). In addition, using an intraperitoneal mouse model, it
was shown that FbaB is an important virulence factor, as a FbaB knockout showed a 50%
reduction in lethality compared to the wild-type strain (93).
1.5.2.2 M protein
The best known surface structure of S. pyogenes is the M protein, encoded by the emm
gene (94). The M protein is an α-helical coiled-coil, extending by ~50 nm from the
surface of the cell, and ending with a short non-helical N-terminus (95, 96). Combined of
many different sections, the common M protein framework is comprised of a signal
sequence, a hypervariable terminus (A repeats), a less variable central domain (B
repeats), and a highly conserved C-terminus (C repeats) (97-100). Known to be involved
in virulence, it was first shown to be important with adherence in 1972 by Ellen et al.
when an M protein deficient S. pyogenes adhered to human buccal epithelial cells in
fewer numbers that the wild-type (101). This decrease could be repeated when the wildtype was pre-treated with anti-M protein antibodies, and this phenotype was shown
numerous times by other groups (71, 101-104). Nevertheless, finding the M protein
ligand has been complicated due to the multiple adhesins present, as well as the many
different ligands to which the M protein binds.
One M protein ligand was found to be the soluble and insoluble forms of Fn (100, 105107). This was best demonstrated when L. lactis, unable to bind Fn or epithelial cells,
was given this ability when expressing M protein (100). While shown to bind to the B
repeat region of the M protein, Fn has failed to bind to some M protein types, with M1,
M3, and M5 showing definite binding (100, 106, 108, 109).
Another M protein ligand is the complement regulatory protein (CD46), a membrane
protein that prevents autologous complement activation (110). Specifically, the C repeat
of M protein was found to bind to the short consensus repeat regions 3 and 4 of CD46
(111). Once again, variability within M proteins was demonstrated when two of three S.
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pyogenes strains attached to human CD46 expressed via mouse cells (104). Feito et al.
also showed CD46 binding even with emm deleted, indicating the presence of other
adhesins (112).
The M protein has also been shown to bind cell surface glycosaminoglycans (GAGs).
Composed of repeating, unbranched disaccharide units, there are several different classes
based on this composition. Binding to M protein were the dermatan sulphate and heparan
sulphate classes (113, 114). Binding occurred predominantly via the C repeat region
towards the C-terminus end (114).
Finally, there has also been contradictory evidence indicating that sialic acid and fucose
glycoproteins, contained within mucin, both do and do not act as a ligand for M protein.
Further evidence is required in order to determine whether or not either of these are
potential ligands (115-117).
1.5.2.3 Pili
Another surface structure shown to be important for adhesion by S. pyogenes has been
pili. While long known to be present on Gram-negative bacteria, it has only been in the
last 11 years that pili have been found on Gram-positive bacteria, in particular S.
pyogenes (118). Genes encoding S. pyogenes pili are located in the highly variable
fibronectin-binding, collagen-binding T antigen (FTC) region of the genome, and there
are nine different types (118, 119). These types are created through variations in gene
sequence and overall operon structure. Regardless of these variations, the basic pili
structure of S. pyogenes is composed of a single backbone protein polymerized to form
long strands with an ancillary protein cap (118, 120-126). Many in vitro experiments
demonstrated that the central region of the ancillary protein cap was used by S. pyogenes
to adhere to host cells, although the corresponding ligand has never been discovered (120,
121, 124, 126, 127). Becherelli et al. also recovered fewer numbers of a cap protein
knockout compared to wild-type using an intraperitoneal mouse model (126). On the
other hand, Crotty Alexander et al. observed increased lethality of a mutant containing a
knockout of the backbone protein compared to wild-type in three mouse models
(subcutaneous, pneumonia, and sepsis). An explanation for this outcome is that pili does
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indeed provide adhesion for colonization, but when single bacteria break away to invade
the blood or deeper tissue, the presence of pili provides a pattern easily identified by
phagocytes (127). Therefore, further work is required to determine the precise function
of pili in S. pyogenes.
1.5.2.4 Hyaluronic acid capsule
The capsule of S. pyogenes is composed of hyaluronic acid, a high molecular weight
disaccharide comprised of repeating units of glucuronic acid linked to Nacetylglucosamine (GlcNAc), and is a molecular mimic to the hyaluronic acid produced
by humans (128, 129). Although produced at various levels by different strains, it
provides protection from phagocytosis, demonstrated by the inability of the mutant
lacking the capsule to survive in blood compared to the wild-type (13, 130-133). Further
in vitro work demonstrated that hyaluronic acid utilizes CD44 as a ligand to bind to cells.
Strangely, hyaluronic acid mutants were actually able to bind better than wild-type
counterparts in vitro, presumably because hyaluronic acid masks other potential adhesins
(128, 134). While this may appear as a disadvantage, the hyaluronic acid capsule may
still provide a benefit against the human host.

Utilizing intraperitoneal injection,

pneumonia, and throat colonization models with mice, as well as baboon throat
colonization model, the hyaluronic acid capsule mutant was cleared significantly faster or
failed to cause disease when compared to the wild-type strain. The theory is that the
hyaluronic acid capsule does indeed help with adhesion, and also provides a significant
protection against phagocytosis to allow colonization (13, 128, 130-132).
1.5.2.5 Lipoteichoic acid
Lipoteichoic acid (LTA) is a cell wall polymer composed of an unbranched 1,3-linked
glycerolphosphate backbone, linked to the bacterial membrane via a lipid anchor. The
hydroxyl group of C2 is also modified with D-alanyl or glycosyl groups to varying
degrees (135). LTA from S. pyogenes was found to stick to various cells (PMNs, buccal
epithelial cells, HEp-2), and pre-treatment of host cells with LTA prevented adherence by
S. pyogenes, thus demonstrating LTA as an adhesin (71, 136-141). Furthermore, utilizing
an intranasal mouse model, treatment with LTA prior to S. pyogenes challenge
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demonstrated a drastic reduction in colonization and the survival of all mice (141). The
receptor for LTA on these various cells was determined to be Fn as S. pyogenes could no
longer bind to Fn or Fn coated beads when pre-treated with LTA (73, 106). Specifically,
it has been suggested that ester-linking fatty acids of LTA recognize a fatty acid binding
site on Fn (142, 143).
1.5.2.6 Adhesin expression and tissue tropism
S. pyogenes possess a large number of adhesins that creates a complex system that is also
difficult to study due to the many overlapping functions.

It is also thought that

differential distribution and regulation of these genes would allow S. pyogenes to produce
an adhesin profile to allow for tissue-specific tropism (44). In support of this concept,
research has shown that S. pyogenes strains do not all adhere to the same cells in vitro,
indicating that they are expressing different genes.
Numerous groups showed no difference in adherence to buccal cells when the M protein
was removed (108, 115, 144, 145). Conversely, Courtney et al. found differences when
using HEp-2 epithelial cells and Wadstrom et al. found differences with human
pharyngeal epithelial cells (115, 144, 145). Okada et al. was able to show that loss of
PrtF1 only had an effect on the adherence to Langerhans cells, and the loss of M protein
only showed an effect with keratinocytes (146). Similarly, Hanski et al. showed the
importance of PrtF1 but not M protein with hamster trachea cells (77). Fibronectin
binding protein 54, on the other hand, has been shown to be necessary for adhering to
human buccal cells, but unnecessary for HEp-2 cells (147). Lastly, extracellular factor
protein showed no change with Detroit 562, Ca9-22, and HEp-2 cells, however, did show
a significant decrease in adherence to HaCaT cells (all epithelial cells) (148).
Based on data such as this, the theory of a two-step adhesion process arose. The first step
involves a hydrophobic interaction between a lipid moiety of LTA and the fibronectin
sector of the host cell. While this reaction is weak and reversible, it allows the repulsion
between negatively charged S. pyogenes and host cell membranes to be overcome. The
second step is then the attachment of an adhesin creating a tissue specific interaction that
is almost irreversible with its receptor (50, 149, 150). Adhesins other than M protein
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potentially included in the model include PrtF1, SOF, and PrtF2. Understanding the in
vivo regulation of these adhesins and how the adhesion process occurs could greatly
increase our knowledge of S. pyogenes and how it is able to colonize and potentially
cause disease.
1.5.3 Secreted proteins
Along with surface structures, S. pyogenes secretes many proteins that aid in colonization
and survival. A wide range of functions include degradation of DNA from neutrophil
extracellular traps by the DNAse Sda1, inhibition of the complement system by
streptococcal inhibitor of complement (SIC) and C5a peptidase, and inhibition of
opsonophagocytosis via Mac protein (6, 151).

S. pyogenes also secretes multiple

proteases, a major one being SpyCEP, which degrades chemokines (152).
Streptococcal pyrogenic exotoxin B (SpeB) is a cysteine protease that has garnered
considerable attention due to its predominant secretion and indiscriminate specificity
(153). Some of its targets include immunoglobulins, C3b, chemokines, and fibronectin of
the host, as well as self proteins such as M protein, C5a peptidase, Sda1, and
streptokinase (153, 154). Contradictory evidence has hindered the exact role of SpeB in
virulence, nevertheless, the ability to vaccinate against S. pyogenes infection utilizing
anti-SpeB antibodies suggests an important role (155-157).
Also secreted are the pore forming toxins streptolysin S (SLS) and streptolysin O (SLO).
SLS is a 2.8 kDa peptide that inserts into the membrane of targets such as erythrocytes,
leukocytes, and platelets. A carrier molecule such as albumin, LTA, or RNA is also
required to function (158). Targeting the same cells is SLO, an oxygen labile, 61 kDa
protein that oligomerizes binding to target membrane cholesterol (159, 160). Conflicting
results have made identifying their function in virulence uncertain, but it appears that they
contribute to tissue destruction and the inhibition of neutrophil recruitment (159-163).
Finally are SAgs, potent immunostimulatory toxins that bind to the MHC class II of
antigen presenting cells and the TCR of T cells, in a way that activates the T cell
independent of the antigenic peptide (164). This results in an enormous activation of T
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cells and an immense cytokine response, secreting predominantly IL-2, IFN-γ, TNF-α,
IL-1β, and IL-6, with the ability to cause widespread tissue damage and organ
dysfunction (165).

Their purpose has been widely speculated since they cause the

activation of the immune system, and possibly the death of the host, seemingly decreasing
their own chances for survival. However, their importance was recently shown in a
humanized mouse model of colonization when S. pyogenes failed to colonize efficiently
once certain SAgs were knocked out.

Restoration of the SAgs re-established the

colonisation phenotype demonstrating their role in colonization (166).
1.5.4 Invasion
Another characteristic of S. pyogenes is the ability to invade different types of eukaryotic
cells (167-169). S. pyogenes is able to invade host cells without causing any overt
damage, yet can still be shed in the saliva, and can persist within cells in the absence of
clinical disease (170). Internalization occurs through the interaction of integrins on the
surface of epithelial cells with receptors on S. pyogenes via a bridge such as Fn, causing a
remodelling of the cytoskeleton structure (171). Integrins are protein heterodimers made
up of transmembrane α and β subunits with various combinations. This defines adhesion
specificity, allowing for the interaction with extracellular matrix ligands such as Fn,
vitronectin, laminin, and collagen (172). The best characterized receptors are PrtF1/SfbI
and the M protein which interact with integrin α5β1 via whole Fn (173-176). Many
interactions can induce clustering which leads to cellular signalling with different
signalling cascades shown to be created between M protein and PrtF1/SfbI (171, 177).
The M protein causes actin polymerization which leads to a cytoskeleton rearrangement
leading to surrounding and engulfment by microvilli using a “zipper-like” method (177179). Strains expressing PrtF1/SfbI, on the other hand, cause the formation of large
invaginations using caveolae-mediated endocytosis without actin polymerization (180182). The biological significance for S. pyogenes to enter cells has yet to be fully
elucidated (16, 169).
1.5.5 Molecular basis of tissue tropism
S. pyogenes strains can be further subdivided according to the disease they cause, and
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therefore the niche in which they prefer, based on a specific genetic profile, with some
exceptions known to exist (44). As sequencing of many emm genes became available,
specific profiles first began to form based on emm strains and the diseases caused. Based
on the combination of four different subfamily regions encoding part of the peptidoglycan
domain of the emm protein, S. pyogenes strains were divided into five patterns from A to
E (183-185). Patterns A, B, and C are comprised of strains that cause pharyngitis, pattern
D is comprised of strains that cause impetigo, and pattern E included strains that seem to
have no preference and can cause both pharyngitis and impetigo (185). Pattern E strains
may be particularly important as these isolates may allow for the transfer of genetic
material, including mobile genetic elements, between pharyngeal and skin strains. A
world wide sampling over six continents showed an overall distribution of 21% pattern
A-C, 38% pattern D, and 37% pattern E (4% unidentifiable) (4). Continued sequencing
has identified numerous other genes specific to each pattern.
An important genetic component of tissue tropism includes mga, formerly referred to as
mry or virA, located upstream of emm.

mga [multiple gene regulator of group A

Streptococcus (186)] is a positive transcriptional regulator of the emm family genes along
with speB, scpA, and sof, among others. Continual sequencing showed the divergence
pattern of mga matching the pattern of the emm cluster downstream. When looking for
genetic links to niche specialization, Bessen et al. found that mga could be divided into
two alleles based on its sequences. First, mga-1 alleles were found in A-C strains, while
mga-2 alleles were found in D and E (183, 185, 187). Comparison of mga within the
same allele showed minimal nucleotide diversity with differences of only 3.3% and 2.5%
within mga-1 and mga-2, respectively. Comparison between alleles, on the other hand,
showed a nucleotide diversity of 24.5%. Comparing amino acid diversity showed similar
results of 2.9% and 1.5% within mga-1 and mga-2, respectively, and 20.7% between the
two alleles (187).
Another gene combination important with tissue tropism is that of plasminogen (Plg)binding group A streptococcal M protein (PAM), one of the emm-like genes, and
streptokinase (Ska). Host Plg binds to PAM, which interacts with Ska, yielding bacterial
bound plasmin (188). Ska, a broad spectrum proteinase involved with dissolving blood
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clots, is made up of three domains: alpha, beta, and gamma. When comparing sequences,
beta showed the most divergence, causing ska to be divided into two major groups, with
one sub group (ska-1, -2a, and -2b).

Pattern A-C is represented mostly by ska-1;

however, those that did have ska-2 were all ska-2a. The vast majority of pattern E strains
possessed ska-1 and all A-C and E pattern strains lacked PAM. When looking at D
pattern strains, the majority possessed ska-2b and also possessed PAM. The D strains
that did possess ska-1 lacked PAM. Since emm and ska are separated by 33-38 kb on the
chromosome, it is less likely that they are associated due to tight linkage and is more
likely due to epistasis from essential function for each other (188).
sof is another gene linked with tissue tropism, and while SOF is distinct from the M
protein, it parallels the M protein by serological specificity. Located 10-16 kb upstream
of the emm and emm-like genes, sof is regulated by mga (189, 190). Once thought to be a
lipoproteinase, SOF has now shown to bind high density lipoprotein in human blood
causing the release of lipid cargo, which in turn leads to serum opacity (191, 192). When
comparing this to emm chromosomal patterns, sof is found in 100% of pattern E strains
and very few other strains (44).
Also shown to be involved in tissue tropism is the FCT region, a section of the
chromosome 300 kb downstream from mga. This region is highly recombinatorial and
contains Fn- and collagen-binding proteins as well as T antigen loci (119). Observed
under linkage disequilibrium with mga are the regulators of FCT; rofA, a positive
transcriptional regulator, or nra, a negative transcriptional regulator.

Strains of S.

pyogenes contain only one or the other in most cases with rofA or nra occupying the same
locus of the FCT region between strains (44, 187). Along with either nra or rofA includes
many

microbial

surface

components

recognizing

adhesive

matrix

molecules

(MSCRAMMs) that bind to human fibronectin or collagen (prtF1 and prtF2). This
feature makes the proteins produced in the FCT region important for host tissue
adherence (189). The majority of A-C pattern strains contain rofA along with mga-1,
while D pattern strains harbour nra with mga-2. The E pattern strains contain rofA,
similar to A-C strains, but possess mga-2 similar to D pattern strains (44, 187). Along
with this, the collagen binding protein encoded by cpa is present in the majority of pattern
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D strains, but only about half of pattern E strains, and few pattern A-C strains. For prtF1,
the distribution is the opposite being present in the majority of A-C and E strains and
being present in few D strains. Finally, prtF2 is distributed similar to that of cpa (189).
Another protein, S. pyogenes nicotinamide adenine dinucleotide (NAD) glycohydrolase
(SPN), has also been implicated in playing a role in tropism. This enzyme cleaves the
glycosidic bond of β–NAD+, producing nicotinamide and adenosine diphosphate ribose
(ADP-ribose) (193). Activity of SPN can partially predict the emm pattern type; an active
SPN shows an E pattern 85.5% of the time, D pattern 10.9% of the time, and A-C only
3.6% of the time. When SPN is inactive, the D patterns predominates at 63.8%, the A-C
pattern at 31%, and the E pattern at 5.2% (194).
Lastly, SAgs also have a molecular connection to particular emm pattern types. It had
been assumed that SAgs would be spread equally between strains since they are contained
on mobile genetic elements. However, when looking at the alleles of streptococcal
pyrogenic exotoxin A or C (speA, speC) from sequenced S. pyogenes strains, non-random
association was found. Patterns A-C contained speC2 while pattern E contained speC1,
despite both patterns being well represented of the nasopharyngeal reservoir. Pattern D
also matched E containing speC1. speA consists of numerous alleles but was found to
have arose from only two lineages termed I and II. This data showed speA to be the
opposite of speC with E and A-C, with being of lineage I while D contained speA of
lineage II (195).
Through the increasing ease at which genomes can be sequenced and the data accessed,
the complex issue of tissue tropism with S. pyogenes is becoming more clear. While first
grouped based solely on the emm gene sequence, an entire genomic sequence can now be
associated with the disease causing phenotype, allowing for a more complete picture.
Continually investigating the genome in order to understand how it functions will allow
for a more complete phenotype associated with every genome.
1.5.6 emm types, diseases, and the associated non-suppurative sequelae
While each emm type pattern based on molecular evidence is associated with non-
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invasive pharyngitis and/or impetigo, patterns have also been associated with poststreptococcal sequelae such as APSGN and ARF.

Accepted dogma of S. pyogenes

disease philosophy has been that ARF occurs following S. pyogenes pharyngitis (196). In
early documented cases of ARF published in the 1880s, not a single patient was reported
to have a skin disease before, during, or after an ARF attack (197). In the 20th century,
ARF continued to be seen as a consequence of pharyngitis in the general population, but
with increased occurrences to students at boarding schools and cadets in military
academy. The first clear evidence of pharyngitis causing ARF was the use of randomized
penicillin treatment for pharyngitis in military barracks in the 1950s. The risk of ARF
within the penicillin treated group was 70% lower (197). It was also shown that not all
pharyngitis strains cause ARF, with those causing ARF being termed rheumatogenic (42).
Looking at specific molecular characteristics of the rheumatogenic strains, they fall under
the A-C pattern and also lack the ability to produce lipoprotein lipase and SOF (42, 198).
Based on these factors, rheumatogenic strains contain the M types 1, 3, 5, 6, 14, 18, 19,
24, 27, and 29. Falling under the A-C pattern further demonstrates the idea that ARF is
preceded by pharyngitis (1, 4, 42). However, some differences do occur, such as in
Polynesian populations of Hawaii, where ARF was caused by S. pyogenes with M types
71, 93, and 98 (D pattern) and M types 92, 103, and 112 (E pattern). Despite the decline
of ARF in the industrial developed world, this disease remains endemic in the developing
countries, and particularly among indigenous peoples (5).
Driven by the epidemiological evidence from the northern Australian indigenous people
is the idea that impetigo could also be a driving force behind ARF in impetigo endemic
regions (199). The Australian indigenous people have the highest ARF rate in the world
at ~550 per 100 000, yet rates of pharyngitis are low (200-202). Impetigo, on the other
hand, is very common with frequencies of 50-70% every year (199, 201, 202). In
addition, the classic rheumatic emm types are barely present, representing only 2% of the
strains in one report (203), 6% of another (204), or were not present at all (201). This
lead McDonald et al. to conclude that common and recurring skin infections may lead to
an immune response against throat infections, and that ARF, at least in this area, may
follow impetigo infection (202). The link between impetigo and ARF is interesting, but
as Kaplan and Bisno described, the lack of antibodies fails to provide tangible proof of
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active immunity, and has pointed out that other studies have shown the ability of
rheumatogenic strains to persist within communities giving rise to the disease, despite
being sometimes notoriously hard to isolate from ARF patients (196). Further work is
required to be able to completely confirm or deny this theory.
Another question is the reason for the increased rate of ARF for the Australian indigenous
people compared to the general population. Interestingly, other native populations also
possess an increase incidence of ARF within their populations. The Māori and Pacific
Islanders of New Zealand show a rate of ARF 10 to 20 times above the general New
Zealand population, respectively (205). Looking at just the 5-14 year age group, those
most likely to get the disease, the rate is a staggering 20 to 40 times the normal
population. For the general population of all three groups, this leads to death rates per
100 000 people at 7.3 and 7.0 for the Māori and Pacific Islanders, respectively, and 3.7
for the general New Zealand population (206). A Hawaiian study comparing Caucasian
to Hawaiian and other Polynesian residents of the rate of ARF showed rates ranging from
19.2 to 120.7 times greater than Caucasian people based on information from patients of
21 years and younger (207). Further research including all age groups demonstrated that
the ethnic population still has a greater risk to ARF by 4.8 times. Most importantly, this
was not due to socioeconomic status, therefore, showing a potential genetic link for an
increased risk of ARF for certain populations (208).
APSGN, on the other hand, has followed infection of both the throat and skin (196). The
most common strains that cause APSGN from skin infections include M types 2, 49, 60,
and 61 of the E pattern, along with M59 of pattern D and M57 of pattern A-C. Those
known to cause APSGN from throat infections are M1 and M12 from the A-C pattern and
M4 and M25 of the E pattern (1, 4). Strains of pattern E seem to be the most common
cause of APSGN from a molecular level. In Guizhou, China, an outbreak occurred with
pattern E making up 73.9% of the strains, with the remaining patterns making up less than
9% each (10). Even in some instances when the rare M types were the ones causing
disease, such as M types 48 and 73 in Trinidad and M type 63 in China, they were all still
pattern E (10, 209).
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1.5.7 Molecular mimicry
Autoimmune diseases, such as ARF and RHD, are caused when the immune system
recognizes self antigens as foreign, which can then lead to inflammation and possibly
even the destruction of specific tissues (210). This self-recognition can be induced due to
what is known as molecular mimicry, defined as the sharing of epitopes between antigens
on both the host and a pathogen (211).

Occurring between disparate proteins or

molecules, epitopes must be close enough in homology to share amino acids determinants
or conformational shapes, but still distant enough in order to be recognized as foreign by
the immune system (212).

There have been defined antigens for mimicry such as

identical amino acid sequences, homologous but non-identical amino acid sequences, and
lastly, mimicry occurring on two dissimilar epitopes such as peptides and carbohydrates
(211).

Although it is rare to identify a single pathogen that initiates a specific

autoimmune disease, ARF has been known to be caused by S. pyogenes for many decades
(210).

This has lead to considerable research involving molecular mimicry with S.

pyogenes and host tissues.
Cavelti first discovered the presence of anti-cardiac antibodies in ARF patients in 1945,
and was able to produce them in rats using dead streptococci, showing that damage could
still occur to the heart without the need for active dividing bacteria (43). While present in
those with non-supportive sequelae such as ARF and RHD, these antibodies can also be
found in some patients with uncomplicated diseases such as pharyngitis, but at
significantly lower titers (43, 213, 214). Most commonly affected is the mitral valve,
which separates the left atrium, receiving oxygenated blood from the lungs, from the left
ventricle, which pumps oxygenated blood through the aorta. The aortic, tricuspid, and
pulmonary valves are less commonly affected, roughly in that order, with the pulmonary
valve being rarely affected (41, 42).
It is thought that monoclonal antibodies created against the α-helical coiled-coil shape of
M protein and GlcNAc of the group A carbohydrate are the cause of this disease. These
antibodies are also able to bind to smooth muscle cells, cardiac myocytes, endothelial
cells, valvular interstitial cells, basement membrane, and elastic regions (215, 216).
Structures identified to contain the α-helical coiled-coil structures to which antibodies
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bind to include laminin, keratin, and the intracellular proteins myosin, tropomyosin, and
vimentin. Various experiments were able to show cross-reactivity by deriving antibodies
from GlcNAc, M protein, laminin, myosin, and others that could bind to all reciprocal
antigens (215-220).
The theory of ARF is that antibodies bind to elements on the mitral valve, causing
damage through complement. This causes a disruption in the endothelial layer, exposing
more antigenic sites. Endothelial cells, as a result, also express more vascular cell
adhesion molecule-1 (VCAM-1).

This leads to inflammation and the attraction of

lymphocytes that are able to extravasate under the endothelial layer forming nodules,
leading to a Th1 response with the cytokines IL-1, TNF-α, and IFN-γ expressed.
Repeated bouts of ARF can leave scarring on the heart valve tissue, preventing proper
function (211, 216). Surgery may also be required to correct severely damaged valves
and, depending on the circumstances, can involve repair or complete replacement of the
valve. It has been shown that valve repair should be utilized when possible due to better
overall outcomes compared to valve replacement (221).
Other theories also exist to explain the cause of ARF and RHD. Root-Bernstein proposed
that while the overall cause is still via molecular mimicry, due to the rarity of cases in
relation to the number of S. pyogenes infections it must occur only when a dual infection
happens along with the coxsackie virus, which can cause myocarditis (222).

Dual

infections of the cardiomyocytes allows an inflammatory response with binding of
antibodies to laminin, collagen, and other exterior antigens, causing damage to expose
myosin and other internal antigens (222). Tandon et al., on the other hand, suggested that
the interaction between the N-terminus of the M protein and the CB3 region in collagen
type IV creates an antibody response against collagen, as well as an inflammatory
response, thus no specific molecular mimicry was involved (223).
APSGN, as previously described, is also associated with non-invasive diseases. As far
back as the 18th century, APSGN following scarlet fever was well known and potentially
dangerous. It was first postulated in 1903 by Clemens von Pirquet that APSGN was
caused by antibody-driven immune reactions that harmed the body rather than being
beneficial (37).

Schick first demonstrated this idea around 1908 by comparing the

26
difference in time between the response to injections of a heterologous protein to the
onset of APSGN after scarlet fever (224). Later in the 20th century it was realized that not
only was scarlet fever caused by S. pyogenes, but also APSGN (37). Sera from patients
with APSGN were shown to contain antibodies against type IV collagen, laminin, heparin
sulfate proteoglycan, and galactosamine-containing proteoglycan of the basement
membrane (225, 226). Along with these antibodies, complement protein 3 (C3) and other
immunoglobulins were also found deposited on the glomeruli in APSGN patients (224).
Since Schick’s work, it has been generally accepted that APSGN is an immune-mediated
disease along with the idea that like rheumatogenic S. pyogenes, there are also
nephritogenic strains. Despite this, the responsible antigen(s) from S. pyogenes still
remains debatable (227). One of the most popular candidates is nephritis-associated
plasmin receptor (NAPlr) (228). NAPlr is a glycolytic enzyme with plasmin binding
activity, and shows adhesion to fibronectin, myosin, and actin (228, 229). In patients
with ASPGN, anti-NAPlr antibodies were found in the sera and in glomerular biopsies
with antibodies bound to glomerular endocapillary neutrophils, mesangial cells,
endothelial cells and the glomerular basement membrane (228-232). There have been
some discrepancies, however, as Batsford et al. was unable to find these same antibodies
within ASPGN patients in either sera or biopsies and hypothesized that these differences
could be do to dissimilarities in genetics and demographics of the groups used between
researchers (227, 231). Despite this, some still believe the importance of NAPlr in the
cause of the disease with the following theory. In the initial stages, before antibody
production, NAPlr accumulates in the renal glomeruli on the mesangial matrix and
glomerular basement membrane, entering in circulation from a throat or skin infection.
Here it traps plasmin, in its active form, causing damage by degrading the glomerular
basement membrane through its own action or through the further activation of promatrix
metalloproteases. This also leads to inflammation due to the recruitment of neutrophils
and macrophages (230, 232). Once antibodies are formed, immune complexes have the
ability to pass through the damaged glomerular basement membrane where they
accumulate in the subepithelial space creating “humps”, a distinguishing characteristic of
the disease. Finally, the activation of complement is the last step leading to the overt
disease stage (232).
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The other common antigen associated with APSGN is SpeB. Poon-King et al. isolated a
plasmin-binding protein, that also bound with antibodies in APSGN sera, and N-terminal
sequencing showed that it was SpeB (233). ASPGN patients showed high anti-SpeB
(zymogen or protease form) titers compared against controls without the disease (227).
Biopsies showed staining of anti-SpeB antibodies to mesangial areas and regions of
peripheral capillary walls. Double staining showed some co-localization with NAPlr and
localization with both C3 and IgG within the humps (227, 232). SpeB is also known for
its plasmin binding activity, which like NAPlr, may cause inflammation leading to the
penetration of leukocytes and antigen-antibody complexes (234).
Most interesting is the finding of Luo et al., using a mouse model of APSGB. Injecting
mice with a protease negative SpeB strain of S. pyogenes resulted in IgG deposits in the
glomeruli, along the glomerular capillary walls, and in the mesangium of the kidney.
Along with this, leukocyte infiltration and C3 deposition was found, along with
proteinuria. When passively immunizing with a monoclonal anti-SpeB antibody, it was
found to bind heat shock protein 70 and thioredoxin on mouse kidney endothelial cells.
Antibody deposits and complement activation were also evident in the glomeruli along
with proteinuria, showing glomerular damage.

This provided not only evidence of

molecular mimicry and associated auto antigens, but also the potential non-importance of
protease activity from SpeB (235).
1.6 Identification of genes important for in vivo survival and pathogenesis
In order to fully understand the multifaceted process of S. pyogenes colonization at the
molecular level, an approach is required that can identify numerous components
simultaneously. More specifically is the identification of genes activated only by the
environment created by the in vivo model. There are many different techniques that have
been developed in order to identify genes in this way. Each has its own strengths and
weaknesses, and sometimes are more suitable depending on the model and pathogen
being used. Some strategies include signature-tagged mutagenesis (STM), microarray,
RNA sequencing (RNA-seq), differential fluorescence induction (DFI), in vivo induced
antigen technology (IVIAT), in vivo expression technology (IVET), and recombinasebased in vivo expression technology (RIVET), and each will be discussed below.
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1.6.1 Signature-tagged mutagenesis
STM is a negative selection method that uses random integration of a transposon. First
used in Salmonella enterica serovar Typhimurium (S. typhimurium), this method
successfully identified known virulence genes, therefore, validating the method, as well
as many new virulence genes (236). In STM, a transposon is flagged with a specific
DNA tag to allow for specific PCR identification from a mix of multiple clones. In
practice, a number of transposons, each with a different tag, are used to generate multiple
transposon libraries, created from the organism of interest. These clones are separated,
via plating, and individual clones are picked and maintained using microtiter plates. A
portion of the library of clones is assembled as a pool containing one clone from each of
the differently tagged transposon libraries. They are grown in vitro, and from here a
portion is removed and pooled (the input pool), and DNA is extracted. The remaining
pool is then exposed to the in vivo environment. The group of clones is recovered (the
output pool), and DNA is extracted. PCR is then used do identify the clones present in
both the input and output pools using primers specific for each transposon tag. The
presence of a clone within the input pool but absent in the output pool identifies it as a
gene dispensable in vitro but required in vivo. The clone can then be identified from the
plates where it is stored for further analysis. This must then be repeated for the remaining
clones (236-239).
This method has been successfully used in many different Gram-negative and positive
bacteria including Listeria monocytogenes (240), Neisseria meningitides (241),
Burkholderia cenocepacia (242), S. aureus (243), Streptococcus agalactiae (244), and
also, importantly, S. pyogenes (239). While transposon libraries can be created with
relative ease, it does require the storage of thousands of individual clones for the
screening process, which can be labourious since STM is a negative selection screening
system.
1.6.2 Microarray
One common technique used currently to evaluate global gene expression is the
microarray (245). Along with gene expression profiling, microarrays can also be used for

29
(but not limited to) pathogen detection, genome comparison, single nucleotide
polymorphism (SNP) detection, and alternate exon splicing. For a basic microarray, an
array of known probes is bound to a solid support and an unknown target is then
hybridized to the array where it can be analyzed and quantified (246). Many different
microarray technologies exist varying in how the probe support is constructed and
analyzed, but the most basic, and probably the most common, are the printed and the in
situ microarrays (247).
Printed microarrays have probes created either by PCR or using oligonucleotide
synthesis. Based on the different production methods, PCR probes typically range from
200 bp to 800 bp, while oligonucleotides probes typically range from 25 bp to 150 bp.
The probes are then printed onto supports, such as glass, with the PCR probes first being
denatured. To increase the accuracy of measurements, each gene has multiple probes
associated with different regions of the gene (248). This leads to printed microarrays
containing approximately 10 000 to 30 000 probes, but are considered low density (247).
Next, the RNA target is extracted and converted to cDNA from two sources; the organism
of interest obtained from the model system and the organism grown in vitro in laboratory
conditions. The cDNA is also labelled with fluorescent dyes; the two different sources
each represented by a different colour. From here equal amounts of cDNA from each
condition are added to the slide to allow hybridization to the immobilized probes in a
competitive manner. The chip is scanned to determine the expression of the genes by
measuring the intensity of the fluorescent signal. The range of colour intensity represents
the change of gene expression between the two samples (245, 249, 250).
In situ-synthesized microarrays use oligonucleotide probes that are printed directly onto
quartz wafer chips used as supports. Similar to printed arrays, probes range from 25 bp to
150 bp but in situ arrays typically carry more that 106 probes and therefore are considered
high density. These microarrays have high specificity due to the increased number of
probes per gene, classically using 11 probes for every 600 bp. In addition, probes with
mismatches are also included to ensure no mispairings are occurring. The RNA is
extracted, converted, and labelled in the same manner, however, in situ microarrays do
not use competitive hybridization, and instead, compare the two samples on two separate
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identical microarrays (247, 250).
Microarrays have many associated benefits. They allow gene expression of an entire
organism to be measured at once from a single RNA sample, eliminating the requirement
of clone libraries (251). Also, the microarray can be performed with a relatively small
amount of RNA obtained from the source. However, microarrays can only be constructed
for organisms for which the genome sequence is known. Microarrays are also currently
not cost effective, requiring specialized equipment for operation (251). Also important to
consider is that the upregulation of mRNA still does not necessarily indicate the
expression of protein, as other mechanisms may yet control translation of the gene
product. Finally, microarrays only provide a snapshot time point from which the RNA
was extracted. Therefore, an accurate depiction of the organism might not be shown, as
certain genes may not be captured during their change in regulation.
1.6.3 RNA sequencing
RNA-seq uses deep sequencing in order to both map and sequence the transcriptome in
question. Instead of capturing transcripts of interest via hybridization like microarrays,
the transcripts are sequenced and mapped, without reference transcripts, creating a map of
structure and expression level (249, 252). While different sequencing technologies are
used, RNA-seq sample preparation is relatively the same. Briefly, RNA is converted to
cDNA using random hexamers or poly-A primers. Followed by RNA degradation, the
cDNA is made double stranded. The addition of adapters to both ends creates known
sequences for PCR primers. The sample is then amplified via PCR and sequenced. The
number of reads each gene receives allows the level of expression to be determined (252,
253).

To date, the major RNA-seq systems include SOLiD sequencer, 454 FLX

Pyrosequencer, and Illumina Genome Analyzer, each with their own technology for the
PCR process.
RNA-seq provides many benefits despite being at an early stage. Most importantly,
unlike hybridization technology, it can be used without a reference genome or transcript.
Since it works at the level of the nucleotide by sequencing small fragments, RNA-seq can
find anomalies such as SNPs, discern transcription boundaries, and identify where exons
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splice. Finally, RNA-seq has much greater sensitivity for genes at both low and high
expression, creating a more accurate overall readout (252). However, RNA-seq still
remains very costly to use, with numerous sample reads required to ensure coverage of
the genome and accuracy (249, 254).

Challenges also currently exist within the

bioinformatics programs used as long stretches of single nucleotides or repeats can be
difficult to interpret accurately. Sample preparation can also bias the fragments towards
either the 5’ or 3’ end, at the RNA or cDNA stage, respectively (252). Finally, the large
amount of sequencing data requires appropriate bioinformatics resources and expertise.
While user friendly software is being developed, using command line languages is still
necessary to make use of these large data files (249).
1.6.4 Differential fluorescence induction
Another method used to identify genes induced in specific environments is DFI. This
promoter trap approach utilizes green fluorescent protein (GFP) as a selectable marker
and exploits fluorescence-activated cell sorting (FACS) to allow high-throughput
screening of gene expression (255). A genomic library of fragments cloned upstream of a
promoterless gfp is created and transformed into the organism of interest. If the fragment
is an active promoter, gfp will be expressed, identifying the clone. The pool of clones is
first grown under standard in vitro conditions allowing the activation of all constitutive
promoters. Using FACS, these clones can be eliminated. The remaining pool of clones
can then be grown under the condition of interest. Promoters specific for this condition
will cause GFP expression, allowing these clones to be separated using FACS. This pool
of clones can then be plated to identify single clones that can be sequenced to determine
the active promoter (255). Other groups have utilized a method where the pool of clones
is grown under the condition of interest first, identifying all active promoters, followed by
growth under standard conditions to identify the promoters specific to the condition of
interest (256-259).
DFI has shown versatility due to its ability to work for both Gram-positive and Gramnegative bacteria including Streptococcus pneumoniae (257), S. aureus (258), S.
typhimurium (255), and L. monocytogenes (259). DFI is able to use a positive selection
technology to screen a large number of clones rapidly by using the semi-automated
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approach of flow cytometry.

To date, DFI has never been used with S. pyogenes,

however, successful creation of the system would require some modification.

S.

pyogenes seems to possess a high background rate when viewing with green fluorescence
under a microscope (unpublished results). This may require the use of a red fluorescent
gene, which is currently an active area of research in our laboratory.
1.6.5 in vivo-induced antigen technology
In vivo-induced antigen technology (IVIAT) is a technique that identifies the
immunogenic antigens of a pathogen as opposed to genes or their promoters. Briefly,
sera from infected individuals are pooled and incubated with the organism of interest
grown in laboratory conditions.

This allows for the absorption of the antibodies

associated with in vitro growth from the collected sera. Next, a genomic library from the
organism of interest is created in protein expression vectors that are expressed in
Escherichia coli, followed by colony hybridization with the pool of remaining antibodies
that has not been absorbed. Any antibodies that bind are interpreted as in vivo induced
antigenic determinants. Following this, colonies that bind the in vivo enriched sera have
plasmids extracted and sequenced to determine the gene upregulated in vivo.
Confirmation can then be determined by repeating the system using individual clones and
qRT-PCR utilizing model systems (238). IVIAT has been used successfully on a number
of bacterial pathogens including Mycobacterium tuberculosis, Vibrio cholerae (260), and
S. pyogenes (261).
IVIAT demonstrates the ability to identify in vivo induced genes utilizing a system that
can probe the organism of interest using material obtained from the organisms intended
site of infection, and not a model system.

This has tremendous advantages as the

organism is behaving in its natural state and therefore the results are more easily
interpreted.

Along with this, IVIAT allows the screening of many clones at once.

However, the screening process tends to be laborious and the serum must be properly
absorbed against the organism of interest in order to ensure that all antibodies against in
vitro proteins are removed. Despite these efforts, there always seems to be a fair number
of false positives as demonstrated by the groups utilizing this technique (261, 262).
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1.7 Genes important for in vivo survival and pathogenesis of S. pyogenes
Most of these technologies have been utilized to identify in vivo induced genes required
by S. pyogenes to grow under various conditions. These have helped to further improve
knowledge about how S. pyogenes reacts with the human host from both pharyngitis and
deep tissue infections. Below represents a summary of the important findings learned
about this human pathogen utilizing these technologies.
The STM method has recovered a total of 29 genes shown to be required for S. pyogenes
in vivo growth (239). Six of the genes identified have also been previously identified
including hasA, mga, smeZ, amrA, and two sil genes, lending support to the validity of the
other genes.

Genes identified covered a range of categories including transport,

regulators, cellular processes, and secreted proteins.

Some of the interesting genes

involved in virulence included transport. The first was a putative macrolide efflux pump
(mefE) that was shown to be involved in biofilm formation but did not provide any
antibiotic resistance (239, 263). Another was an ABC transporter, salT, which is part of
the salivaricin bacteriocin locus.

Interestingly, S. pyogenes does not produce the

bacteriocin and so the function of the transporter remains unknown. Other putative
transporters and cytosolic proteins of unknown function were also identified showing
there are still many genes for which we have yet to learn the function (239, 263).
RNA-seq has been performed on S. pyogenes twice, both involved in the identification of
small RNA (sRNA). Tesorero et al. was able to find a small RNA with a link to acid
stress during growth and infection by identifying the mRNA involved (264). Another
group, Deltcheva et al., identified a novel sRNA that forms part of the complex involved
in the processing of pre-crRNA (CRISPR RNA; clustered, regularly interspaced short
palindromic repeats), short RNA elements that interfere with exogenous DNA elements
(265).
Microarrays have probably given the most information and have been used in many
models spanning ex vivo [human blood (266) and saliva (267)], in vitro (a range of
temperatures) (268), and in vivo [mouse soft tissue infection models (269, 270) and a
cynomolgus macaque model of pharyngitis (271)]. The first microarray chip for S.
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pyogenes was created incorporating 92% of the known ORFs in strain SF370 and used to
determine how temperature regulated gene expression. It was shown that 9% of the
represented genes expressed a change when grown at 29°C, with a large number of those
genes from the extracellular proteome (268). When using ex vivo experimentation, the
strain and the technology changed. The microarray utilized shorter oligonucleotides of a
higher density, creating much greater coverage of the genome, and was designed to cover
six different S. pyogenes strains. Using this microarray technology, the two component
system sptR/S was found to play a key role for persistence in saliva and was controlling
genes involved with nutrient acquisition, response to oxidative stress, and evasion of
innate and acquired immune responses (267, 272). When S. pyogenes was exposed to
blood, the greatest change in gene expression was seen at the 30 minutes (min) period
with 76% of the genome demonstrating a difference in expression. The streptokinase
gene, ska, was upregulated along with adhesins such as emm1, collagen-binding proteins,
and capsule; all of this indicating that mga was an important factor. S. pyogenes also
changed the expression of many genes involved with metabolic functions, through the
covR/S two-component system, in order to adapt to its new environment (266).
Numerous in vivo studies have also been performed to analyze gene expression at the
genome level. From the mouse model of soft tissue infection, it was proposed that S.
pyogenes goes through a three-step process in order to establish itself in a host:
establishment, adaptation, and dissemination. These steps involve the orchestration of a
number of genes at each stage. Establishment implicated the activation of genes involved
in adherence and evasion of the immune system. Adaptation involved continued immune
evasion as well as aggregate formation and rapid replication. Finally, the dissemination
stage included nutrient acquisition along with tissue breakdown and shedding (269).
Experimental pharyngitis using cynomolgus macaques also identified three separated
phases of disease including colonization, acute, and asymptomatic. Colonization and
inflammation was associated with the expression of SAgs and the different phases of
diseases were associated with the regulators from two two-component systems (covR/S
and spy0680/spy0681). covR/S was not expressed during the colonization phase, but was
turned on during the acute phase, and repressed during the asymptomatic phase.
spy0680/spy0681 was turned on during the colonization and asymptomatic phases (271).
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Realizing that two-component systems were important for the survival of the organism,
the mouse abscess model was used with two-component system knockout mutants. The
spy0680/M5005_spy0681 knockout showed significantly larger abscess sizes compared to
the wild-type, while the other strains showed no difference. This was not surprising as it
is a known repressor and has been shown to be active during the asymptomatic phase of
experimental pharyngitis in cynomolgus macaques (270).
Utilizing microarray data from nine strains isolated from patients before 1987, clusters
were created composed of three invasive strains and six pharyngeal strains. Based on
genome expression differences of ~10% they were divided into the pharyngeal
transcriptome profile (PTP) and the invasive transcriptome profile (ITP). The distinction
between the two genomes was found to be a seven bp insertion creating a truncated covS,
the histidine kinase of the covR/S two-component system (273). Later work showed that
SpyCEP, a protease that increases expression in the covR/S truncation, was able to cleave
chemokines associated with neutrophil activation, explaining their absence from sites of
infection (274). Important work also asked how S. pyogenes was changing from a
metabolic perspective, and how this changed pathogenicity. It was found that catabolite
control protein A (CcpA) controlled virulence factors as well as carbohydrate utilization
genes, having a severe affect on mouse oropharynx colonization (275). Further work was
done to examine the maltose repressor (MalR), a surface carbohydrate binding protein. A
malR knockout showed a significant reduction in colonization, but no lack of invasive
disease, demonstrating how carbon sources can determine pathogenesis (276). Future
work continues to use the same type of gene chip covering research in many different
areas with to increase our overall knowledge of S. pyogenes.
Finally, utilizing the IVIAT method, 16 genes were initially identified in S. pyogenes,
after which three were identified to be truly upregulated in vivo, as determined by qRTPCR analysis. These genes included coaA, a putative pantothenate kinase, pbp1A, a
putative penicillin binding protein, and tdcF, a hypothetical protein (261). coaA catalyzes
the first step in the biosynthetic pathway leading to coenzyme A, essential in the
metabolism of fatty acids, carbohydrates, and amino acids (261). Penicillin-binding
proteins are essential for cell morphology and are typically involved in peptidoglycan
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synthesis, but pbp1A was also found to be important for the resistance of phagocytosis in
S. agalactiae (261). tdcF encodes a hypothetical protein with 60% homology to a protein
in Vibrio vulnificus that was found to have a translation initiation inhibitor function.
These two genes may have a similar function found in S. pyogenes (261).
1.8 Rationale and Hypothesis
Each of the systems discussed have both strengths and weaknesses, and have been able to
provide valuable information about S. pyogenes from different models and systems,
including from the in vivo environment. One of the major drawbacks of the techniques
mentioned is the limitation of the extracted data to a single time point. Utilizing RNAseq, microarray, or DFI, data analysis shows gene expression only at the time of
extraction, and therefore is unable to catch genes where expression might have increased
and then fallen back to normal levels. STM allows the ability to identify genes necessary
at different time points since once the gene is needed the clone will be removed from the
pool. However, using this method requires the storage of a massive number of individual
clones and in vivo studies also require large numbers of animals, making the method cost
inhibitory. Finally, the limiting characteristic of IVIAT is due to the use of E. coli as a
protein expression vector. Should expression of the protein be toxic, difficult to express,
or expressed in low quantity, the protein would not be detected by the antiserum.
Another in vivo-induced potential model that is able to overcome some of the weaknesses
of these systems is recombinase-based in vivo expression technology (RIVET). RIVET
uses a method where a permanent change is inherited when a promoter is activated, which
can then be screened for, and potentially allows all activated clones throughout the in vivo
growth period to be identified. This strategy has never previously been used with S.
pyogenes before, but has been performed on many Gram-positive organisms to date
including S. aureus (277), M. tuberculosis (278), Lactobacillus plantarum (279),
Enterococcus faecalis (280, 281), and Streptococcus thermophilus (282). In order to
learn more about S. pyogenes, RIVET will be used for the first time in this organism.
It is hypothesized that RIVET will provide a novel tool that will be able to identify S.
pyogenes genes that are important for colonization of the nasopharynx.
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1.9 Major Objectives
In order to test this hypothesis there are two major objectives.
Objective 1: To construct and evaluate a functional RIVET system using S. pyogenes
strain MGAS8232, utilizing a potential counter-selective gene.
Objective 2: To use the system within our established nasopharyngeal model to allow for
the identification of in vivo-induced genes that are required for the colonization and
adaptation of the nasopharyngeal niche, furthering our knowledge of the organism S.
pyogenes.
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2.1 Introduction
2.1.1 In vivo expression technology
IVET was developed as a method to identify bacterial genes that are required in order to
circumvent the immune system of the host and cause disease. The presumption was that
environmental cues, differently represented in various host tissues, control the expression
of specific genes (1). The first type of IVET system was developed utilizing a purA
auxotrophic strain of S. typhimurium, which has greatly attenuated growth in minimal
media and in vivo. Therefore, in order to survive in vivo, purA would have to be
expressed. By cloning genome fragments prior to purA, in vivo induced promoters could
be identified from clones that survived growth in vivo. Briefly, S. typhimurium genomic
DNA was partially digested into various sizes and cloned into a suicide vector, creating a
transcriptional fusion with both purA and lacZY, potentially controlling both genes. After
transformation, the vectors were incorporated into the chromosome. The pool of clones
was then passed through the chosen mouse model, recovered, and plated on rich media in
order to separate constitutive promoters from those that were induced in vivo. Clones
with constitutive promoters still expressed lacZY and were identifiable by a colourimetric
assay. Those showing no colour, and therefore had no lacZY expression, were only active
in vivo. These clones were also verified by lack of growth in minimal media, showing that
purA was not expressed. In order to confirm in vivo activity, in vitro versus in vivo lacZ
expression was measured by inoculating single clones into mice (1). This was later
developed to be used by Pseudomonas aeruginosa utilizing a purine deficient strain.
Clones were identified post-in vivo growth by finding smaller sized colonizes on media
with a minimal amount of the required purine. This system was used to identify in vivoinduced genes in a mouse, and in human cystic fibrosis mucus (2, 3).
While this initial technology was successful, it was limited to the complementation of a
purine auxotrophic strain. To expand the system, the purA gene was replaced with a
chloramphenicol resistance marker. As before, a pool of plasmids containing random
chromosomal

fragments

was

created

and

cloned

prior

to

the

promoterless

chloramphenicol gene. The pool of plasmids was then amplified and transferred into S.
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typhimurium via conjugal transfer utilizing E. coli. Since the plasmid cannot replicate in
S. typhimurium, only cells with chromosomal integrations could survive. The cells were
then injected into mice, after which chloramphenicol was injected twice daily and added
to drinking water. Once colonies were recovered, in vivo active promoters were those
that grew in vitro showing no colour, and therefore did not express lacZ and could no
longer resist chloramphenicol, due to the silencing of the in vivo-induced promoters. One
noticeable problem was the cloning of multiple fragments into some plasmids. Therefore,
potential clones were all verified via sequencing to ensure that only the fragment
immediately to the 5’ end of the cat-lac fusion was used for integration into the
chromosome.

In addition to a mouse model, a macrophage model was also used

successfully as the in vivo system (4). Both of these IVET systems were used to identify
S. typhimurium genes in various in vivo models (5), along with Yersinia enterocolitica (6,
7), demonstrating the versatility of the IVET model.
2.1.2 Recombinase-based in vivo expression technology
Over the years, IVET technology has been continually improved. A major limitation of
the assay was sensitivity, as the system required continual expression of a gene to allow
the survival of the clone, and therefore any promoters demonstrating any short bursts of
expression would not be detected. In order to overcome this, a reporter system utilizing a
heritable change was used to replace purine autotrophy (8, 9). The chromosomal library
was cloned in front of a promoterless resolvase gene (tnpR), which recognizes res sites on
DNA. TnpR mediates strand exchange between two res sites causing excision of the
DNA in a non-reversible reaction, termed resolution. In order to make use of this system,
a tetracycline marker was placed between two res sites, termed a cassette, and inserted
into the chromosome of V. cholera. The chromosomal library was then cloned upstream
of tnpR in plasmids that were then also integrated into the chromosome. Clones were first
grown in vitro, followed by plating on tetracycline to eliminate those that contained
constitutive promoters. Therefore, all colonies that were able to grow contained inactive
promoters (or fragments not containing promoters) and were picked, pooled, and used to
challenge mice. After recovery, patch plating was performed to recover tetracycline
sensitive clones, and therefore those with in vivo active promoters (8, 9). This method
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was a vast improvement over other IVET models due to the fact that it eliminated the in
vitro promoters before the in vivo selection. This also showed the first discovery of
antisense RNA transcripts utilizing IVET (9).
Lowe at al. performed the first IVET in a Gram-positive species, S. aureus, several years
later (10). The chromosomal library was cloned in front of a promoterless tnpR and
transformed into a strain containing an integrated kanamycin marker flanked by res sites.
Without making use of a colourimetric assay, in vitro promoters were first eliminated by
growth in the presence of kanamycin. Following a murine abscess model, bacteria were
recovered and in vivo induced promoters were identified by kanamycin sensitivity via
colony patching (10). Continual use and evolution of IVET beyond this point started to
cause a change in the name of the system. IVET only referred to the earlier scheme in
which the library fragments were cloned in front of a purine or antibiotic gene, while the
system utilizing library fragments to express tnpR to excise a chromosomal fragment
between res sites was now referred to as recombinase-based in vivo expression
technology or RIVET (11-15).
There has been one additional major development in the RIVET system, which is now
called second generation RIVET, that enhances post-in vivo screening. First performed in
M. tuberculosis, a counter-selectable gene was included within the cassette (16).
Counter-selection works by converting a non-toxic pro-drug into a toxic form, causing
death. Meanwhile, the absence of the gene means the non-toxic pro-drug remains in its
native form, and has no effect. In this case, the sacB gene causes sensitivity to sucrose,
presumably due to the accumulation of levans (17). In order to identify promoters, a M.
tuberculosis chromosomal library was cloned upstream of tnpR, and this was transformed
into Mycobacterium smegmantis containing a res-kan-sacB-res cassette within the
chromosome. Growth in vitro in the presence of kanamycin eliminated all in vitro
expressing promoters and the remaining clones were then grown in vivo, recovered, and
then grown on sucrose. All clones that contained in vivo induced promoters expressed
tnpR, resolved the cassette, and were not affected by sucrose due to the loss of sacB (16).
Second generation RIVET has been used with numerous Gram-positive species with sacB
and uracil phosphoribosyl-transferase (upp) as popular counter-selection methods (16, 18-
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20).
2.1.3 Utilization of the RIVET method in S. pyogenes
Based on the second generation RIVET system as described, a cassette was to be
constructed for S. pyogenes consisting of two selection markers for pre- and post-in vivo
selection (Figure 2.1). However, the Cre recombination system was applied in this work
due to its immediate availability and its previous successful use with Streptococcus
gordonii in our laboratory. The Cre recombinase recognizes loxP sites to cause the
permanent resolution event. The cre gene comes from the E. coli P1 bacteriophage and,
together with the loxP site, is important in the viral life cycle. The P1 DNA must be
circularized before being packaged, and so loxP sites at either end of the linear DNA
strand are recombined via Cre to form a circular DNA strand (21). Therefore, similar to
the tnpR-res system, loxP sites flanking selectable markers in the chromosome can be
removed, or resolved, with the expression of cre within the cell. A single loxP site
contains two 13-nucleotide inverted repeats separated by an 8-bp spacer (bold and
underlined)

making

a

34

bp

site

(ATAACTTCGTATAATGTATGCTATACGAAGTTAT) (21, 22). Two Cre molecules
bind to each loxP site to perform the reaction, and if the loxP sites are oriented in the
same direction, the DNA between the sites becomes excised via recombination.
However, when the loxP sites are oriented in opposite directions, the DNA between the
sites is simply inverted, and would remain within the chromosome. To perform the
reaction it has been found that no energy co-factors are required, only buffers and simple
salts (21).
In order to gain further understanding by how S. pyogenes is able to both colonize and
compete within the nasopharynx, it is important to understand how S. pyogenes adapts
and alters gene expression in this in vivo environment. Herein, a RIVET system was
engineered and constructed, tested, and used for the first time with S. pyogenes in an
established mouse pharyngeal model to provide clues as to how this important bacterial
pathogen survives within this limited biological niche.
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Figure 2.1: Overview of the RIVET design
A) A genetic RIVET cassette was inserted into the genome of S. pyogenes. The cassette
contained an antibiotic resistance (tetracycline, tetR) marker and a counter-selection gene
(thymidine kinase, tk). B) Random genomic fragments from S. pyogenes were cloned
upstream of a promoterless cre gene, and the plasmids (erythromycin resistant, ermR)
were transformed into S. pyogenes containing the cassette. C) The S. pyogenes promoter
library was incubated in vitro under erythromycin and tetracycline selection.
Erythromycin retains the plasmids and tetracycline eliminates any in vitro active
promoters, as any active promoters will express cre, cause excision of the cassette, and
the loss of tetracycline resistance. The pool of remaining clones was used in an in vivo
model of colonization. Clones containing in vivo active promoters express cre and
resolve the cassette. Clones were then recovered via patching for loss of tetR. Initially,
counter-selection, the conversion of a non-toxic pro-drug to a toxic form, was attempted,
however it proved to be unreliable. Sequencing and bioinformatics were subsequently
used to identify the in vivo induced fragments and the associated gene(s). False positives
were ruled out by transforming single plasmids back into cassette-containing S. pyogenes
and grown in vitro and in vivo.
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2.2 Materials and Methods
2.2.1 Bacteria and growth conditions
Bacterial strains used in this study are listed in (Table 2.1). All cloning was carried out
using E. coli XL1-Blue grown on Brain Heart Infusion (BHI) media (BD Biosciences,
Franklin Lakes, NJ, USA) media supplemented with 1.5% agar (BD Biosciences,
Franklin Lakes, NJ, USA) or Luria Burtani (LB) broth (BD Biosciences, Franklin Lakes,
NJ, USA) broth shaking at 250 rpm. Erythromycin (erm) was supplemented at 150 µg
mL-1 as required. S. pyogenes MGAS8232 is an M18 serotype isolated from a rheumatic
fever patient in Utah in 1987 with a genome of 1.985 Mbp (NC_003485.1) (Smoot et al.,
2002). This strain was grown statically in Todd Hewitt broth (BD Biosciences, Franklin
Lakes, NJ, USA) with the addition of 1% yeast extract (THY) (EMD Millipore, Billerica,
MA, USA) at 37°C. As appropriate, 1.5% agar (Invitrogen Life Sciences, Burlington,
Ontario, Canada) and/or erm (1 µg mL-1) and/or tetracycline (tet) (0.5 µg mL-1) was
added. Bacillus subtilis was grown statically overnight in BHI media at 37°C. All
antibiotics were purchased from Acros Organics (Thermo Fischer Scientific, New Jersey,
NJ, USA).
2.2.2 S. pyogenes total DNA extraction
Briefly, for total DNA extractions two mL of overnight culture was washed twice with
one mL of 0.2 mM sodium acetate. The pellet was resuspended in 500 µL Tris EDTA
Glucose buffer (10 mM Tris, 2 mM EDTA, 25% glucose), adding 5 µL 200 mg mL-1
lysozyme and 5 µL 10 U µL-1 mutanolysin. Cells were incubated for 1 hour (h) at 37°C.
After centrifugation (21 000 × g), the pellet was resuspended in 500 µL lysis buffer (50
mM EDTA, 0.2% SDS) with 5 µL 20 mg mL-1 proteinase K, 5 µL 20 mg mL-1 RNase and
incubated at 65°C for 2 h. Next, 50 µL 5 M potassium acetate was added, thoroughly
mixed to precipitate proteins and centrifuged at 21 000 × g for 10 min. The supernatant
was put into a new tube and mixed with 500 µL ice cold 95% ethanol to precipitate DNA.
After one wash with 70% ethanol, DNA was dried and resuspended in 100 µL Qiagen
Elution Buffer (Qiagen, Toronto, Ontario, Canada).
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Table 2.1: Bacterial strains used in this study
Name

Genotype

Reference

E. coli Xl1-Blue

recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac
[F ́ proAB lacIqZ∆M15 Tn10 (tetR)]
Isolated 1987, M18 serotype, 1.895 Mb,
NC_003485.1
4.216 Mb, NC_000964

Stratagene, USA

MGAS8232 with upp removed from the chromosome

This study

MGAS8232 containing the loxP-tetR-tk-loxP cassette
within the chromosome

This study

S. pyogenes
MGAS8232
B. subtilis 168
S. pyogenes
MGAS8232 Δupp
S. pyogenes
MGAS8232 Cas2

(23)
(24)
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2.2.3 Polymerase chain reaction
All

primers

were

designed

using

Primer3Plus

(http://primer3plus.com/cgi-

bin/dev/primer3plus.cgi) and are shown in (Table 2.2).

The provided melting

temperature (Tm), calculated with sequences without the added restriction enzymes or
other additional sequences, was used as the annealing temperature. Primers were ordered
from Sigma-Aldrich (Oakville, Ontario, Canada) and resuspended in Milli’Q water at a
100 mM stock. All PCR was performed using the following cycle: 5 min at 95°C, [30
seconds (sec) 95°C denature, 1 min Tm°C anneal, 1 min per 0.8 kb of length 74°C
extension] × 36 cycles, followed by 5 min at 74°C. All reactions utilized Pfu polymerase
and Pfu buffer (20 mM Tris-HCl (pH 8.8), 10 mM KCl, 10 mM (NH4)SO4, 5 mM
MgSO4, 0.1 mg mL-1 bovine serum albumin, 0.1% Triton X-100) produced in house.
Primers were used at a final concentration of 1 µM each and both Pfu and the DNA
template were added at 1 µL per 100 µL of total reaction volume. All reactions were
performed in a Peltier Thermocycler PTC-200 or a MJ Mini Gradient Thermal Cycler
(Bio-Rad Laboratories Inc, Hercules, CA, USA).
2.2.4 DNA visualization
DNA was visualized on 0.8% w/v agarose (Invitrogen Life Sciences, Burlington, Ontario,
Canada) gels. DNA was loaded using dye made in lab (5% w/v glycerol, 0.04% w/v
bromophenol blue, 0.04% xylene cyanol) and electrophoresed for 1 h at 100 V. All gels
were run with the 1 kb Plus DNA Ladder as a size standard (Invitrogen Life Sciences,
Burlington, Ontario, Canada). Gels were stained utilizing ethidium bromide (0.1%) for 15
min and visualized under ultraviolet light.
2.2.5 Plasmid isolation, DNA digestion, and ligation
Plasmids were isolated from E. coli using the Qiagen Miniprep Kit (Qiagen, Toronto,
Ontario, Canada) following the manufacturer’s instructions. All plasmids used are listed
in (Table 2.3). Digestions were carried out utilizing restriction enzymes from New
England Biolabs (Ipswich, Massachusetts, USA) or Roche (Mississauga, Ontario,
Canada) following the manufacturer’s instructions. All DNA was measured using a.
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Table 2.2: Primers used in this study
Name

Sequence 5' to 3'ab

Restriction Site

upp Up For
upp Up Rev
upp Down For
upp Down Rev
snPgyra for
snPgyra rev
sacB For

XbaI
BamHI
PstI
XhoI
BamHI
NcoI
SalI

sacB RT for
sacB RT rev
0442 RT for
0442 RT rev
upp RT for

CCCTCTAGAGTGGTGCCGATTTATTTGATG
CCCGGATCCGCGAAATAACTTGACATTTTCC
CCCCTGCAGCTGGTGATCGTTTATTTGGGAC
CCCCTCGAGCGGCCTTGATAAAGTTCATGG
CGCGGATCCGCAAAAGCTCATACGGTCTT
GCGAAGCTTCCATGGGATCTTGCATTTAAGGAATGCTC
CCCGTCGACAGGAGGATGAAAGAAACGAACCAAAAGC
CATA
CCCCTGCAGTTATTTGTTAACTGTTAATTGTCCTTGTTCA
AGGATGC
GCGGATCAAAAATGACGATT
CCTTTCGCTTGAGGTACAGC
ACTAGCGACGACGATTGCTT
ATAGCCAGTTGGCCACAAAC
CGGAGTGGTTCCTATCCTCA

upp RT rev
clpP RT for

TTCACGCTCTTCCACATCAG
CGTCGTCAAACCACATCAAC

n/a
n/a

clpP RT rev
tsf for
tsf rev loxp

n/a
XhoI
ClaI

pepO rev
tk RT for

ATCCCAATACCAGCACGAAG
CGCCTCGAGACTTGCTCAATTGAACCACG
GCGATCGATATAACTTCGTATAGCATACATTATACGA
AGTTATCCGTTTTGACACAACAAAAAGA
CGCGGATCCAGATAAAAAGTTGATCTTTGTGAAAAC
CGCAAGCTTTTAGAAATCCCTTTGAGAATGTTT
GCGCCATGGCTTCATACCCATGTCA
CCCTCTAGATTAGTTAGCTTCACCCATTTCACG
GCGTCTAGAATAACTTCGTATAATGTATGCTATACGA
AGTTATACACCAATAAGGAAGCAAAAA
GCGCCGCGGAGCCTAAATGATTGGTGGA
GCTCCACCACCAGCTCTTAC

tk RT rev

GGTCGATGTGACGGTCTTCT

n/a

sacB Rev

tet for
tet rev
tk pET for
tk rev
pepO for loxp

pepO RT for
pepO RT rev
tsf RT for
tsf RT rev
cre F pTRK

ATTCTGAGCCTTCCTCACGA
CGAAGAAGGCAACGAAAAAG
GGCGTTATGGACGCTAAAAA
TGCGTTTACCAATTCAACGA
GCGCCTGCAGAAGGAGGCACTCAAAATGTCCAATTTAC
TGACCGTA
cre R pTRK
GCGCCCCGGGCTAATCGCCATCTTCCAGCAG
cre F FOR pMSP
GCGCTCTAGAAAGGAGGCACTCAAAATCTCCAATTTAC
TGACCGTA
cre F REV pMSP
GCGCTCTAGAAAGGAGGCACTCAAAATCTCCAATTTAC
TGACCGTA
cre R REV pMSP
GCGCCTGCAGCTAATCGCCATCTTCCAGCAG
cre R FOR pMSP
GCGCCTGCAGCTAATCGCCATCTTCCAGCAG
M13 For
GTAAAACGACGGCCAGT
M13 Rev
CAGGAAACAGCTATGAC
a-restriction sites underlined; b-loxP sites bolded

PstI
n/a
n/a
n/a
n/a
n/a

BamHI
HindIII
NcoI
XbaI
XbaI
SacII
n/a
n/a
n/a
n/a
n/a
PstI
XmaI
XbaI
XbaI
PstI
PstI
n/a
n/a
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Table 2.3: Plasmids used in this study
Name
pTRKL2
+

pG host5
pMSP3535
pMSP3535::cre
reverse
pMSP3535::cre
forward
pTRKL2::cre
pG+host5::Δupp
pCAS4tet
pDG1515
pUC57::tk
pTRKL2::PgyrA::sacB
pTRKL2::PgyrA::upp
pTRKL2::PgyrA::tk

Notes

Source/Reference

R

(25)

R

(26)

R

erm shuttle vector with nisin inducible promoter
(Pnis)
cre cloned in reverse orientation of Pnis as control

(27)

cre cloned in proper orientation to Pnis

This study

cre cloned without a promoter to accept library
fragments
pG+host5 containing the construct used to remove
upp from the S. pyogenes MGAS8232 genome
pG+host5 containing the loxP-tetR-tk-loxP cassette
for insertion into the genome of S. pyogenes
MGAS8232
tetR
vector
designated
for
homologous
recombination in B. subtilis
Codon optimized tk

This study

pTRKL2 containing sacB under control of the
MGAS8232 gyrase A promoter
pTRKL2 containing upp under control of the
MGAS8232 gyrase A promoter
pTRKL2 containing tk under control of the
MGAS8232 gyrase A promoter

This study

erm low copy shuttle vector
erm temperature sensitive shuttle vector

This study

This study
This study
(28)
GenScript, Corp.

This study
This study

69
NanoDrop spectrophotometer (Thermo Scientific, Wilmington, Delaware, USA).
Ligations were performed utilizing 0.5 µg or 1 µg of plasmid. Sticky end inserts were
ligated in an insert:plasmid ratio of 1:1 and incubated for 1 h at 16°C. Blunt end ligations
were incubated overnight at 4°C in a 5:1 ratio. Total reaction volumes were kept at 20 µL
and used T4 DNA Ligase (New England Biolabs, Ipswich, Massachusetts, USA).
2.2.6 E. coli competent cells
To prepare competent E. coli, a 1% inoculation from an overnight E. coli culture was
made into PSI broth (2% w/v Tryptone, 0.5% w/v yeast extract, 0.5% w/v magnesium
sulphate, pH 7.6) and grown at 37°C with aeration until an OD600 of 0.5 was reached.
Bacteria were cooled on ice for 15 min then centrifuged at 5000 × g. The pellet was
resuspended 0.4× the original volume in TfbI buffer (100 mM rubidium chloride, 50 mM
manganese chloride, 30 mM potassium acetate, 10mM calcium chloride, 15% v/v
glycerol, pH 5.8) and chilled for 15 min. The bacteria were centrifuged and resuspended
in 0.04× the original volume in TfbII buffer (75 mM calcium chloride, 10 mM rubidium
chloride, 10 mM 3-[N-morpholino]propanesulfonic acid, 15% v/v glycerol, pH 6.5),
aliquoted (200 µL) and placed immediately at -80°C.
2.2.7 E. coli transformation
For transformation, competent E. coli cells were thawed on ice, 10 µL of the ligation
reaction was added, and cells were incubated on ice for 30 min. After heat shocking at
42°C for 45 sec, cells were left on ice for another 2 min, 900 µL of LB media was added,
and cells are incubated at 37°C for 1 h with shaking at 250 rpm. Cells were plated onto
BHI agar containing 150 µg mL-1 erm and incubated at 37°C until colonies formed.
2.2.8 Colony PCR to identify clones
In order to identify clones, individual colonies were numbered, picked using a sterile
toothpick, and touched to the bottom of a PCR tube. A PCR master mix containing M13
primers (flanking the multiple cloning site of plasmids used) was added to each tube (20
µL) to identify clones containing inserts. Products were amplified and visualized on an
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agarose gel to identify clones. All clones were verified with sequencing at London
Regional Genomins Centre, London, Ontario, Canada.
2.2.9 S. pyogenes competent cells
To prepare competent S. pyogenes cells, THY broth containing 0.6% glycine was
inoculated 1:50 with an overnight culture. After 2 h, hyaluronidase was added to a
concentration of 1 mg mL-1. Once the OD600 was between 0.25 to 0.3, bacteria were
centrifuged at 7000 × g for 5 min. Bacteria were resuspended in 0.4× of the original
volume in 15% glycerol. The bacteria were centrifuged and resuspended in 0.04× the
original volume in 15% glycerol, aliquoted (200 µL) and placed immediately at -80°C.
2.2.10 S. pyogenes electroporation
To transform S. pyogenes, tubes of competent S. pyogenes cells were allowed to come to
room temperature and 2 µg DNA was added to each tube of cells, mixed, and transferred
to a 2mm electroporation cuvette. Using the BioRad GenePulser (Mississauga, Ontario,
Canada), cuvettes were pulsed using 2100 V and a pulse length of 1.1 ms. Bacteria were
then transferred to 10 mL THY and recovered at 37°C.

After 6 h, bacteria were

concentrated 10×, plated on THY containing the appropriate antibiotics, and incubated at
the required temperature.
2.2.11 Construction of S. pyogenes MGAS8232 Δupp via homologous recombination
Using the PCR primers listed in Table 2.2, two 500 bp portions of the chromosome
immediately flanking upp were PCR amplified and purified using the QIAquick PCR
Purification Kit (Qiagen, Toronto, Ontario, Canada) as per the manufactuer’s instructions.
The upstream PCR product, along with pG+host5, was digested with XbaI and BamHI,
ligated, transformed into competent E. coli, and screened for positive clones. Once
verified via sequencing, this intermediate clone was digested with PstI and XhoI along
with the downstream PCR product.

These were then ligated and transformed into

competent E. coli, to generate pG+host5::Δupp.
sequencing.

The final clone was verified with
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pG+host5::Δupp, cells were grown at 30°C in THY erm for 4 days, replacing media every
24 h. Next, cells were shifted to 40°C and grown for an additional 4 days in THY erm,
changing media every 24 h. At this temperature, the plasmid no longer replicates, and
cells that have integrated the plasmid will remain resistant to erm. The culture was then
plated for single colonies. Clones were grown individually in THY erm, genomic DNA
was extracted, and PCR was used to ensure integration of pG+host5::Δupp into the
chromosome. Once confirmed, clones were grown in liquid culture at 30°C for 4 days in
THY, replacing media every 24 h. Two functioning origins of replication create an
undesirable situation within the cell, forcing a recombination event to occur. The culture
was then plated to obtain single colonies that are patched onto plates with and without
antibiotics to isolate colonies that have lost the plasmid, all at 40°C. Individual clones
were then screened by PCR for the correct deletion/insertion. Clones were then verified
with sequencing.
2.2.12 Verification of S. pyogenes MGAS8232 Δupp
In order to test for sensitivity to 5-fluorouracil (5-FU), MGAS8232 Δupp and MGAS8232
wild-type were grown overnight in THY, serially diluted 10-fold, and plated on M9T1
(M9 salts, 1% Tryptone, 0.1% glucose, 1.5% agar) with and with out 30 µM 5-FU (EMD
Millipore, Billerica, MA, USA) and grown overnight at 37°C. A sample from both
MGAS8232 Δupp and MGAS8232 wild-type overnight THY cultures were also taken for
qRT-PCR analysis. For growth curve analysis MGAS8232 Δupp and MGAS8232 wildtype was grown in triplicate overnight in THY. All samples were normalized to an OD600
0.01 and plated in triplicate using 200 µL per well. Following this, 50 µL of mineral oil
was placed in the top of each well and the plate was analyzed using a Bioscreen C
Automated Microbiology Growth Curve Analysis System (Growth Curves USA,
Piscataway, NJ, USA) at 37°C with constant ‘medium’ shaking, reading every 0.5 h over
a 24 h period.
2.2.13 Construction of counter-selection plasmids
The sacB gene was PCR amplified from the genomic DNA of B. subtilis subs. subtilis str.
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168, purified using the QIAquick PCR Purification Kit (Qiagen, Toronto, Ontario,
Canada), and digested with SalI and PstI. pTRKL2::PgyrA::sacB was created in a two step
ligation process first cloning sacB into SalI and PstI digested pTRKL2. PgyrA was then
PCR amplified from S. pyogenes MGAS8232, digested with BamHI and XhoI, and ligated
into the BamHI and SalI digested intermediate plasmid.

Clones were verified with

sequencing at each stage. The human herpes simplex virus-1 thymidine kinase gene was
codon optimized for S. pyogenes and synthesized by GenScript Corp (Piscataway, NJ,
USA). PgyrA was amplified from MGAS8232 DNA and digested with BamHI and NcoI
and tk was amplified from pUC57::tk (GenScript Corp) and digested with NcoI and XbaI.
pTRKL2 was digested with XbaI and BamHI, and in one ligation reaction, the promoter
was fused to tk to create pTRKL2::PgyrA::tk. The construct was verified with sequencing.
2.2.14 Testing counter-selection plasmids
To test the different counter-selection genes, each was first transformed into S. pyogenes
MGAS8232 as described in (2.2.10). S. pyogenes containing each plasmid construct, as
well as pTRKL2 as a control, was grown overnight in THY erm, serially diluted 10 fold,
plated on the respective media, and grown overnight at 37°C. S. pyogenes containing
pTRKL2::PgyrA::sacB was plated on THY erm with and with out 15% sucrose. Overnight
growth from THY erm liquid culture was also used for qRT-PCR analysis. S. pyogenes
containing pTRKL2::PgyrA::tk was plated on BMEM (DMEM/F12, 1x vitamin solution,
sodium bicarbonate, 1.5% agar) erm with and with out ganciclovir (Cedarlane Labs,
Burlington, Ontario, Canada) at 1000 µg mL-1. Media components were purchased as
follows: M9 salts, Tryptone, and agar from BD Biosciences (Franklin Lakes, NJ, USA),
glucose and sodium bicarbonate from Sigma-Aldrich (Oakville, Ontario, Canada), and
DMEM/F12 and vitamin solution from Gibco Life Sciences (Burlington, Ontario,
Canada)
2.2.15 S. pyogenes RNA extraction
S. pyogenes cells, from frozen or grown overnight in liquid media, were incubated with
RNAprotect Cell Reagent (Qiagen, Toronto, Ontario, Canada) according to the
manufacturers instructions. The cells were pelleted and resuspended in 500 µL Tris
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EDTA Glucose buffer (10 mM Tris, 2 mM EDTA, 25% glucose), adding 5 µL 200 mg
mL-1 lysozyme and 5 µL 10 U µL-1 mutanolysin. Cells were incubated for 1 h at 37°C.
After centrifugation (21 000 × g), the pellet was resuspended in 500 µL lysis buffer (50
mM EDTA, 0.2% SDS) with 5 µL 20 mg mL-1 proteinase K and incubated at 65°C for 2
h. The RNeasy Kit (Qiagen, Toronto, Ontario, Canada) was used according to the
manufacturers instructions with the lysed cells.
2.2.16 Quantitative reverse transcriptase polymerase chain reaction
cDNA was generated from the processed RNA with SuperScript II Reverse Transcriptase
and Random Primers (both from Invitrogen, Burlington, Ontario, Canada) according to
the manufacturers instructions. Primers were designed to maintain an amplicon length of
~200 bp and Tm of ~60°C. Along with the proS control, all genes to be measured were
first amplified from wild-type DNA and the samples were purified using a Qiagen
QIAquick PCR Purification Kit (Qiagen, Toronto, Ontario, Canada), quantified using a
NanoDrop spectrophotometer (Thermo Scientific, Wilmington, Delaware, USA), and
serially diluted using Qiagen Elution Buffer to 10-10. The qRT-PCR reactions were
performed in triplicate using iQ SYBR Green Supermix (Bio-Rad, Mississauga, Ontario,
Canada) with the appropriate primers and template. The primer set for each gene was
added to reactions with the following: no template, DNA gradient of the gene being
measured from 10-3 to 10-10, and the cDNA from the sample being measured. Samples
were run on a Rotor-Gene 6000 (Corbett Life Science, Kirkland, Quebec, Canada) and
analyzed with the provided software. All cycles used an initial 95°C at 5 min followed by
40 cycles of 10 sec 95°C denature, 10 sec 60°C anneal, and 15 sec 72°C extension.
2.2.17 Construction of the loxP-tetR-tk-loxP cassette (pCAS4tet)
Based on previous bioinformatic analysis of Rho-independent terminators (de Hoon et al.,
2005), a chromosomal location downstream of two opposing genes (pepO and tsf) with
their own Rho-independent terminators was used to insert the cassette. Two regions of
~500 bp were designed, flanking the insertion site, to allow for homologous
recombination of the cassette into the genome. The downstream recombination site was
PCR amplified from the MGAS8232 genome and ligated into the XbaI and SacII sites of
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pG+host5. Next, the upstream recombination amplicon was inserted into the XhoI and
ClaI sites of the intermediate clone.

In order to incorporate the loxP sites, these

sequences were included in the recombination site primers proximal to the cassette. Next,
PgyrA::tk was PCR amplified and cloned between the loxP sites utilizing BamHI and XbaI.
Lastly, tetR was amplified from pDG1515, digested with HindIII and BamHI, and cloned
into the intermediate digested with ClaI and BamHI to create the final cassette. Clones
were verified with sequencing at each stage and for the final construct designated
pCAS4tet. Each insert was also verified by individual excision from pCAS4tet and
visualized by gel electrophoresis. The pCAS4tet was further tested for proper excision ex
vivo using Cre recombinase (New England Biolabs, Ipswich, Massachusetts, USA) with
supplied positive control and empty vector (negative control) according to the
manufacturer’s instructions. DNA was then visualized on an agarose gel.
2.2.18 Construction and verification of S. pyogenes MGAS8232 Cas2
Using the recombination sites, the cassette within pCAS4tet was inserted into the
chromosome of MGAS8232 via homologous recombination using the same method
outlined in 2.2.11. Successful integration of the cassette was verified via sequencing. To
test for spontaneous excision of the RIVET cassette, S. pyogenes MGAS8232 Cas2
(Cas2) was grown overnight in THY tet and subcultured (1%) into THY without any
antibiotics. From here, daily subcultures would continue into THY without antibiotics. A
sample was taken daily, serially diluted 10-fold, and plated onto THY agar with or
without tet. Colony forming units (CFUs) were counted and compared for analysis.
To test excision of the RIVET cassette via Cre, pMSP3535, pMSP3535::cre reverse, and
pMSP3535::cre (Table 2.3) were transformed into MGAS8232 Cas2 and grown
overnight in THY erm/tet. Two samples were taken of each and resuspended in fresh
THY erm with or without nisin at 100 ng mL-1. After overnight growth, cells were
serially diluted 10-fold, plated on THY agar containing erm or tet, and grown overnight.
CFUs were counted and compared for analysis

75
2.2.19 Creation of the S. pyogenes promoter library and removal of in vitro activated
promoters
Total genomic DNA (gDNA) from wild-type MGAS8232 was digested with various
amounts of Sau3AI (0, 0.25, 0.5, 1, 2, 4 Units of enzyme) for 1 h. Digestions were used
in 1:2 ratio ligations with pTRKL2::cre digested with BamHI.

Ligations were

transformed into E. coli, and all colonies were scraped off plates, concentrated, and mixed
plasmids were isolated using the Qiagen Miniprep Kit (Qiagen, Toronto, Ontario,
Canada). These plasmids were then transformed into Cas2. Instead of plating, cells were
grown in liquid in the presence of erm and tet for 24 h to remove in vitro active promoters.
A small sample was taken, serially diluted 10-fold, and plated to determine CFUs, while
the remaining cells were frozen at -80°C for further in vivo experiments.
2.2.20 Identification of in vivo induced promoters
Animal experiments were conducted in accordance with guidelines established by the
Canadian Council on Animal Care and approved by the Animal Use Subcommittee at the
University of Western Ontario (Appendix 1). Using ~108 Cas2 CFUs from batches in
which in vitro promoters were removed, the cells were warmed to room temperature for
30 min, and subsequently inoculated through the nasal route into C57BL/6 mice that
expressed both human HLA-DR4 and HLA-DQ8 mice (29) according to the method of
Kasper et al. (30). After 48 h, mice were sacrificed and the complete nasal passages were
removed, homogenized, and plated as described (30). Colonies were enumerated on THY
erm plates and the remaining cells were maintained at -80°C. From this frozen stock,
~150 CFU was plated onto THY agar plates and grown overnight. Colonies were patched
onto THY agar plates with and without tet to screen for the loss of the cassette. Tet
sensitive clones were subsequently grown, DNA was extracted, transformed into E. coli
to purify plasmids, and inserts were sequenced. Homology searches of potential promoter
regions were performed using the Basic Local Alignment Search Tool nucleotide
(BLASTn) tool at the website of the National Center for Biotechnology Information
(http://www-ncbi-nlm-nih-gov). Further analysis was conducted using the Comprehensive
Microbial

Resource

at

the

scripts/CMR/CmrHomePage.cgi).

J.

Craig

Venter

Institute
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2.3 Results
2.3.1 Selection of a suitable counter-selection method
In order to enhance the screening method of the RIVET system, a counter-selection
strategy was first investigated.

Counter-selection has been used in S. pyogenes

successfully before as a method to screen for double cross over clones when creating
mutants (31). Based on a strain with natural resistance to streptomycin from a mutated
rpsL gene, the plasmid containing the genetic crossover contains a wild-type rpsL that
would provide no protection against streptomycin. Since the wild-type sensitive allele is
dominant over the mutant resistant allele, when both are present the strain is sensitive to
streptomycin. When the sensitive gene is removed, the clone becomes resistant (32, 33).
However, due to the lack of natural streptomycin resistance in MGAS8232, an alternative
counter-selection was necessary. Three potential counter-selection methods were tested
for their potential use: sacB (levansucrase), uracil phosphoribosyltransferase (upp
[UPRTase]), and Herpes simplex virus 1 thymidine kinase (HSV1-tk).
The first potential counter-selection method attempted was sacB. The sacB gene encodes
levansucrase, which catalyzes the hydrolysis of sucrose to glucose and fructose as well as
the polymerization of fructosyl groups to form levan (34). It was shown previously that B.
subtilis could be made sensitive to sucrose when expressing sacB with a mutation within
the signal peptide. It was hypothesized that the lethality of a mutated levansucrase is
caused by the detrimental accumulation of levans (34). Thought it could be made more
efficient, the entire signal peptide was removed. Therefore, sacB was cloned from the B.
subtilis 168 genome, without the signal peptide, and cloned into the pTRKL2 plasmid
under the control of the S. pyogenes gyrA promoter (PgyrA). After the clone was verified
with sequencing, the clone pTRKL2::PgyrA::sacB was transformed into S. pyogenes
MGAS8232. Along with an empty vector control, pTRKL2::PgyrA::sacB was tested on
media containing up to 15% sucrose. The transcription of sacB was confirmed via qRTPCR; however, even when grown on the highest concentration of sucrose,
pTRKL2::PgyrA::sacB did not cause any lethality (Figure 2.2).
The second attempt to generate a counter-selection system in S. pyogenes was the use of
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Figure 2.2: Evaluation of sacB as a counter-selection gene in S. pyogenes
A) Serial 10-fold dilutions of S. pyogenes MGAS8232 containing pTRKL2 (vector) or
pTRKL2::PgyrA::sacB grown on THY agar or THY agar including 15% sucrose. B) qRTPCR analysis of sacB transcription from S. pyogenes containing pTRKL2 or
pTRKL2::PgyrA::sacB after overnight growth in THY.

Expression is relative to the

housekeeping gene proS. N=3, unpaired t-test, *** p<0.0001.
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the upp gene. In the cell, UPRTase normally converts uracil to UMP, allowing the cell to
use exogenous uracil. However, UPRTase can also convert 5-FU, a toxic pyrimidine,
into 5-fluoro-UMP. This is then metabolized into 5-fluoro-deoxyuracil monophosphate
which inhibits thymidylate synthetase, an enzyme required for growth (35). Since upp is
endogenous to S. pyogenes, a knockout first had to be created. Utilizing molecular
recombination techniques outlined in the Materials and Methods, MGAS8232 Δupp was
generated.

Following this, growth on media with or without 5-FU, along with

MGAS8232 wild-type as a control, demonstrated that 5-FU was no longer toxic to
MGAS8232 Δupp (Figure 2.3A).
Further testing against MGAS8232 Δupp was carried out to ensure that the mutation had
no obvious detrimental effects. First evaluated was a growth curve against MGAS8232
wild-type to ensure that growth was not affected. Curiously, MGAS8232 Δupp grew at a
faster rate to a higher overall OD than MGAS8232 wild-type (Figure 2.3B). Next, RNA
was extracted from both MGAS8232 wild-type and MGAS8232 Δupp, and the expression
of the genes immediately upstream and downstream to upp were compared. While there
was no difference in the expression of the upstream gene, spyM18_0442, the downstream
gene, clpP, showed increased expression with MGAS8232 Δupp (Figure 2.3C).
Therefore, MGAS8232 Δupp contained differences that could have undesirable effects on
in vivo growth, and for this reason, upp was not chosen for a counter-selectable marker.
The last counter-selection method evaluated was the thymidine kinase (tk) gene from the
Human Herpes Simplex Virus-1 (HSV). The HSV-tk has relaxed specificity and can
phosphorylate substrates other than thymidine. This allows for the addition of pro-drugs
(e.g. ganciclovir) that can be phosphorylated by HSV-tk, but are not phosphorylated by
native tk. Once the pro-drug is phosphorylated by HSV-tk to the mono state, it can be
then recognized by cellular kinases and converted to the di- and tri-phosphorylated state,
where it can be incorporated into replicating DNA, causing cessation of DNA replication,
leading to cell death (Figure 2.4A).
In order to engineer this human viral gene to be expressed in a prokaryote, the cDNA was
codon optimized for S. pyogenes and synthesized. Once produced, tk was cloned under
the control of PgyrA in pTRKL2, transformed into MGAS8232 and tested with the pro-
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Figure 2.3: Evaluation of upp as a counter-selection gene in S. pyogenes and
MGAS8232 Δupp fitness
Serial 10-fold dilutions of S pyogenes MGAS8232 wild-type (top dilutions) or
MGAS8232 Δupp (bottom dilutions) were grown on A) M9 tryptose agar or M9 tryptose
agar containing 30 µM 5-FU. B) Growth curves comparing MGAS8232 wild-type and
Δupp. Overnight cultures were subcultured to OD600 0.01, and grown for 24 h, with OD
measured every 0.5 h. N=3. C) qRT-PCR transcriptional analysis of spyM18_0442, upp,
and clpP from MGAS8232 wild-type and Δupp after overnight growth in THY. N=3,
unpaired t-test, ns=0.8490 (spyM18_0442), *** p=0.0004 (upp), * p=0.0464 (clpP).
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Figure 2.4: Ganciclovir method of counter-selection and initial test in MGAS8232
A) Ganciclovir (GCV) and incorporation via HSV1-tk. Due to its lack of specificity,
HSV1-tk is able to mono-phosphorylate GCV (inset) to GCV-MP. The kinases of S.
pyogenes then have the ability to di- and tri-phosphorylate GCV-MP. GVC-TP can then
be incorporated into DNA, preventing further incorporation of nucleotides, stopping DNA
replication, and leading to cell death. B) Evaluation of HSV-tk and GCV as a counterselection pair in S. pyogenes.

Serial 10-fold dilutions of S. pyogenes MGAS8232

containing pTRKL2 (vector) or pTRKL2::PgyrA::tk grown on BMEM agar and BMEM
agar containing 1000 µg/ml GCV.
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drug ganciclovir. At the highest concentration tested, a counter-selection phenotype was
demonstrated in which ~2 logs of growth were lost (Figure 2.4B). This then provided a
potential counter-selection method that could be built into the RIVET design for S.
pyogenes.
2.3.2 Construction of pCAS4tet
To engineer a RIVET system, a suitable location for the cassette to be inserted into the S.
pyogenes MGAS8232 genome had to be found prior to construction could begin. An
appropriate location would not compromise growth or the expression of nearby genes. It
was decided to identify two genes that terminated facing each other to avoid disrupting
any promoters. Additionally, two genes were selected each with predicted transcriptional
terminators so that the cassette could be placed between, and therefore not disrupt any
transcriptional units. Using the work of Hoon et al., it was possible to find many
promising sites, and ultimately the region between pepO and tsf was selected as an
appropriate location (36).

Using 500 bp of chromosomal DNA to allow for

recombination, the cassette could be inserted between the transcriptional terminators.
These two chromosomal fragments were PCR amplified, each containing the necessary
loxP site on one PCR primer, and each fragment was cloned into pG+host5. Between the
loxP sites tet and PgyA::tk, were then cloned, forming the cassette (Figure 2.5A). Once
completed, pCAS4tet, was verified via sequencing and restriction digestion analysis
(Figure 2.5B). Finally, pCAS4tet was tested for its ability to excise the cassette using the
Cre protein. Using empty pG+host5, a positive control (linear stranded DNA with loxP
sites), and pCAS4tet, all were incubated with and without Cre protein and analyzed by
agarose gel electrophoresis (Figure 2.5C). The negative control, pG+host5, showed no
changes with the presence of Cre, however the positive control showed the addition of
bands, indicating that Cre had caused recombination of the loxP sites contained within the
DNA. Lastly, in pCAS4tet, when incubated with Cre the top band of DNA seems to have
been split into two (arrows), as well as the addition two faint bands of approximately 3.5
kb and 5.5 kb (arrows) (Figure 2.5C). This indicated recombination of the loxP sites by
Cre, and therefore, potential resolution of the cassette.
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Figure 2.5: Visual verification of pCAS4tet construction and excision of the cassette
via Cre
A) Plasmid map showing the completed pCAS4tet indicating restriction enzymes used.
The loxP sites are enlarged to show their position.

B) pCAS4tet was verified via

restriction enzyme analysis. Each component was removed from the construct as
indicated by restriction enzyme digestion and ran on a 0.8% agarose gel. C) Verification
of excision of the cassette from pCAS4tet ex vivo. The negative control (pG+host5), the
positive control (provided with Cre protein), and pCAS4tet were incubated with or
without Cre and ran on a 0.8% agarose gel. Arrows indicate recombination products of
pCAS4tet.

86

A)

BamHI
ClaI HindIII

XhoI

tet

loxP

XbaI

tk

SacII

loxP

pepO

tsf

pCAS4tet
erm

L

B)

1

2

3

4

5

6

L

Ladder
1. pCAS4tet uncut
2. Cassette
3. tetracycline
4. thymidine kinase
5. pepO recombination site
6. tsf recombination site
Ladder

4 kb
3 kb
1.6 kb
1 kb
0.5 kb

-ve
DNA

L

C)

+ve
DNA

pCAS4tet

4 kb
3 kb
1.6 kb
1 kb
0.5 kb

Cre

-

+

-

+

-

+

87
2.3.3 Creation and verification of the cassette containing strain Cas2
Next, pCAS4tet was transformed into MGAS8232 and the cassette was inserted into the
chromosome, via recombination events similar to the construction of MGAS8232 Δupp,
to create Cas2. Using qRT-PCR, the expression of pepO and tsf was compared between
Cas2 and MGAS8232 wild-type grown in vitro. These results showed no significant
difference in gene expression between the two strains (Figure 2.6A). Secondly, Cas2
was subcultured for 7 days in vitro without tet to determine if any spontaneous resolution
of the cassette occurred. There appeared to be little noticeable spontaneous loss of the
cassette (Figure 2.6B).
Further testing was also performed to ensure that the cassette could be excised from the
chromosome properly. In order to analyze this, a plasmid containing cre under the
control of a nisin inducible promoter was transformed into Cas2. Included were two
controls: cre in the reverse orientation, and the empty vector. Overnight cultures were
given fresh media with erm, with or without nisin, and plated on THY erm, as a control,
and THY tet, the next day (Figure 2.7). As expected, all strains were able to grow on
THY erm regardless of the presence or absence of nisin. On the THY tet plate, the empty
vector and cre in reverse controls both showed the similar amount of growth with or
without nisin. This indicated that no cassette excision was occurring. With cre in the
forward orientation, loss of growth was evident on the THY tet plate both in the presence
and absence of nisin. Excision of the cassette in the absence of nisin was most likely
occurring because of small amounts of cre expression due to the leakiness of the nisin
promoter. In contrast, those grown overnight in nisin showed no growth on THY tet,
indicating that the cassette was properly excised under the control of Cre.
Cas2 was also tested for counter-selection, and gave an initial positive result, however
with further testing, the method was unfortunately deemed unreliable in Cas2 (data not
shown).

While qRT-PCR was able to verify HSV-tk transcription (Figure 2.6A),

Western blot analysis failed to indicate the presence of protein from whole cell
MGAS8232 and Cas2 extracts (data not shown). A positive control confirmed that
antibodies were functional.
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Figure 2.6: Assessing Cas2 suitability
A) Measuring transcription of genes flanking the cassette. qRT-PCR analysis of pepO, tk,
and tsf transcription after overnight growth comparing MGAS8232 wild-type and Cas2
relative to proS housekeeping gene.

N=3, unpaired t-test, ns=0.1439 (pepO),

***p<0.0001 (tk), ns=0.0838 (tsf). B) Cassette stability in Cas2.

Cas2 was grown

overnight in THY containing tet, and subcultured daily in THY. Each day 10-fold
dilutions of the overnight culture were plated on THY agar and THY agar tet. CFUs were
counted the next day with the THY agar count set as 100%.
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Figure 2.7: Evaluation of cassette resolution in S. pyogenes Cas2
Using the nisin inducible vector pMSP3535, Cas2 was transformed with vector, cre
reverse, or cre forward. Two sets of overnight cultures were given fresh THY with erm,
and half were also given nisin. Following overnight growth, serial 10-fold dilutions were
plated on A) THY agar with erm and B) THY agar with tet.
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2.3.4 Creation of a genomic library and removal of in vitro active promoters
In order to create a S. pyogenes promoter library, genomic DNA was extracted from
MGAS8232 and digested with various amounts (0, 0.25, 0.5, 1, 2, 4 Units) of the
restriction enzyme Sau3AI for 1 h. Verified on an agarose gel, Figure 2.8A demonstrates
successful digestion. The DNA was then purified, pooled, ligated into the pTRKL2::cre
plasmid in a 1:2 ratio (vector:insert) and transformed into E. coli. In order to ensure
fragment variability, random clones were selected and PCR amplified to determine the
insert length, with one representative gel shown in Figure 2.8B. All E. coli clones were
then pooled and plasmids were extracted. The plasmids, containing library fragments,
were transformed into Cas2, and grown overnight in the presence of erm and tet in order
to eliminate the clones expressing in vitro promoters. The surviving clones were then
concentrated and frozen.
2.3.5 Identification of promoter regions induced in vivo using an acute
nasopharyngeal infection model
For the in vivo identification of promoters, 108 cells were taken from the frozen library
stocks and inoculated into the nasal passages of each of four HLA-DR4/DQ8 mice. The
complete nasal turbinates (cNTs) were recovered, and after 48 h, counter-selection was
attempted, but proved to be unreliable (data not shown). Colonies were therefore patched
to identify clones for which the cassette had been resolved. In total, 171 plasmids were
isolated and sequenced, leading to 82 unique sequences after duplicates were removed
(Appendix 2). Sequences were analyzed using BLASTn to determine which portion of
the MGAS8232 genome was contained within the plasmid. The inserts were divided into
four different categories based on their position in the chromosome. The first were
‘typical’ promoters in which the fragment was upstream of the 5’ end of an annotated
ORF. Second were ‘cryptic’ promoters, where the fragment was contained completely
within an ORF and facing the same direction. Third were ‘antisense’ promoters, which
were also contained completely within an ORF, but were facing the opposite direction.
While not typical of obvious ORFs, these cryptic and antisense promoters could be
involved in the regulation of the genome as sRNA molecules. Lastly, some plasmids also
contained

multiple

inserts,

which

likely

arose

from

cloning

artifacts.
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Figure 2.8: Confirmation of S. pyogenes MGAS8232 gDNA digestion and cloned
fragment size variability
A) Digestion of S. pyogenes genomic DNA. MGAS8232 gDNA was digested with 0,
0.25, 0.5, 1, 2, and 4 Units of Sau3AI for 1 h and analyzed on a 0.8% agarose gel. B)
Verification of fragment variability in the genomic library. Plasmids were extracted from
a random number of transformed bacteria and fragment size was measured using PCR
with flanking primers. Included are no template as a negative control (-) and cre only
positive control (+). Representative PCRs are shown on a 0.8% agarose gel.
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Since it would be difficult to determine which insert acted as the promoter in each case,
they were removed from further analysis.
To further classify the identified promoters, they were divided by sense (including
‘typical’ and ‘cryptic’) and antisense, and using the gene they were associated with,
further divided based on function using the J. Craig Venter Institute Comprehensive
Microbial Resource (Figure 2.9). This allowed us to determine how the in vivo induced
loci were distributed according to their potential function. The majority of processes
associated with sense clones include amino acid biosynthesis, degradation of proteins,
peptides, and glycopeptides, cell envelope, cell processes, and energy metabolism. While
the highest category for antisense clones was hypothetical proteins, the highest categories
with functions were cellular processes and DNA metabolism. Some interesting
differences between the two categories are the presence of amino acid biosynthesis and
regulatory functions, found only in the sense clones, while only the antisense clones
contain the purines, pyrimidines, nucleosides, and nucleotides category.
2.3.6 Analysis of ‘typical’ promoter
From the total number of clones, nine ‘typical’ promoters were found (Table 2.4).
Function was predicted using Basic Local Alignment Search Tool protein (BLASTp)
analysis to similar known proteins. Of particular interest were clones IVI100 and IVI156,
representing a minor structural protein for ΦSpeC and a bacteriocin-like protein,
respectively. Previous work in our lab has shown ΦSpeC to spontaneously excise from
the chromosome in vitro, however, this has never been further explored in vivo.
Additionally, a role for bacteriocins in niche adaptation by S. pyogenes has not been
previously studied. These two genes possibly provide new areas of research related to
colonization of the host. In order to test the validity of these promoters, the promotercontaining plasmids of IVI100 and IVI156 were transformed back into Cas2 and reevaluated both in vitro and in vivo, to establish if the promoters activated as previously
determined.
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Figure 2.9: Separating RIVET clones based on function
Potential in vivo-induced promoter elements were divided between sense and antisense,
and using the J. Craig Venter Institute Comprehensive Microbial Resource. The
sequences were further divided based on the predicted function of the associated gene.
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Cellular'process'12.1%
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Unknown' function'4.5%
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Table 2.4: Potential ‘typical’ promoters identified
Clone

Corresponding Description
Gene
IVI49 spyM18_2257
chromosome segregation protein
IVI53 spyM18_1223
amino acid ABC transporter, periplasmic
amino-acid binding protein
IVI60 spyM18_0197
hypothetical protein
IVI72 spyM18_0784
tagatose-6-phosphate aldose/ketose isomerase
IVI84 spyM18_2004
conserved hypothetical protein
IVI87 spyM18_1912
pyruvate formate-lyase
IVI100 spyM18_0771
hypothetical protein, phage associated
IVI156 spyM18_0544
putative BlpM homologue
IVI176 spyM18_0414
conserved hypothetical protein
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2.3.7 Clone IVI156 contained an in vivo-induced promoter
Cas2 containing either IVI100 or IVI156 was grown in vitro overnight in THY erm and
then plated on THY erm agar and THY erm/tet agar. For a control, Cas2 containing the
promoterless pTRKL2::cre was used. As with the initial RIVET screen, both IVI100 and
IVI156 showed no promoter activity in vitro, as indicated by the maintenance of tet
resistance in the Cas2 (Figure 2.10).
resistance.

The promoterless control also maintained tet

Next, multiple cultures of each clone were grown overnight in vitro,

combined, enumerated, and frozen. From the frozen stock, 108 of the negative control, as
well as IVI100 and IVI156 were each used to inoculate HLA-DR4/DQ8 mice. The
recovered clones were then plated and compared as they were for the in vitro portion
(Figure 2.10). As expected, the negative control showed no loss of the cassette. Clone
IVI100 appeared to show some loss of growth on THY tet, although this was not
statistically different, potentially indicating partial loss of the cassette in vivo. This may
indicate activation of this promoter only occured in a portion of the cells in vivo. Clone
IVI156, on the other hand, showed complete loss of tet resistance, indicating full in vivo
activation.
2.4 Discussion
S. pyogenes is a prominent human pathogen that is responsible for over 700 million
global infections each year. In order to accomplish this, S. pyogenes must be able to
colonize its host efficiently. Since humans remain the only natural host, S. pyogenes has
evolved ways in which to efficiently colonize via the skin or pharynx. Colonization is a
complicated process involving many facets from both the bacterium and the host. In
order to further understand this process, we took a broad approach and constructed a
versatile RIVET system to identify genes in S. pyogenes that were induced specifically
within the pharyngeal environment using a mouse model.
Following the method for the second generation RIVET, a counter-selection method was
initially included in order to make post-in vivo selection more efficient. Three different
methods were attempted with varying success. The sacB gene provided no counter-

100

Figure 2.10: Verification of promoter activity from clones IVI100 and IVI156
The two clones, IVI100 and IVI156,along with pTRKL2::cre as a negative control, were
transformed individually into Cas2, grown in vitro, and inoculated into HLA-DR4/DQ8
mice (in vivo). From each condition, serial 10-fold dilutions were plated on THY agar
with or without tet and enumerated. N=6 for cre and IVI157, N=7 for IVI100.
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selection phenotype in the presence of sucrose (Figure 2.2A). Although it was shown
that the sacB gene was transcribed under our experimental conditions, we cannot rule out
potential problems with translation or the protein product itself (Figure 2.2B). This
problem could have been related to the complete removal of the signal peptide. While the
upp/5-FU combination was quite robust as a counter-selection system, the polar effects
caused by the knockout were undesirable for use in vivo (Figure 2.3). Additionally, use
of upp could not be used broadly in S. pyogenes, as each strain would require mutation of
the endogenous upp gene. One gene that did seem to have some initial success was that
of HSV1-tk in conjunction with GCV (Figure 2.4B).

Unfortunately, continued use

produced inconsistent results post-in vivo. Similar to sacB, transcription of HSV-tk was
shown (Figure 2.6A), however, the presence of the protein itself was not (unpublished
data). This could be due a weak antibody or poor translation of the gene. There is also
the possibility that S. pyogenes is able to break down GCV and metabolize it, hence the
high concentration initially required. Whatever the reason, should counter-selection be
explored in the future with S. pyogenes, there are still several different methods that could
be attempted. Although more laborious, patching colonies onto THY tet to identify clones
that had resolved the cassette was successful, therefore this method was used in lieu of
counter-selection.
Once Cas2 had been created along with the library, in vitro promoters were removed and
the remaining fragments were exposed to the in vivo model. From this pool, 82 unique
plasmids were recovered representing in vivo induced fragments (Appendix 2). These
potential promoters controlled genes that covered a broad range of categories with some
noticeable differences between the sense and antisense groups (Figure 2.9). In particular,
the antisense fragments created an interesting group as these potential promoters would
likely be involved in negative regulation of the corresponding gene product.
Compared to eukaryotes, the bacterial chromosome is quite compact and was once
thought to be relatively simple, with protein being the only regulatory mechanisms (3739). It has only been in the past 12 years that regulatory RNAs are commonly being
found and shown to contain important regulatory roles (40). Regulatory RNAs generally
fall into one of three categories: an element contained within the 5’ untranslated region
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(UTR) of the mRNA, trans-encoded sRNA that target one or more genes that are located
elsewhere on the chromosome, or cis-encoded sRNA that are encoded on the opposite
strand of the gene they target (40, 41). Multiple studies have recently found putative
sRNAs within S. pyogenes, supporting the idea that they represent important regulatory
mechanisms (42-46). Three of these, fasX, pel, and rivX, have been studied extensively
with fasX and rivX representing trans-encoded sRNAs and pel representing a cis-encoded
sRNA.

Using microarray analysis, fasX (fibronectin/fibrinogen-binding/haemolytic-

activity/streptokinase-regulator-X) was shown to have many mRNA targets after
exposure to human plasma (47). By binding to the 5’UTR of the target mRNA, fasX was
able to improve mRNA stability and translation for some targets and reduce it for others.
It was best known for its ability to increase the expression of streptokinase and
streptolysin S while it negatively affected the adhesion genes Fbp54, Mrp, and pili (4749). The pleiotropic effect locus (pel) is a 459 bp transcript found to have a positive
regulatory affect on the M protein, streptokinase, SpeB, and streptolysin S. Once the
region was sequenced it was discovered that sagA, the structural gene of streptolysin S,
was within pel, while the remaining eight genes of the operon were further downstream.
Contained within different reading frames from each other, the termination sequence for
pel is contained within sagA and sagB (50-52). While it is unknown how pel specifically
regulates virulence factor expression, it has been demonstrated that it works at the RNA
level by showing continual function even when translation has been prevented (52). Also
shown to function without translation, rivX is an sRNA that provides a link between the
regulators CovRS and Mga. The two-component system CovRS, along with some other
unknown environmental factor(s), is able to suppress rivX, which is able to enhance Mga
expression either directly, or though another regulator.

This then has an affect on

numerous virulence factors such as speB and emm (53, 54). This demonstrates the
complicated systems used in order to control the expression of bacterial genes.
The RIVET system seems to have uncovered some potentially interesting cis-encoded
sRNAs. Three of these sRNAs potentially control the virulence factors Mga, SpeA and
MF3. Mga is an important regulator controlling greater than 10% of the genome through
both activation and repression (55). At its core, Mga controls genes encoding adhesion,
invasion, and immune evasion, and therefore is vital during the early stages of
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colonization (56, 57). Showing peak expression during exponential growth, Mga causes
the self-autoinduction as well as the induction of M and M family proteins, SOF, C5a
peptidase, and SIC, among others (56, 58, 59).

Virtaneva et al. demonstrated this

expression pattern along with SpeA, SMEZ, and two different DNases (spd3 and sdaD2)
using cynomolgus macaques in an in vivo model (60). Continual growth then leads to
early and late stationary phases representing a state of persistence, and potentially spread,
and continual change of gene expression. This further leads to the repression of mga and
its associated genes as well as speA, spd3 and sdaD3 (59, 60). Therefore, it is possible
that S. pyogenes makes use of sRNA for quick repression of mga, speA, and mf3 along
with others.
From the group of sense clones, nine appeared to represent typical promoters, driving the
expression of a gene(s) (Table 2.4). The corresponding proteins were searched using
BLASTp to identify a potential function and three appeared to be involved with
metabolism. This is not surprising since S. pyogenes is able to grow in multiple niches
within the human body including the pharynx, the skin, and also within deeper tissues.
Each environment represents its own set of challenges, one in particular being that of
nutrient availability. In order to survive, S. pyogenes must alter the expression of genes
within its chromosome accordingly to make use of the nutrients available.
Within the upper respiratory tract, S. pyogenes is most prevalent within the oropharynx,
but can also be found within the nasopharynx and the nasal cavity (61). The oropharynx
represents the area immediately behind the oral cavity, starting with the soft palate and
the base of the tongue, and ending at the posterior pharyngeal wall (62). Running up the
pharynx above and beyond the soft palate until reaching the nasal septum is the
nasopharynx, past which is the nasal cavity (63, 64). There are few sources from which
S. pyogenes can obtain nutrients within the pharynx and nasal cavity with relatively the
same provisions between niches. Common nutrients include those obtained from the
dead and dying cells of the host and other foreign cells, along with molecules from the
interstitial fluid of the host. Another major nutritional component in each niche is the
fluid created for that area: nasal fluid is present in the nasal cavity, airway surface liquid
(ASL) lines the nasopharynx and the posterior of the oropharynx, and saliva coats the oral
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cavity and the anterior of the oropharynx (61, 65). These fluids provide many functions
including lubrication, protection, and pH balance. The fluids are relatively similar with
major differences including water content and the concentration of certain solutes. Nasal
cavity fluid and ASL consist of 90-95% water, while saliva consists roughly of 99%
water. Some of the major solutes contained within these fluids include proteins, mucin,
DNA, urea, and various electrolytes. In addition, saliva can also contain food debris that
may provide several nutrients (61, 65-67).
One of the typical promoters involved with metabolism, IVI87, controls the protein
pyruvate formate-lyase, which is involved in carbohydrate utilization. The preferred
carbon course of S. pyogenes is glucose, and when it is found in excess a state of
homofermentative glycolysis is maintained. Through glycolysis, glucose is converted to
pyruvate, which is then converted to lactate, and excreted (68). However, within the
upper respiratory tract there exists a very limited availability of free carbohydrates such
as glucose (65). S. pyogenes starts to compensate for this by changing to a process of
mixed-acid fermentation, allowing for the continued production of adenosine triphosphate
(ATP) via the recycling of NAD+. Mixed-acid fermentation starts with the activation of
pyruvate formate-lyase, demonstrated by clone IVI87, to begin converting pyruvate to
Acetyl-CoA and formate (69-71).

Acetyl-CoA can then be used in two pathways:

conversion to acetate creating ATP, or conversion to ethanol in the process of converting
NADH back to NAD+ (72).

However, in order to sustain itself within the upper

respiratory tract, S. pyogenes must also find an alternate carbon source (70, 73, 74).
One important carbon source used by bacteria in the upper respiratory tract, including
various types of streptococci, is that of mucin (75-78). Mucin is a large repeating
network of interconnecting molecules, reaching up to 1000 kDa, consisting of a protein
backbone containing carbohydrate side chains linked via serine or threonine (65, 79).
These carbohydrate side chains include fucose, galactose, N-acetylgalactosamine, Nacetylglucosamine, and sialic acid (80). S. pyogenes can utilize galactose through the lac
operon and some strains, but not all, contain fucosidases, sialidases, and other genes that
assist in the degradation of N-glycans (81). S. pyogenes also possess the enzymes EndoS
and hyaluronidase that release N-acetylglucosamine from the Fc region of IgG and
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hyaluronate, respectively (65, 82).

RIVET also indicated the expression of

spyM18_0784, via clone IVI72, a tagatose-6-phosphate aldose/ketose isomerase, involved
in the pathway for the metabolism of N-acetylgalactosamine (83). This could indicate the
use of a N-acetylgalactosamine as a carbon source within the pharynx by S. pyogenes.
The last identified activated gene that may be involved with metabolism was
spyM18_1223, the binding protein for a polar amino acid ABC transporter. The binding
protein captures the substrate, delivering it to the membrane domains that transfer it
across the cytoplasmic membrane (84, 85). Detection of spyM18_1223 by other groups
has also supported in vivo induction. When grown in THY, spyM18_1223 was shown to
be below antibody detection level (86). However, when grown in blood antibody binding
was detected and, more importantly, spyM18_1223 expression was found to have
increased two-fold when analyzed from S. pyogenes positive pharyngitis patients (87, 88).
This suggested that spyM18_1223 was only expressed under certain metabolic
environments, including one that was replicated within the mouse nares.
The next typical promoter activated in the mouse colonization model controlled
spyM18_2257 or parB. Binding to parS sites present at the oriC of the chromosome,
ParB is thought to bind to other proteins and aid in chromosome segregation (89). In
other streptococcal strains ParB has shown to be expressed as both an operon with the
upstream gene htrA, as well as an individual gene with its own promoter (90, 91). In this
case, Clone IVI49 identified the activation of parB individually in vivo.

Since

chromosome segregation would be occurring in vitro, it is possible that parB was only
being expressed in the operon form in vitro but switched to the individual form in vivo to
be picked up by RIVET. This change in expression could occur due to changes in the
nutrients available and the appearance of other means of stress.
For three promoters, spyM18_0197, spyM18_0414, and spyM18_2004, very little is
known of the controlled gene(s) other than the domains present on the potential protein
that is produced. The protein product of spyM18_0414 contains a single cystathionine βsynthase (CBS) pair (domain), which can be found in all three kingdoms of life. CBS
domains can be found in proteins of a wide range of functions including channels,
kinases, and metabolic enzymes (92, 93). The function of this particular protein remains
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unknown. The second protein, encoded by spyM18_0197, contains a transglutaminase
domain. Transglutaminases are enzymes responsible for a variety of post-translational
modifications to proteins, principally introducing a cross-link between lysine and
glutamine residues (94). Some pathogens highjack the transglutaminase, such as S.
aureus, which uses the host transglutaminase of plasma factor XIIIa to cross-link itself to
fibrin (95). Other bacteria produce toxins that are transglutaminases that target host Rho
proteins, modifying them post-translationally and impairing their GTPase activity (96).
Finally, Francisella tularensis demonstrated attenuated growth in macrophages and mice
when a protein with a transglutaminase domain was deleted (97).

How exactly S.

pyogenes uses spyM18_0197 has yet to be determined, but it has been shown to be useful
for the survival of other organisms. The third protein was spyM18_2004, containing a
PilT N-terminus (PIN) domain. PIN domains are found in all three kingdoms of life and
function in signalling and riboexonuclease activity (40, 98, 99).

Once again, it is

unknown how exactly this protein is used by S. pyogenes.
Lastly, two of the typical promoters had been selected for further study, the first being
spyM18_0771, a structural component of ΦSpeC. The exact function of spyM18_0771 is
unknown, however it is similar to Gp58, a minor structural protein from a Lactococcus
delbrueckii bacteriophage. While there was no activation from this promoter in vitro,
there only appeared to be a subpopulation of the in vivo group in which the promoter may
have been activated (Figure 2.10). Unpublished observations in our lab have shown the
spontaneous excision of ΦSpeC in vitro at the genetic level using PCR, and this
bacteriophage element can be induced using mitomycin C. Other groups have also shown
the production of active ΦSpeC upon co-culture with human pharyngeal cells (100). We
believe that during in vitro growth, the phage DNA may be recombining in and out of the
chromosome, but not progressing any further in the lytic phase. In vivo, an unidentified
signal may induce the phage, including structural components, allowing for the detection
of the spyM18_0771 promoter. Why only a certain number of cells seem to express the
phage in vivo could be due to microenvironments within the mouse cNT.
The second promoter selected for further testing was upstream of spyM18_0544, which
showed full in vivo activation (Figure 2.10). The spyM18_0544 gene encodes a putative
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bacteriocin-like peptide with 50% similarity to the blpM bacteriocin gene of S.
pneumoniae. While bacteriocins, in particular lantibiotics, have been characterized from
S. pyogenes, there are no reports to our knowledge of functional Class II bacteriocins
from this organism. As a human pathogen, virulence factors involved with the interaction
with the human body garner much more attention. However, when interacting with the
human host, S. pyogenes will encounter many other species of bacteria, some of which
are vying for the same space. The outcome of these interactions will also likely be
critical because failure to compete with the natural microbiota will also prevent
colonization from occurring. Further work on this mechanism is required to determine
how S. pyogenes might make use of this tool when colonizing.
The development of the RIVET system for the first time in S. pyogenes was a successful
endeavour that led to the identification of numerous in vivo-induced genes. RIVET was
able to identify not only just genes, but also potentially sRNA under the control of an
inducible promoter.

Although further validation is necessary, these promoters help

demonstrate the complex nature at which the chromosome and its elements are regulated
and how multifaceted the colonization process is at the molecular level. RIVET was able
to identify promoters from several different categories with many including metabolism
and virulence factors. One very interesting promoter identified was IVI156, controlling a
bacteriocin-like protein. A bacteriocin would make an important niche adaptation tool for
S. pyogenes as it may allow for the elimination of competing bacteria. Further research
will determine how S. pyogenes uses it as part of its colonization process.
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3.1 Introduction
3.1.1 Competition for the ideal niche
In nature, almost all microbes are found growing and interacting in complex systems,
however our knowledge of these networks still remains incomplete largely due to the
inability to culture the majority of microbial species (1). Living in symbiosis with the
human body are bacteria, archaea, viruses, fungi, and protists. These microbes growing
within us can be mutual (beneficial to both), commensal (beneficial to one, the other is
unaffected), or parasitic (one growing at the expense of the other) (2). The adult human
body is host to approximately 1014 cells within various niches, each home to multiple
species of bacteria (1-4). These microbes help maintain a healthy existence by promoting
differentiation of host tissues, liberating nutrients from unusable dietary substances,
stimulating the immune system, and importantly, protecting from invasion by pathogens
(5). Discussed earlier, the body defends against pathogens utilizing physical barriers,
antimicrobial peptides, and the complement and immune systems. In addition to this, the
microbiota creates an unfavourable environment or competes directly with pathogens, a
process referred to as “colonization resistance” (5, 6). However, sometimes a disruption
can occur within this homeostatic balance allowing an exogenous organism to colonize a
particular niche, which can be detrimental when this invader is a pathogen (7, 8).
Favourable niches on the human body where S. pyogenes is able to grow and survive are
the skin and pharynx, each having a unique environment and microbiota. In order to live
within a favourable habitat, bacteria possess mechanisms, or tools, in order to provide a
competitive advantage over other organisms. These include secondary metabolites such
as antibiotics, glycolipids, toxins, non-ribosomal antimicrobial peptides, and bacteriocins
(9-11). While S. pyogenes maintains an arsenal of virulence factors that target host
defences, the microbiota provide a different challenge. In Chapter 2, the use of the
RIVET system showed the activation of the bacteriocin gene spyM18_0544 when S.
pyogenes MGAS8232 was exposed to the nasopharynx of the mouse model. Use of a
bacteriocin may provide the ability for S. pyogenes to overcome colonization resistance
presented by the microbiota of the host. Further work shown here attempted to determine
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the role of this bacteriocin as a necessary tool for colonization by S. pyogenes.
3.1.1.1 The skin
The human skin has a large microbiota consisting of bacteria, viruses, and eukaryotic
organisms. It can be an inhospitable environment for many microbes due to the low pH,
lack of moisture, a temperature below that of 37°C, and the presence of antimicrobial
compounds such as fatty acids, peptides, and enzymes. In addition to this, the continual
sloughing of dead skin cells on the surface can also prevent bacteria from colonizing (2,
9, 12). The main organisms making up the microbiota on the skin consist of the genera
Corynebacterium,

Staphylococcus,

Propionibacterium,

Micrococcus,

Malassezia,

Brevibacterium, Dermabacter, and Acinetobacter (2, 11). These microbiota utilize many
methods to prevent pathogens such as S. pyogenes from colonizing. For example, S.
epidermidis produces antimicrobial peptides and Propionibacterium acnes produces fatty
acids, both that are harmful to S. pyogenes (13, 14). S. pyogenes can be found on the
skin, but it is often in a transient stage, and rarely part of the natural microbiota. In the
transient stage, S. pyogenes is unable to grow or multiply, therefore, leaving them unable
to colonize asymptomatically.

However, in some instances S. pyogenes is able to

disseminate in a local area to cause an infection (2, 8, 12, 15).
3.1.1.2 The oral cavity
The human oral cavity is a unique environment containing different areas such as the
teeth, gums, cheeks, tongue, hard and soft palate, tonsils, pharynx, and esophagus, each
having its own microbiota (9, 16). It is a moist environment, kept at a relatively constant
temperature between 34°C and 36°C, with most areas maintaining a pH close to neutral
(7, 17). The human mouth contains Archaea, amoeba, fungi, and bacteria with the most
common phyla in the pharynx being Firmicutes, Bacteroidetes, Proteobacteria,
Actinobacteria, and Fusobacteria (2, 3, 18, 19). Within the mouth, S. pyogenes colonizes
the tonsils within the nasopharynx and oropharynx and can be found asymptomatically
ranging from 5% to 10% of healthy adults and ranging as high as 20% in school children
during the winter months (20).

Within the oral cavity, S. pyogenes faces multiple

mechanisms of colonization resistance. Lactobacilli exist within the oral tract and the
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lactic acid produced by these bacteria has been shown to degrade the LTA of S. pyogenes
(7, 15). In addition, lactobacilli work indirectly by decreasing production of IL-17 and
IL-23 through the induction of TLR2/TLR4, preventing an inflammatory response and
decreasing the cytotoxic response and growth of S. pyogenes (21). Streptococcal species
also play an important role as they make up a large proportion, if not the majority, of the
oral microbiota (16-19). Multiple strains of Streptococcus oralis and S. salivarius were
able to show antagonistic properties against S. pyogenes. Planktonic S. oralis and S.
salivarius prevented the growth of S. pyogenes when grown together, possibly indicating
nutrient competition, while pre-treatment with either individually also reduced S.
pyogenes cell adhesion (8, 22). Similar to lactobacilli, S. salivarius strains also caused
immune modulation via a decrease in IL-6, TNF-α, and IL-1β, reducing the inflammatory
response (22). Finally, S. salivarius also possesses a bacteriocin with potent antibacterial
activity against S. pyogenes (8, 22). As demonstrated, the resident bacteria provide a
difficult obstacle to overcome for successful colonization by S. pyogenes. Therefore, the
production of an antimicrobial directly affecting the host microbiota, such as a
bacteriocin, could allow S. pyogenes to circumvent their defences and more easily
colonize.
3.1.2 Bacteriocins
Bacteriocins are ribosomally synthesized polypeptides that possess antibacterial activity.
Produced by both Gram-positive and Gram-negative bacteria, bacteriocins can be active
against single species or across genera (15, 21, 23, 24). Importantly, bacteria also possess
mechanisms making them immune to their own bacteriocins. Bacteriocins range in terms
of size, target, mode of action, and mechanism of immunity, with activity between nano
and picomolar concentrations (24-26).

It is estimated that upwards of 99% of the

Bacteria and Archaea have at least one bacteriocin, but extensive genome analyses would
be required to make this more accurate (24). Research on this area, particularly with
Gram-positives, has become more popular due to the realization that they are far more
prevalent than previously thought, and because they are proving to have useful
applications in several industries.
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3.1.2.1 Potential Uses
Since bacteriocins are potent antimicrobials they have potential commercial uses in
various fields. Bacteriocins with the broadest spectrum of activity, in most cases, are
hampered for commercial productivity due to poor solubility (27, 28).

In the food

industry, consumers demand products with minimal processing, lacking chemical
preservatives, yet still maintain a long shelf life.

Food-safe bacteria can produce

bacteriocins, typically lactic acid bacteria (LAB), which provide an alternative to
undesirable chemicals. These bacteriocins can potentially prevent the growth of both
pathogens and spoilage organisms (24, 29, 30). Bacteriocins can be introduced either
through the addition of starter cultures within food products, the addition of purified
bacteriocins, or using food products from the first method as an ingredient in another (30,
31). Bacteriocins have been approved in numerous countries for use in dairy foods,
meats, fermented and non-fermented vegetables, juices, canned vegetables, and others
(32).
Bacteriocins may also have potential as alternatives to antibiotics in order to combat the
growing problem of antibiotic resistant strains. The potential advantages of bacteriocins
includes 1) the current lack of widespread immunity, 2) the potential specificity prevents
the widespread destruction of the bacterial communities within the body, and 3)
bacteriocins possess a higher potency than antibiotics with little toxicity to human cells
(28). The bacteriocin nisin A has been demonstrated to be effective against methicillin
resistant S. aureus, and importantly, shows effectiveness against biofilms, normally
resistant to vancomycin (33).

E. faecalis resistant to vancomycin has also shown

susceptibility to bacteriocins (34). Furthermore, with animals in the food industry,
bacteriocins have been able to reduce the incidence of post weaning diarrhea in piglets,
therefore, improving growth, in addition to vastly reducing the population of
Campylobacter jejuni in chickens, and in another instance, increasing the overall growth
rate of chickens while reducing the number of Bacteroides and Enterobacteriacae (32).
Despite having little toxicity to normal eukaryotic cells, some bacteriocins have shown to
have anti-neoplastic potential (32). Numerous bacteriocins including microcins, pyocins,
pediocins, and colicins have all shown activity against cancer cells derived from humans
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and various animals (35). Interestingly, bacteriocins still seem to have a specific cell
target range they affect much like their bacterial target. While their activity against
bacterial targets is understood in some cases, how they are able to inhibit eukaryotic cells
has not been established (8, 22, 35, 36).
3.1.2.2 Bacteriocin Classification
Gram-positive bacteriocins are divided into groups in a system first created by
Klaenhammer (37). Over the years this classification system has been changed and
debated as the number of bacteriocins has increased, as well as the knowledge of their
form and function. Based on the beginning of Klaenhammer’s system, the most agreed
upon division consists of three groups: (I) Lantibiotics are bacteriocins that derive their
name from the addition of unusual amino acids such as lanthionine, β-methyllanthionine,
and dehydrated residues. Produced as prepropeptides, they undergo post-translational
modification by specific enzymes to modify these residues. A final enzyme cleaves the
signal peptide during secretion of the mature peptide. Smaller than 5 kDa, lantibiotics are
peptides that are active against the target cell membrane. Various groups have subdivided
lantibiotics based on structure, enzymes used for modification, modified residues, and/or
conserved sequences, however, there does not appear to be any sort of consensus. The
most well-known and researched lantibiotic is nisin, produced by L. lactis. (II) Class II
bacteriocins are small heat-stable, membrane active, non-lanthionine peptides that are less
than 10 kDa. The vast majority are produced in an immature form containing a signal
sequence, which is cleaved at the double glycine (Gly-Gly) processing site upon
secretion, producing the active form. Class II bacteriocins are predicted to form a β-sheet
structure, with amphiphilic helices containing differing amounts of hydrophobicity, and
an overall moderate to high heat stability (100-121°C). Class II bacteriocins can also be
further subdivided based on structure. Class IIa contain the pediocin-like bacteriocins,
such as pediocin PA-1, that include a group of Listeria-active peptides that possess an Nterminal consensus sequence of -Tyr-Gly-Asn-Gly-Val-Xaa-Cys-. Class IIb bacteriocins
are made up of two peptides for activity (labelled α and β), with lactococcin G (Lcn G) as
the first found and best studied. Class IIc bacteriocins are peptides that are made circular
by the covalent linking of the N- and C- termini and Class IId bacteriocins consists of
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single, linear, non-pediocin peptides including those that are leaderless, sec-dependent or
otherwise, without an assigned class. Further subdividing has been considered due to the
different peptides involved. The Class III bacteriocins consist of large heat-labile
proteins, greater that 30 kDa, and are divided into lytic proteins (Class IIIa) and non-lytic
proteins (Class IIIb). Examples include lysostaphin and helveticin J, respectively (25, 32,
38-40). Some groups have suggested the reclassification of class III bacteriocins to
bacteriolysins since they are deemed lytic enzymes rather than peptides (24, 38). There
has also been some debate of the existence of peptides containing non-proteinaceous
moieties and therefore the addition of a Class IV. This includes antimicrobial peptides
requiring post-translational cysteine S-glycosylation for function, but some groups argue
that they are S-linked glycopeptides and not bacteriocins (41-43). Further research is
required in order to determine whether or not this could represent another class of
bacteriocins. While each class has a unique method of action, immunity, and control,
specifically Class IIb will be specifically looked at further since the putative bacteriocin
genes identified via RIVET were consistent with a Class IIb bacteriocin.
3.1.2.3 Class IIb mechanism of action
All known Gram-positive bacteriocins function by disrupting the membrane of their
target (32, 44). Class IIb bacteriocins are typically effective against a narrow range of
targets, many staying within the same species (45-47). This specificity seems to be
determined predominately by residues within the N-terminus of the peptides, with the βpeptide seeming especially important (48, 49). The best-known Class IIb bacteriocin is
Lcn G of L. lactis. Lcn G is made up of two distinct amphiphilic helical peptides (Lcn-α
and Lcn-β) that must be present in a ratio of approximately 1:1 for activity (28, 50-53).
The presence of GxxxG motifs on both peptides allows the formation of a parallel
transmembrane helical-helical structure with the residues 1 to 13 of Lcn-α aligning with
the residues 14 to 24 of Lcn-β. This structure is perpendicular to the membrane, creating
a pore (32-34, 50, 53-56). The pore allows the flux of potassium, sodium, and other
monovalent cations, with the exception of protons. This causes depletion in ATP pools as
the cell attempts to maintain osmotic balance, eventually leading to the dissipation of
membrane potential and cell death (51, 52). Recently, a probable receptor for Lcn G on
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L. lactis target cells was found as undecaprenyl pyrophosphate phosphatase (UppP).
UppP is a membrane spanning protein that was expressed in cells sensitive to Lcn G.
When UppP was no longer expressed, normally sensitive L. lactis cells become resistant.
However, the exact involvement of UppP in Lcn G pore formation has yet to be
elucidated (57).
3.1.2.4 Class IIb immunity
Self-immunity to Class IIb bacteriocins such as Lcn G is achieved using a single
immunity gene (58). These immunity proteins lack a signal sequence and have been
shown to be present in the membrane and the cytoplasm (35, 59, 60). Through the use of
hybrid experiments it was shown that it is not the toxicity itself that triggers the
immunity, but recognition of the bacteriocin. Based on the knowledge of Class IIa
bacteriocins, it is speculated that Lcn G binds to its receptor, presumably UppP, creating a
conformational change and inducing membrane leakage.

The immunity protein is

thought to recognize the bacteriocin-receptor complex where it can bind to prevent further
leakage (37, 57, 61, 62).
3.1.2.5 Class IIb expression and control
Two-peptide bacteriocins can be found constitutively expressed by some strains while
others are transcriptionally regulated by quorum-sensing systems.

Quorum sensing

systems are composed of an induction peptide (IP), a histidine protein kinase (HPK), and
a response regulator (RR), with the last two collectively known as a two-component
system (24, 38, 43, 45). The IPs, also known as pheromones, are small, unmodified
peptides ranging from 19 to 24 amino acids containing an N-terminal secretion signal that
is recognized by the same export machinery as the bacteriocin it controls (63).
Pheromones allow the cell to measure its density within the environment and respond
accordingly by triggering the expression of genes through the two-component system
(64). During initial growth, the pheromone, its required transporter, and two-component
system are expressed at a low constitutive level. When the pheromone reaches the
threshold level, it triggers activity of the two-component system (autoinduction) through
binding to the outer cell membrane bound HPK (45, 64, 65).

Inducing an
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autophosphorylation event on a conserved histidine residue on the cytoplasmic side of the
protein, this phosphate is then transferred to the cytoplasmic RR. This changes the
conformation of the RR allowing for a direct interaction with the binding sites of
associated promoters, consisting of two repeated sequences separated by a spacer, leading
to massive expression of the bacteriocin and associated genes, as well as more
pheromone, two-component system, and transporter (45, 65). Transcription occurs for a
certain amount of time until, due to an unknown mechanism, the genes are downregulated causing expression to revert to basal levels (64).
3.1.3 Bacteriocins of S. pyogenes
Identified by creating a zone of inhibition of an agar plate, it was first discovered in 1949
that a small number of S. pyogenes possessed antimicrobial activity (31, 66). It was not
until many decades later this inhibitory zone was identified as the lantibiotic streptococcin
A-FF22 (SA-FF22) (41, 67, 68). SA-FF22 showed no activity against Gram-negative
strains, but was active against a wide range of Gram-positive strains including S.
agalactiae, Streptococcus equi, Streptococcus cremoris, L. lactis, Bacillus cereus, and B.
subtilis (69, 70). Production of SA-FF22 requires the chromosomally encoded operon
scnKRAA’MTFEG, which consists of a two-component system (scnKR), the lantibiotic
(scnA), modification and transport enzymes (scnMT), and an immunity complex
(scnFEG). Presently there is no known function of scnA’. Production of the lantibiotic
begins as a prepropeptide of 51 amino acids and after modification and cleavage of the
leader sequence, export results in a final 26 amino acid peptide. A similar lantibiotic was
also isolated from M49 strains of S. pyogenes showing only minor differences in amino
acid sequences (27, 69, 71).
S. pyogenes also produces another less well-characterized lantibiotic called streptin.
Streptin is active against a wide range of Gram-positive species such as L. lactis, S.
pneumoniae, S. salivarius, Streptococcus sanguis, Actinomyces species, and Clostridium
species, among others. Streptin showed no activity against a wide range of Gramnegative species with Prevotella intermedia being the only exception (27, 51, 52, 57, 69,
72, 73). Production of streptin is required by the operon srtIRKATCBFEG located on the
chromosome. While the process is similar of SA-FF22, streptin utilizes three genes for
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modification and secretion (srtTCB) and also possesses an additional gene involved in
immunity (srtI) (7, 73). While there has also been some thought that the streptin operon
is also involved in streptolysin S formation, other groups have shown no link, indicating
that more research in that area is required (7, 58, 73, 74).
S. pyogenes can also produce a Class III bacteriocin termed streptococcin A-M57 (SAM57) that is encoded on the 3.3 kb plasmid pDN571. Represented by the gene scnM57,
the only other gene appearing on the plasmid is repA for replication, indicating that all
other required genes must be chromosomally encoded. It is believed that SA-M57 is
produced as a prepeptide and secreted by a Sec-dependent transport system to yield a
mature peptide of 16.9 kDa. An immunity protein has not yet been identified. While it
has not been tested with a large number of organisms for activity, SA-M57 has shown
activity against S. epidermidis, M. luteus, L. lactis, and Actinomyces species, to name a
few. There has been no activity against any Gram-negative species to date (9, 75-77).
While bacteriocins are not highly characterized within the S. pyogenes species, they do
seem to be actively present and could potentially provide an additional advantage when
colonizing a niche. In Chapter 2, spyM18_0544 was identified as being induced in S.
pyogenes MGAS8232 by an unidentified signal while colonizing the upper respiratory
tract of humanized mice. This gene represents a putative bacteriocin, which is likely part
of a larger operon including the necessary components.

Bacteriocins represent an

interesting antimicrobial that is possessed by many bacteria and may help in colonization.
We hypothesized that spyM18_0544 (herein referred to as blpM), and the downstream
operon, represents a functional bacteriocin system that S. pyogenes uses for colonization
of the nasopharynx.
3.2 Materials and Methods
3.2.1 Bacterial strains
All strains used are shown in Table 3.1 and grown as previously described in 2.2.1.
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Table 3.1: Bacterial strains used in this study
Name

Genotype

Reference

E. coli XL1Blue
S. pyogenes
MGAS8232
S. pyogenes
Δblp
S. pyogenes
Cas2

recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F ́
proAB lacIqZ∆M15 Tn10 (tetR)]
isolated 1987, M18 serotype, 1.895 Mb, NC_003485.1

Stratagene, USA

MGAS8232 with the blp operon deleted from the
chromosome
MGAS8232 containing the loxP-tetR-tk-loxP cassette
within the chromosome

This study

(81)

This study
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3.2.2 Reagents
The silCR (DIFKLVIDHISMKARKK) (78, 79) and control (FAKDIISKLVIRMHDKK)
peptides were synthesized by Biomatik Corporation (Cambridge, Ontario, Canada) and
resuspended in Milli’Q water to 10 mg mL-1.
scrambling

the

amino

The control peptide was created by

acids

(http://users.umassmed.edu/ian.york/Scramble.shtml).
transcarboxyirane-2-carbonyl)-L-Leucyl]-agmatine

present

in

Inhibitors
(E-64)

silCR
N-[N-(L-3-

and

4-(2-

Aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) (Sigma-Aldrich, Oakville,
Ontario, Canada) and prepared in Milli’Q water at 1 mM and 1 M, respectively.
3.2.3 Bioinformatics
The genome of S. pyogenes MGAS8232 has been sequenced and annotated
(NC_003485.1) (80, 81). ORFs were found in DNA sequences using ORF Finder
(http://www.ncbi.nlm.nih.gov/projects/gorf/).
aligned

using

ClustalW

Both DNA and protein sequences were
Multiple

Sequence

Alignment

(http://www.ebi.ac.uk/Tools/msa/clustalw2/). Proteins were compared using BLASTp
from NCBI (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Promoter elements were found using
SoftBerry

prediction

of

bacterial

promoters

(http://linux1.softberry.com/berry.phtml?topic=bprom&group=programs&subgroup=gfin
db).
3.2.4 in vitro activation of the blpM promoter
MGAS8232 Cas2 containing IVI156 was grown overnight in THY media containing erm
and tet as previously described. Cells were subcultured into fresh THY erm along with
the silCR peptide (10 µg mL-1) or the control peptide (10 µg mL-1), and with and without
the protease inhibitor E-64 (10 µM) or AEBSF (1 mM). After 24 h, 1 mL of culture was
taken, serially diluted 10-fold, and plated on THY erm, with and without tet. For qRTPCR, a sample was taken at 6 h and processed as described in 2.2.15 for RNA extraction
and 2.2.16 for qRT-PCR
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3.2.5 Creation of the Δblp mutant
All PCR primers and plasmids used are listed in Table 3.2. PCR was used to amplify a
500 bp portion of the chromosome upstream of blpM, as well as a 500 bp portion of the
chromosome downstream of spyM18_0547. Products were purified utilizing a QIAquick
PCR Purification Kit (Qiagen, Toronto, Ontario, Canada) according to the manufacturer’s
instructions. The upstream portion, along with pG+host5, was digested using PstI and
SalI, purified, and ligated using the same method found in 2.2.5. After confirming the
intermediate clone via sequencing, it was then digested with SalI and BamHI, along with
the downstream fragment. The fragments were purified, ligated, and transformed as
previously described. The final clone, pG+host5::Δblp (Table 3.2) was confirmed via
sequencing and transformed into MGAS8232 to undergo chromosomal recombination as
described in 2.2.10.
3.2.6 in vitro and in vivo competition experiments
Wild-type MGAS8232 and MGAS8232 Δblp were grown overnight in THY,
concentrated, and frozen at -80°C. A small portion was serially diluted 10 fold and plated
to calculate CFUs. MGAS8232 and MGAS8232 Δblp were warmed to room temperature
for 30 min and mixed 1:1 based on CFU counts. For in vitro experiments, a 1%
inoculation was grown in 10 mL of THY broth and grown for 24 h, which was chosen to
mimic the actual growth period in vivo. For in vivo experiments, 108 CFUs from the 1:1
mixture were used to inoculate mice as described in 2.2.20. Following harvesting of the
nasal passages at 48h, a sample was serially diluted 10 fold and plated to calculate CFUs
and the remainder was frozen at -80°C. Fifty colonies from each in vivo inoculation were
plated on THY, numbered, and 20 colonies were picked based on a random number
generator (www.randomizer.org/form.htm). Each colony was grown overnight in THY,
total DNA was extracted, and PCR was used to determine if the colony was wild-type or
Δblp based on the presence or absence of the blp operon using primers listed in Table 3.2.
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Table 3.2: Primers and plasmids used in this study
Primer Name

Sequence 5' to 3'a

Restriction Site

blp up for

GCGCTGCAGTCATCTTAGTGACTTTTACTGTC
GG
GCGGTCGACAAGAACAGTATCCTGGTTTCAA
AA
GCGGTCGACCCTCACTAAATATATAAATGAC
TATCTATCACTG
GCGGGATCCTAGAATCACTGCAGAAATAATA
ACAATACC

PstI

Notes

Source/Reference

blp up rev
blp down for
blp down rev

Plasmid Name
+

pG host5
+

pG host5:: Δblp

R

erm temerature sensitive shuttle vector
+

pG host5 containing the construct used to delete the
bacteriocin and immunity protein from the S.
pyogenes MGAS8232 genome
a
-restriction sites underlined

SalI
SalI
BamHI

(82)
This study
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3.3 Results
3.3.1 Bioinformatic analysis of the blp operon
Following the sequencing of the in vivo-induced promoter within clone IVI156,
downstream sequences in MGAS8232 were analyzed. IVI156 contained a nucleotide
sequence immediately upstream of the gene spyM18_0544.

Previously found in S.

H

pyogenes JS95, this genes has been labelled as blpM (9, 83) (Figure 3.1) due to its
similarity to blpM, a gene encoding the first peptide of a Class IIb bacteriocin system in S.
pneumonia (Figure 3.2). The blpMH gene was 228 bp, and encoded a theoretical peptide
of 75 amino acids (Figure 3.2). As mentioned earlier, Class II bacteriocins utilize
double-glycine type leader sequences for export (27, 84) and based on the location of the
double glycine sequence in blpMH, a mature BlpMH peptide of 52 amino acids with a
leader sequence of 23 amino acids was predicted (Figure 3.2).
As a putative Class IIb bacteriocin, a second peptide would be required for activity (27,
85, 86). Immediately downstream of blpMH was spyM18_0545, also annotated as a
bacteriocin peptide.

Utilizing the nomenclature derived from de Saiziew et al. and

Hidalgo-Grass et al., this second gene was designated as blpNH (Figure 3.1) (9, 27).
blpNH had a predicted ORF of 201 bp encoding a theoretical peptide of 66 amino acids
with similarity to BlpN of S. pneumoniae. Once again, based on the location of the
double glycine sequence, BlpNH was predicted to consist of a mature peptide of 48 amino
acids with a leader sequence of 18 amino acids (Figure 3.2).
Also present on both BlpMH and BlpNH are four and five GxxxG motifs, respectively,
which allow for helix-helix interactions between the two peptides to create a membrane
penetrating structure (27, 55). Since the Class IIb bacteriocins require both peptides for
activity, this bacteriocin will herein be referred to as BlpMNH. The use of BLASTp
indicated that BlpMNH was widespread in virtually all fully sequenced strains of S.
pyogenes, with similarities of 97% and above. However, two notable exceptions were
found in MGAS5005 and SF370. While BlpNH was still 97% homologous or above for
both strains, BlpMH was truncated in MGAS5005 and had less than 30% similarity in
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Figure 3.1: The blp operon and sil locus of S. pyogenes MGAS8232
The sequence contained within clone IVI156 is indicated above the gene map. The blp
operon consisted of a Class IIb bacteriocin (blpMNH) along with the potential immunity
genes spyM18_0546 and spyM18_0547. The sil locus is composed of a two-component
system (silAB), the signaling peptides silC and silCR, and an ABC transport system
(silDE). silD is truncated due to a missing nucleotide and is split into two genes, the
second being spyM18_0541

silA%

428226&

silB%
silCR%

spyM18_0541%

silC%

silD%

silE%

434717&

spyM18_0547%

435443&

blpMH% blpNH% spyM18_0546%

clone&IVI156&

433733&
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Figure 3.2: BlpMNH and BlpMN sequences
Leader sequences are separated from mature peptides at the double glycine (indicated by
arrow). GxxxG highlights this motif found in Class IIb bacteriocins.

mature peptide

S. pneumoniae BlpN

S. pyogenes BlpNH
H

*

H

H

*+ +*** ***** **

+*

*

+*

+*

********

+ ************

* *

+

++ + ** *+ * **+

**

* *+*+ *+

*

*

+*

*

** ***

MNTYCNINETMLSEVYGG NSGGAAVVAALGCAAGGVKYGKILGPWGAAIGGIGGAVVCGYLAYTATS

MTTMKELTINDMASISGG NAPGDAVIGGLGGLASGLKFCKLPHPVLAGGCVVGFTVGGAYLGYTAN

* +* **+* *

MNTKMMEQFHEMDIAMLSSIEGG KNNWQTNVFEGGSAAFGGWGLGTAICAASGVGAPFMGACGYIGAKFGVALWAGVTGATGGF

↓

S. pneumoniae BlpMH

leader

MEIKKLETFHQMTIEKLAKVEGG KNNWQANVSGVIAAGSAGAAIGFPVCGV---------ACGYIGAKTAITLWAGVTGATGGF

S. pyogenes BlpMH
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SF370. Finally, further comparison of BlpMNH indicated that it was also present within
several other streptococcal species including Streptococcus dysgalactiae, S. equi, and
Streptococcus uberis.
Bacteriocin systems also require an immunity gene, which is typically found downstream
from the bacteriocin structural genes. Downstream from blpNH was a potential ORF
annotated as spyM18_0546, predicted to encode a 33 amino acid peptide (Figure 3.1).
Using BLASTp, the peptide was found in some strains of S. pyogenes (e.g.
SPYJRS4_0399) and S. dysgalactiae subsp. equisimilis, (SDE12394_02605), however, it
was found to be of 69 amino acids in length. Alignment was only found for the first 25
amino acids of the N-terminus between spyM18_0546, SPYJRS4_0399, and
SDE12394_02605 (Figure 3.3). Comparison of the nucleotide sequence showed one less
adenine nucleotide within the transcription region of spyM18_0546, alternating the
reading frame, and potentially creating a premature stop codon (Figure 3.3). This peptide
could potentially be an immunity protein, although its function remains unknown.
Further downstream was spyM18_0547, theoretically encoding a peptide of 42 amino
acids that could also potentially function as a bacteriocin immunity protein (Figure 3.1).
BLASTp analysis showed spyM18_0547 to be well conserved within 30 S. pyogenes
strains, such as HSC5 (L897_02190). However, spyM18_0547 may actually be truncated,
as the most common predicted size is a 64 amino acid peptide found in over 130 strains,
including common studied strains such as SF370 (spy_0486). Comparison of the peptide
and nucleotide sequences of spyM18_0547, L897_02190, and spy_0486 showed the loss
of a single adenine base pair within the coding sequence of spy_0486, upstream from the
start codon of spyM18_0547 and L897_02190 (Figure 3.4). This peptide potentially
produces an immunity protein as well, though the correct sequence and the corresponding
sequence is once again unknown. The predicted blp operon DNA sequence and matching
peptides is represented in Figure 3.5.
3.3.2 Bioinformatics of the regulation and transport of BlpMNH
In addition to the bacteriocin structural and immunity genes, Class IIb bacteriocins also
require dedicated transporters, and additionally, often encode proteins involved in
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Figure 3.3: Comparison of spyM18_0546 DNA and protein sequences from various
strains
spyM18_0546 is shown to have a premature stop codon (starting at base pair 100) due to
the loss of a single adenine nucleotide (should be base pair 77) when compared to the
same peptide from S. pyogenes JS94 (SPYJRS4_0399) and S. dysgalactiae subsp.
equisimilis ATCC 12394 (SDE12394_02605). Base pair numbers are indicated on the
right.
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spyM18_0546
SPYJRS4_0399
SDE12394_02605

spyM18_0546
SPYJRS4_0399
SDE12394_02605

spyM18_0546
SPYJRS4_0399
SDE12394_02605

spyM18_0546
SPYJRS4_0399
SDE12394_02605

ATGATCTATACGATTTTTATTATTATGAATGCGTCTATAATGTTTTTAATCATTGTTGAT
M I Y T I F I I M N A S I M F L I I V D
ATGATCTATACGATTTTTATTATTATGAATGCGTCTATAATGTTTTTAATCATTGTTGAT
M I Y T I F I I M N A S I M F L I I V D
ATGATCTATACGATTTTTATTATTATGCATGCGTCTATAATGTTTTTAATGATTGTTGAT
M I Y T I F I I M H A S I M F L M I V D

60
60
60

GCCATTCATAAAAAAA-TGTTGATAAATCTATACCATATTTAGTGTTTTTAATTTTCAAT 119
A I H K K
M L I N L Y H I * - - - - - GCCATTCATAAAAAAAATGTTGATAAATCTATACCATATTTAGTGTTTTTAATTTTCAAT 120
A I H K K N V D K S I P Y L V F L I F N
GCCATTCATAAAAAAAATGTTGATAAATCTATACCATATTTAGTGTTTTTAATTTTCAAT 120
A I H K K N V D K S I P Y L V F L I F N
CAATTATCCCTTTCGGAAAAATCGGTAAACATGTTATCTATCGTAGCTTTGGTAGCGTCA 179
- - - - - - - - - - - - - - - - - - - CAATTATCCCTTTCGGAAAAATCGGTAAACATGTTATCTATCGTAGCTTTGGTAGCGTCA 180
Q L S L S E K S V N M L S I V A L V A S
CAATTATCCCTTTCGGAAAAATCGGTAAACATGTTATCTATCGTAGCTTTGGTAGCGTCA 180
Q L S L S E K S V N M L S I V A L V A S
TTATTTGTTTTTATCGATAAAAGAAAATAG 209
- - - - - - - - - TTATTTGTTTTTATCGATAAAAGAAAATAG 210
L F V F I D K R K *
TTATTTGTTTTTATCGATAAAAGAAAATAG 210
L F V F I D K R K *
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Figure 3.4: Comparison of spyM18_0547 DNA and protein sequences from various S.
pyogenes strains
spyM18_0547 and L897_02190 are annotated with a start codon further downstream in
comparison to others such as spy_0846. In addition, spy_0846 is missing a single adenine
nucleotide (base pair 18) within its coding region. Base pair numbers are indicated on the
right.
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spyM18_0547
L897_02190
spy_0486

spyM18_0547
L897_02190
spy_0486

spyM18_0547
L897_02190
spy_0486

spyM18_0547
L897_02190
spy_0486

ATGGAAGTGCTAAAAAAATGGTCTGACTATCATAAATGGAGGCGGAAAAGACGGAGCAAA
- - - - - - - - - - - - - - - - - - - ATGGAAGTGCTAAAAAAATGGTCTGGCTATCATAAATGGAGGCGGAAAAGACGGAGCAAA
- - - - - - - - - - - - - - - - - - - ATGGAAGTGCTAAAAAA-TGGTCTGGCTATCATAAATGGAGGCGGAAAAGACGGAGCAAA
M E V L K N
G L A I I N G G G K D G A N

60
60
59

TATCTTTTTGACAGGGATGGCAGGTGCTGCGCAGGGAGTGACAGTTTGTGCTCAGACAGG 120
- - M T G M A G A A Q G V T V C A Q T G
TATCTTTTTGACAGGGATGGCAGGAGCTGCGCAGGGAGTGACAGTTTGTGCTCAGACAGG 120
- - M T G M A G A A Q G V T V C A Q T G
TATCTTTTTGACAGGGATGGCAGGTGCTGCGCAGGGAGTGACAGTTTGTGCTCAGACAGG 119
I F L T G M A G A A Q G V T V C A Q T G
CGTATTTATCCCTTGGCAAGGTTATATTTTGTGTGGAGCAGCTGGTGCTGCTACAAATAT 180
V F I P W Q G Y I L C G A A G A A T N I
CGTATTTATCCCTTGGCAAGGTTATATTTTGTGTGGAGCAGCTGGTGCTGCTACAAATAT 180
V F I P W Q G Y I L C G A A G A A T N I
CGTATTTATCCCTTGGCAAGGTTATATTTTGTGTGGAGCAGCTGGTGCTGCTACAAATAT 179
V F I P W Q G Y I L C G A A G A A T N I
TATCTGGCCTCACTAA 196
I W P H *
TATCTGGCCTCACTAA 196
I W P H *
TATCTGGCCTCACTAA 195
I W P H *
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Figure 3.5: The blp operon sequence in S. pyogenes MGAS8232
The DNA and predicted amino acid sequences encoded within the blp operon of
MGAS8232. The nucleotide and translation products for the blp locus are given below for
the indicated region with corresponding nucleotide numbers as annotated in the S.
pyogenes MGAS8232 genome sequence. Directions of the ORFs are indicated by arrows.

141
←silE
AACAAATGTTTTTCGATAGGATATCATTTGTAAAAGACCTTTCTATTAAATACTAAGCTA
V F T K R Y S I M

434260

TTATGACATATATATAGGGAGTTTTTATCAAAAATCTTAAAAGGTATTTATAAAAGCATG

434320

AATGGTATCATTTAAACTTCTTAATTAATTAACTATTGTCACAGCGTAAGTGTAGAGAGG

434380

ATAAAAAGACATTTCATGATGAAAAATAGCCTTTTAAGATTTTGAAACCAGGATACTGTT

434440

CTTTATGATATTCTGTACTAGCTCGAGGTTGCAACGAGACAAATTTAAGAATTATGAAAA

434500

spyM18_0544(blpMH)→
GAAGTTATTCGATATGGAGATAAAGAAACTGGAAACATTTCACCAAATGACTATAGAAAA
M E I K K L E T F H Q M T I E K

434560

GCTTGCCAAGGTTGAGGGTGGTAAGAATAATTGGCAGGCAAATGTCAGTGGGGTTATCGC
L A K V E G G K N N W Q A N V S G V I A

434620

TGCAGGTAGTGCTGGAGCTGCTATAGGTTTTCCAGTTTGCGGTGTAGCCTGTGGTTATAT
A G S A G A A I G F P V C G V A C G Y I

434680

TGGAGCTAAAACAGCTATTACTCTTTGGGCTGGTGTAACAGGAGCTACAGGCGGCTTCTA
G A K T A I T L W A G V T G A T G G F *
spyM18_0545(blpNH)→
GAGGAAAGAAAGGATGACAACAATGAAGGAATTAACAATTAATGACATGGCTAGTATAAG
M T T M K E L T I N D M A S I S

434740

TGGAGGAAACGCTCCAGGAGATGCTGTAATTGGTGGTCTTGGAGGCTTAGCTTCTGGATT
G G N A P G D A V I G G L G G L A S G L

434860

GAAATTTTGTAAACTGCCACATCCAGTATTGGCAGGTGGATGTGTTGTAGGATTTACAGT
K F C K L P H P V L A G G C V V G F T V
spyM18_0546→
TGGTGGAGCATATTTGGGATATACAGCAAATTAAATGATCTATACGATTTTTATTATTAT
G G A Y L G Y T A N * M I Y T I F I I M

434920

GAATGCGTCTATAATGTTTTTAATCATTGTTGATGCCATTCATAAAAAAATGTTGATAAA
N A S I M F L I I V D A I H K K M L I N

435040

TCTATACCATATTTAGTGTTTTTAATTTTCAATCAATTATCCCTTTCGGAAAAATCGGTA
L Y H I *

435100

AACATGTTATCTATCGTAGCTTTGGTAGCGTCATTATTTGTTTTTATCGATAAAAGAAAA

435160

TAGTGATTATGCCAATGAATTTAGATATCACTCTTAGCTTTTTAAAATACAAAAGAGTGA

435220

AATTAAAATGAAAAAGACTTCAAAAATATGGAAGTGCTAAAAAAATGGTCTGACTATCAT

435280

spyM18_0547→
AAATGGAGGCGGAAAAGACGGAGCAAATATCTTTTTGACAGGGATGGCAGGTGCTGCGCA
L T G M A G A A Q

435340

GGGAGTGACAGTTTGTGCTCAGACAGGCGTATTTATCCCTTGGCAAGGTTATATTTTGTG
G V T V C A Q T G V F I P W Q G Y I L C

435400

TGGAGCAGCTGGTGCTGCTACAAATATTATCTGGCCTCACTAAATATATAAATGACTATC
G A A G A A T N I I W P H *

435460

TATCACTGATATATAAGTAGTAGAGGAGTGGTATGAAAATTTTAGATATTATTTTTAACC

435520

434800

434980
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regulation of the system. Upstream of blpMH in MGAS8232 was a group of genes that
correspond to the streptococcal invasion locus (sil) (9). The sil locus is comprised of an
ABC transporter (silDE), a pheromone (silCR), a peptide (silC), and a two-component
system (silAB) (Figure 3.1). While its exact purpose is unknown, the sil locus has been
shown to be important for invasive infections (9, 63, 64, 76) and can regulate BlpMNH
and its associated immunity protein (7).
MGAS8232 encodes a full-length silE predicted to produce a 717 amino acid ATPbinding cassette transporter according to BLASTp results.

However, silD and

spyM18_0541 appear to be truncated portions of a complete 454 amino acid SilD, which
works in conjunction with SilE to make a complete ABC-binding cassette transporter.
Analysis of the nucleotide sequence revealed that a missing adenine caused early
termination of MGAS8232 silD and spyM18_0541 appears to encode the C-terminus of
silD (7, 9, 11) (Figure 3.6).
In MGAS8232, further upstream of the putative bacteriocin transporters were silC and
silCR, overlapping each other by 91 bp (7, 9), creating peptides of 39 and 41 amino acids,
respectively (Figure 3.1). SilCR contains pheromone characteristics such as a doubleglycine type secretion signal, creating a mature peptide of 17 amino acids, and an RKK
motif at the C-terminus (9, 11). On the other hand, the peptide SilC appears to lack any
secretion signal or leader sequence indicating it may function in the cytoplasm. BLASTp
analysis of SilCR indicated 100% identity with other S. pyogenes strains encoding the sil
locus, except JS95, which contains a single mutation changing the start codon from ATG
to ATA (9, 78). While silC was not annotated on the MGAS8232 genome, the correct
DNA sequence was present and 100% identitcal to silC in S. pyogenes strains IB7 and
JS95, and S. dysgalactiae subsp. equisimilis strains GGS1800 and N3.
Finally, the two-component histidine kinase and response regulator, encoded by silB and
silA, respectively, were encoded adjacent to the silCR/silC genes (Figure 3.1). Once
again, BLASTp analysis indicated nearly 100% identity between MGAS8232 and the S.
pyogenes strains that encode the sil locus. One exception was silB of JS95 that contains a
short range of 11 different amino acids, seemingly unique to JS95.
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Figure 3.6: The DNA and protein sequence of silD and spyM18_0541
Comparison of silD and spyM18_0541 of MGAS8232 with silD of JS95. The loss of an
adenine nucleotide (base pair 479 in MGAS8232) creates a premature stop codon in
MGAS8232 silD (starting at base pair 580). ORF spyM18_0541 is the C-terminus of silD
starting at base pair 747 and finishing at the proper stop codon of silD. Large stretches of
identical sequence were removed (indicated by ……). Base pair number is indicated on
the right.
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8232 silD
JS95 silD

8232 silD
JS95 silD

8232 silD
JS95 silD

8232 silD
JS95 silD

ATGAATCCAAACCTTTTTAAAAGTGCGGAATTTTATCATCGACGTCATCATAACTTTGCA……
M N P N L F K S A E F Y H R R H H N F A ……
ATGAATCCAAACCTTTTTAAAAGTGCGGAATTTTATCATCGACGTCATCATAACTTTGCA……
M N P N L F K S A E F Y H R R H H N F A ……
……ACGTTTAATCATTTTCTCAAACAAACCCAAGATATAATCATTGGGTTTGCTAAAAAAA-T
……T F N H F L K Q T Q D I I I G F A K K M
……ACGTTTAATCATTTTCTCAAACAAACCCAAGATATAATCATTGGGTTTGCTAAAAAAAAT
……T F N H F L K Q T Q D I I I G F A K K N
GCTGAAGTCAATAATCAAGCAAGTCTTGCTAATCATGCCATTTCAGTTATTACTAGTCAG
L K S I I K Q V L L I M P F Q L L L V S
GCTGAAGTCAATAATCAAGCAAGTCTTGCTAATCATGCCATTTCAGTTATTACTAGTCAG
A E V N N Q A S L A N H A I S V I T S Q

JS95 silD

60

479
480

539
540

CTTGACGAACTTCATCAAAAAATTACAGATTATGAAGAGCTAAAGCGAGCTATTAATAAT…… 599
L T N F I K K L Q I M K S * - - - - - -……
CTTGACGAACTTCATCAAAAAATTACAGATTATGAAGAGCTAAAGCGAGCTATTAATAAT…… 600
L D E L H Q K I T D Y E E L K R A I N N ……

spyM18_0541 ……CAAAATATCTCAGAACTTGAATCTTCAATGGCAAACCTTAGTATCCAACGTGCTAGTACA
…… - - - - - - - - - M A N L S I Q R A S T
JS95 silD
……CAAAATATCTCAGAACTTGAATCTTCAATGGCAAACCTTAGTATCCAACGTGCTAGTACA
…… Q N I S E L E S S M A N L S I Q R A S T
spyM18_0541

60

779
780

GGAAATTTATCTCTTCCAGACACTAGTCATAGGATCAAAATAGATATTTTAAAAACACAA…… 839
G N L S L P D T S H R I K I D I L K T Q ……
GGAAATTTATCTCTTCCAGACACTAGTCATAGGATCAAAATAGATATTTTAAAAACACAA…… 840
G N L S L P D T S H R I K I D I L K T Q ……

spyM18_0541 ……TATTTCAATTACTATAAAGATAAGATACTCAACAGTTTTAATTAA 1364
…… Y F N Y Y K D K I L N S F N *
JS95 silD
……TATTTCAATTACTATAAAGATAAGATACTCAACAGTTTTAATTAA 1365
…… Y F N Y Y K D K I L N S F N *
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Regulation of the sil locus is thought to occur through the expression of silC and silCR.
Expression of silC causes suppression of two operons to very low levels: silE/D/CR and
blpMH/NH/spy_0586 (7, 80). However, once SilCR reaches its threshold level, it activates
SilA via SilB, to initiate expression of the blpMH/NH/spy_0586 and silE/D/CR operons,
causing suppression of silC.

Once SilCR levels decline back to normal levels,

suppression by SilC will once again occur (7, 83). Interestingly, silAB seems to show
little to no response to SilCR, but has demonstrated activity when exposed to decreased
temperature or H2O2 (7, 27, 76). silC is also under the control of its own promoter,
though how either silAB or silC is regulated is still unknown.
It was then proposed that the promoter for blpMH, identified in vivo by the RIVET system,
was under control of SilAB from the sil locus. Examination of the DNA region between
silE and blpMH showed the -35 and -10 regions of both promoters, predicted using online
software (Figure 3.7). Also present were the direct repeats for both blpMH (DR2) and
silE (DR1), the DNA region to which the response regulator SilA binds in order to
regulate expression, originally found by Belotserkovsky et al. in strain S. pyogenes JS95
(27). DR1 and DR2 contain a repeat consensus sequence of ACCTTT[T/C]A[T/A]G
(Figure 3.7). When comparing direct repeat sequences between strains, it was found that
the spacer for DR2 in MGAS8232 was only 10 bp, while this spacer was 11 bp in JS95
(Figure 3.8). Comparing the repeat sequences of numerous S. pyogenes strains showed
that both spacer sizes are present for DR2; with the 10 bp spacer present in strains
MGAS8232, SF370, MGAS5005, and Manfredo, with the 11 bp spacer present in strains
JS95, HSC5, and MGAS315 (Figure 3.8). The spacer for DR1 appears to be 11 bp for all
strains presented.
3.3.3 in vitro activation of blpM
Once the components of the sil locus and blp operon were identified, the ability of SilCR
to induce the system was first tested. Cas2 transformed with the IVI156 plasmid was
grown in THY erm containing either the synthesized SilCR peptide, or a scrambled
peptide control. Cells were plated at various time points and activation of the blp operon
promoter was monitored though the loss of tet resistance. Despite testing at various
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Figure 3.7: Promoter regions of blpMH and silE from S. pyogenes MGAS8232
The underlined and italicized sequences show the predicted -35 and -10 regions of blpMH
and silE. A boxed letter indicates transcription start site with an arrow pointing in the
direction of transcription. Direct repeat pairs for the silE/D/CR (DR1) and blp (DR2)
operons are bolded and labeled as left (L) and right (R) on either side of the
corresponding spacer region according to the direction of transcription.

Consensus

sequence of the repeat sequence is shown below with DR1 sequences shown in reverse
complement to match DR2. Final consensus sequence: ACCTTT[T/C]A[T/A]G.
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←silE

↰

E

TTTTTCGATAGGATATCATTTGTAAAAGACCTTTCTATTAAATACTAAGCTATTATGACA
-10
DR1R

spacer

DR1L

TATATATAGGGAGTTTTTATCAAAAATCTTAAAAGGTATTTATAAAAGCATGAATGGTAT
-35

CATTTAAACTTCTTAATTAATTAACTATTGTCACAGCGTAAGTGTAGAGAGGATAAAAA
DR2L

spacer

DR2R

GACATTTCATGATGAAAAATAGCCTTTTAAGATTTTGAAACCAGGATACTGTTCTTTAT
↱

-35

-10

GATATTCTGTACTAGCTCGAGGTTGCAACGAGACAAATTTAAGAATTATGAAAAGAAGT
blpMH→

TATTCGATATGGAGATAAAGAAACTGGAAACATTTCACCAAATGACTATAGAAAAGCTT
Consensus
DR1L ACCATTCATG
DR1R ACCTTTTAAG
DR2L ACATTTCATG
DR2R GCCTTTTAAG
5’-ACCTTTYAWG-3’
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Figure 3.8: Spacer comparison between S. pyogenes strains
Direct repeat pairs for the silE/D/CR (DR1) and blp (DR2) operons are bolded and
labeled as left (L) and right (R) on either side of the corresponding spacer region
according to the direction of transcription.

DR1R
spacer
DR1L
ATCAAAAATCTTAAAAGGTATTTATAAAAGCATGAATGGTATCATTTAAACTTCTT-ATTAATTAACTATTGTCACAG
ATCAAAAATCTTAAAAGGTATTTATAAAAGCATGAATGGTATCATTTAAACTTCTTAATTAATTAACTATTGTCACAG
ATCAAAAATCTTAAAAGGTATTTATAAAAGCATGAATGGTATCATTTAAACTTCTTAATTAATTAACTATTGTCACAG
ATCAAAAATCTTAAAAGGTATTTATAAAAGCATGAATGGTATCATTTAAACTTCTTAATTAATTAACTATTGTCACAG
ATCAAAAATCTTAAAAGGTATTTATAAAAGCATGAATGGTATCATTTAAACTTCTTAATTAATTAACTATTGTCACAG
ATCAAAAATCTTAAAAGGTATTTATAAAAGCATGAATGGTATTATTTAAACTTCTTA----ATTAACTATTGTCACAG
ATCAAAAATCTTAAAAGGTATTTATAAAAGCATGAATGGTATCATTTAAACTTCTTAATTAATTAACTATTATCACAG
****************************************** *************
**********.******

DR2L
spacer
DR2R
CGTAAGTGTAGAGAGGATAAAAAGACATTTCATGATGAAAAA-TAGCCTTTTAAGATTTTGAAACCAGGATACTGTTC
CGTAAGTGTAGAGAGGATAAAAAGACATTTCATGATGAAAAAACGGCCTTTTAAGATTTTGAAGCCATGATACTGTTC
CGTAAGTGTAGAGAGGATAAAAAGACATTTCATGATGAAAAA-TAGCCTTTTAAGATTTTGAAACCATGATACTGTTC
CGTAAGTGTAGAGAGGATAAAAAGACATTTCATGATGAAAAA-TAGCCTTTTAAGATTTTGAAACCATGATACTGTTC
CGTAAGTGTAGAGAGGATAAAAAGACATTTCATGATGAAAAAACGGCCTTTTAAGATTTTGAAGCCATGATACTGTTC
TGTAAGTGTAGAGAGGATAAAAAGACATTTCATGATGAAAAAACAGCCTTTTAAGATTTTGAAACCATGATACTGTTC
CGTAAGTGTAGAGAGGATAAAAAGACATTTCATGATGAAAAA-CAGCCTTTTAAGATTTTGAAACCATGATACTGTTC
*****************************************
******************.*** **********

MGAS8232
JS95
M1
MGAS5005
HSC5
MGAS315
Manfredo

MGAS8232
JS95
M1
MGAS5005
HSC5
MGAS315
Manfredo
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concentrations, SilCR failed to produce any detectable activation after 24 h (unpublished
data). Reasoning that proteases could potentially be destroying the peptides in vitro the
experiment was subsequently attempted with the addition of the cysteine protease
inhibitor E-64, yet after 24 h all colonies remained tet resistant. Next, a serine protease
inhibitor, AEBSF, was attempted after it was found that blocking the serine protease HtrA
in S. pneumoniae caused an increase in blpMN (29, 86). However, treatment of cells with
AEBSF had no effect (unpublished data). Numerous other methods rather than the
synthetic peptides were attempted including HLA-DR4/DQ8 mouse cNT homogenate,
growth with human peripheral blood mononuclear cells, human neutrophils, and human
serum, in an attempt to create the required environment, yet all failed to activate blpMH in
vitro (unpublished data). Thus, despite all the different methods attempted, the blp
operon could not be activated in vitro.
3.3.4 MGAS8232 wild-type and Δblp competitive in vivo analysis
In order to test the impact of BlpMNH in vivo, a knockout was created to delete the entire
blp operon, designated MGAS8232 Δblp. Used to inoculate HLA-DR4/DQ8 mice as
before, Δblp was mixed 1:1 with MGAS8232 wild-type in a competition model. The
recovered bacteria were plated and 20 colonies were randomly picked and identified as
Δblp or MGAS8232 via PCR. As a control, the experiment was also repeated with
mixtures grown in vitro for 24 h to mimic the cell densities that are reached in vivo.
Growth in vitro appeared to show a slight shift to the wild-type, but still showing a wildtype:Δblp ratio percent averaging 56.7:43.3 (Figure 3.9), demonstrating that the blp
operon is likely not important for in vitro growth. Surprisingly, when wild-type:Δblp was
grown in vivo, the four of the seven mice returned only or predominantly wild-type, while
the remaining returned ratios of wild-type:Δblp in roughly equal numbers (Figure 3.9)
While not the expected result, it seemed to show that lack of the blp operon provided a
disadvantage in vivo against wild-type and that activation of the operon may not always
occur or else cells in vivo may exist in different locations.
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Figure 3.9: Competition between wild-type S. pyogenes MGAS8232 and MGAS8232
Δblp
Wild-type and Δblp were mixed 1:1 and either grown overnight in vitro (N=7) or using
the nasopharyngeal infection model in HLA-DR4/DQ8 mice (N=7). Cells were plated on
THY agar and gDNA was isolated from random colonies and subjected to PCR analysis
to identify cells as either wild-type or Δblp.

152

Percent Survival

100

WT
Δblp

80
60
40
20
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3.4 Discussion
S. pyogenes is an important human pathogen that utilizes the upper respiratory tract and
the skin as the most common reservoirs of its host. Research on this organism generally
focuses on the virulence factors S. pyogenes possess in order to overcome the physical
and immunological defenses of the human body. However, another important part of the
human body is the resident bacteria. These bacteria create a competitive environment that
potentially makes it difficult for invading bacteria to survive (31). Therefore, a tool such
as a bacteriocin could be advantageous for pathogens in order to colonize. While the
bacteriocins used by pathogens seems to receive little attention, E. coli, S. pneumoniae,
Haemophilus influenzae, and Streptococcus mutans have all demonstrated an improved
ability to colonize when compared to bacteriocin-negative controls (64, 87). S. pyogenes
has only been shown to express bacteriocins in a handful of strains and they have
received little notice. Using an upper respiratory tract model, this research is the first of
our knowledge to demonstrate the in vivo activation of a Class IIb bacteriocin in S.
pyogenes and the colonization advantage it may provide.
Based on our results, it appeared that MGAS8232 possessed the bacteriocin BlpMNH,
followed immediately downstream of blpNH by the two ORFs spyM18_0546 and
spyM18_0547, one likely being the required immunity protein (Figure 3.1). Based on
sequence analysis, BlpMNH possessed the requirements of a Class IIb bacteriocin
including GxxxG motifs and a double glycine for separation of the leader sequence from
the mature peptide (Figure 3.2). More recent work in the McCormick laboratory has
been able to demonstrate a functional ex vivo BlpMNH bacteriocin, showing L. lactis with
sensitivity to the combined recombinant BlpMH and BlpNH peptides. Furthermore, L.
lactis was resistant to the antimicrobial activity of BlpMNH when expressing a fragment
that included both spyM18_0546 and spyM18_0547 (McCormick laboratory, unpublished
data). Which ORF encodes the immunity gene has yet to be determined. Furthermore,
this also provides data towards identifying the targets of BlpMNH. Class IIb bacteriocins
are typically effective against a narrow range of targets, many staying within the same
species (45-47, 66). Susceptibility of L. lactis may suggest a wider range of targets than
expected. Determination of further BlpMNH targets could be determined simply by
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testing strains for susceptibility. Likely candidates would be other streptococcal strains
and in particular, those found within the oral cavity such as S. salivarius, S. mitis, S.
oralis, S. gordonii, S. mutans, or S. pneumoniae (41).
Upstream of blpMH are the genes that make up the sil locus (Figure 3.1). While blpMNH
seems to be widely found among virtually all S. pyogenes strains, sil only seems to be
encoded in ~12-25% of the isolates tested (70, 88). Additionally, the locus does not
appear to be functional in all isolates. Sequencing sil+ strains for deletions, frameshifts,
and mutations in the silCR, silC, and silD, Plainvert et al. found that only 56% of strains
appeared to have a functional sil locus based on sequence (69). Furthermore, there
seemed to be no link between the presence of sil and invasive status (27, 69). Plainvert et
al. also found functional sil on both invasive and non-invasive strains at 30% and 28%,
respectively (27, 69). Other groups, including Jing et al. and Billal et al. also found sil+
strains in both invasive and non-invasive strains (89, 90). In fact, the presence of sil
seemed to be more related to emm type, with common types being emm4, emm87,
emm90, emm94, and emm118 (69, 88). The emm type also gave a general indication as to
whether or not sil was functional within the strain. For example, emm87 appeared to be
functional based on sequence nearly 100% of the time, while emm14 (JS95) nearly
always had ATA as a silCR start codon, and emm4 and emm18 are known to have a
truncated silD (69, 79, 88).
Control of sil has demonstrated to be controlled through a regulatory circuit consisting of
silC and silCR (7). When off, SilC represses the blp operon as well as an operon
consisting of the transporters (silDE) and silCR. However, threshold level of SilCR
allows these operons to be turned on, with the expression of silCR interfering with silC
due to the large portion of overlapping sequence (7).

Indeed, the effect has been

identified several times with invasive in vivo models. Starting with JS95 and HSC5,
neither expressing silCR naturally, loss of silC demonstrated the loss of virulence
potential (9, 76) and the addition of exogenous SilCR showed a reduction in virulence
and lesion size (78). While in vitro, ΔsilC showed a reduction in biofilm formation (80)
and the addition of SilCR demonstrated a reduced transcription of spyCEP (83). In
addition, using microarray, it was found that 46 genes were altered with the addition of
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SilCR (27). Nearly half (18 genes) were involved with metabolism, seven had a function
involved with gene regulation, and interestingly, sagA (SLS) transcription was also
increased. Furthermore, sagA transcription was also increased by the addition of SilCR in
a sil- strain, demonstrating that SilCR activates more than just the sil locus and blp operon
(27, 86) Exactly how SilC is able to repress its targets, and any other genes it may
control, has yet to be elucidated.
Upstream of silC is the AlgR/AgrA/LytR family transcription regulator silAB that is
thought to activate the bacteriocin genes as well as the associated transporter genes. The
response regulator, SilA, binds via the LytR-type domain as a dimer to the DNA site
made up of two nine bp direct repeats, [T/A][A/C][C/A]GTTN[A/G][T/G], separated by a
spacer that seems to vary in length (7, 27, 91).

Based on the sequence found by

Belotserkovsky et al. in strain JS95, which included an additional tenth nucleotide, the S.
pyogenes MGAS8232 direct repeat followed the consensus almost exactly at
ACCTTT[C/T]A[T/A]G (Figure 3.7) (27). Belotserkovsky et al. had concluded that the
S. pyogenes pattern was made up of ten nucleotides since modification of the tenth
nucleotide (guanine) showed a detrimental effect to the promoter (27).
Also shown to be important for proper activation is the AT-rich spacer length between
repeats, typically ranging from 10-13 bp (92, 93). The length of this spacer has shown to
be important, as changes such as losing a single nucleotide has shown to have detrimental
effects to expression (27, 55, 94-96). Belotserkovsky et al. showed S. pyogenes JS95 to
have a spacer of 11 bp and that expression was lost when modified to a length of 10 or 12
bp (27). As shown in Figure 3.8, the spacer region of DR2 is 10 or 11 bp depending on
the strain, with MGAS8232 having a 10 bp spacer.

Based on the evidence from

Belotserkovsky et al., this spacer would prevent SilA from binding to DR2, and therefore
prevent transcription of the blp operon.
Assembling the sil locus system within MGAS8232 leads to two major shortfalls. The
truncated silD implies that neither SilCR nor BlpMNH could be secreted. However, the
initial identification of PblpM, and subsequent repetition experiments in vivo, indicated that
the promoter portion identified in pIVI156 was activated in vivo (Figure 2.10).

If

BlpMNH activation did occur by SilA binding, SilCR secretion would have been required,
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indicating that one or both of the silD truncations (Figure 3.1) could form with SilE to
create a working transporter, or alternatively, a different transporter system was used.
However, the failure of blpMNH activation in vitro through the addition of exogenous
SilCR would suggest that activation did not occur through the sil locus. In addition to
SilCR, other potential environmental stimuli also failed to activate the blp operon
including HLA-DR4/DQ8 mouse cNT homogenate, human peripheral blood mononuclear
cells, human neutrophils, and human serum (unpublished data).
While blpMNH could not be activated in vitro, we tested its impact using the in vivo
model known to activate it. A surprising almost ‘all or none’ type of response was
recovered after inoculation by a 1:1 mix with roughly half going either way. In one half,
the ratio recovered between wild-type and Δblp was nearly even, suggesting that blpMNH
was not activated, and therefore, not important for colonization (Figure 3.9). The other
half seemed to demonstrate an activation of the blp operon since there was little to no
Δblp strain recovered (Figure 3.9). It is thought that the MGAS8232 wild-type present
was exposed to the correct environmental stimuli to cause expression of the blp operon,
eliminating Δblp due to the lack of an immunity protein. Why stimulation occurred only
in half of the mice is unknown and continued work will attempt to identify the
environmental condition activating the blp operon. However, this in vivo work does
suggest that while blpMNH is unlikely to be regulated by the sil locus due to SNPs, the
lack of Δblp in some instances would suggest that blpMNH is able to regulate and
transport through another system.
Colonizing the pharynx, S. pyogenes must make a ‘space’ for itself in order to obtain
nutrients and grow against a plethora of other bacteria. Specifically, on the human body
as a host, free nutrients can be limited, causing many different bacteria to attempt to
colonize the same niche. Therefore, bacteriocins provide a powerful tool that could be
used by S. pyogenes, as well as other pathogens, to aid in the colonization process. This
research represents the first attempt to determine the use of the Class IIb bacteriocin
BlpMNH by S. pyogenes when colonizing a nasopharyngeal model. While it seemed that
blpMNH was not under control of sil, it could explain why blpMNH remains within nearly
all strains while functional sil seems to be in such a small percentage. Although the
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mechanism that causes the activation of blpMNH in MGAS8232 still needs to be
established, it appears to be functional, providing a potential mechanism to help
outcompete bacteria also striving for the pharynx of the human host.
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S. pyogenes is a well known pathogen that is responsible for over 500 000 deaths worldwide each year.

While much is known about S. pyogenes pathogenesis, how this

organism is able to successfully attach, colonize, and compete within the human pharynx
remains incomplete (1, 2). This is due to the fact that a large number of factors exhibit
overlapping functions, creating a complex system that is difficult to dissect. In order to
further solve this problem, information needs to be gathered at a genomic level to
evaluate how S. pyogenes alters gene regulation within specific environments. Numerous
methods exist, each having their own advantages and setbacks. In this research, RIVET
was successfully used for the first time with S. pyogenes, to identify genetic elements that
were specifically induced during the entire colonization process of the nasopharyngeal
humanized mouse model.
4.1 Chapter 2 Conclusions
RIVET was chosen due to its ability to detect gene induction activity throughout the
entire infection period, as opposed to alternative methods that capture results at specific
time points. In addition, since each recovered RIVET clone is sequenced, even those
from microenvironments within the model can still be identified. Part of the secondgeneration RIVET system was the use of counter-selection, and while this was attempted
with the use of HSV-tk and ganciclovir, it unfortunately proved too unreliable to pursue.
Despite this set back, patching to identify tet sensitive clones was still successfully
performed to identify 9 potential ‘typical’ promoters, demonstrating a functional system
(Table 2.4).
In the past decade there has been a surge in the increase of sRNA found in bacterial
chromosomes with increasing questions about their role in biological systems and precise
mechanisms of action (3). Several methods have been used in order to identify sRNA in
bacteria including bioinformatics, microarrays, RNA-seq, and RIVET. sRNA may be
better identified in RIVET since they are not locked to a specific algorithm as with
bioinformatics and may experience fewer overall artifacts due to the absence of a cDNA
synthesis step as in microarrays and RNA-seq (3-5).

Potentially, sRNA for three

interesting virulence factors, mga, speA, and mf3, was found utilizing the RIVET system.
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These virulence factors have shown states of repression during the late growth phases of
animal models, presumed to be transitioning to the persistent state (6, 7). It is possible
that S. pyogenes makes use of sRNA as a mechanism of tight repression of these genes, as
well as others, in response to precise in vivo conditions. Many other potential sRNA
candidates were also identified by the RIVET system and have yet to be explored more
thoroughly to identify possible roles in colonization.
When considering ‘typical’ promoters that appeared to control the expression of genes,
three of these, pyruvate formate-lyase, tagatose-6-phosphate aldose/ketose isomerase, and
a polar amino acid ABC transporter are all suggestive of genes being active in an
environment where nutrients are scarce, such as the nasopharynx (8-13). The functions of
the remaining genes identified by RIVET are less obvious due to the limited amount of
available information and their potential role in the colonization process. However,
further verification with clone IVI156 revealed a promoter for the bacteriocin-like gene
spyM18_0544 (blpMH) with consistently induced in vivo activity (Figure 2.10). This lead
to further work to identify how blpMH was used by S. pyogenes in the colonization
process.
4.2.1 Future Work
The promoters identified through RIVET represent potential genetic elements
contributing to the overall adaptation of S. pyogenes when colonizing the nasopharynx in
order to survive. Confirming true in vivo activation through further testing via the RIVET
method or qRT-PCR is the first step in deciphering their role in the colonization process.
In addition to this, further investigational analysis of remaining recovered clones could be
performed in order to identify more in vivo induced promoters.
Continued development of RIVET within S. pyogenes could also successfully make use
of other methods to facilitate a post-in vivo selection screening method in the same vein
as counter-selection. One potential method is the inclusion of a fluorescent marker under
the control of a constitutive promoter within the cassette. This would allow the use of
FACS to identify those cells without the cassette after the in vivo selection. Other groups,
for example, have taken a cassette containing a single antibiotic resistance marker and
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inserted it after the first codon of a second resistant marker causing it to be split, losing
expression of the gene. Resolution of the cassette allowed for the reassembly of the split
gene and the activation of a new antibiotic resistance (14, 15). Lastly, the recessive
nature and streptomycin resistance of rpsL could be exploited. This would require the
addition of the wild-type MGAS8232 rpsL into the cassette, while the chromosomal rpsL
would be mutated, as found in S. pyogenes JRS4, to create a base streptomycin resistance.
When both rpsL versions are present in the same cell the resistant version is recessive
and, therefore, only loss of the cassette allows for streptomycin resistance (16, 17). The
successful addition of one of these systems would allow for a far more efficient screening
process and a greatly improved RIVET system in S. pyogenes.
4.2 Chapter 3 Conclusions
Found to be a Class IIb bacteriocin, blpMH would require blpNH for bacteriocidal activity
and the associated immunity protein for self-survival (Figure 3.1). To our knowledge,
this is the first time blpMNH has been shown to be activated in vivo under biological
conditions. Within MGAS8232, we also believe blpMNH can be under the control of a
regulatory system other than sil. This stems from the inability of wild-type MGAS8232
to respond to the SilCR pheromone in vitro or growth in many ex vivo conditions, yet can
eliminate MGAS8232 Δblp from the correct in vivo environment (Figure 3.9).
S. pyogenes must be able to outcompete endogenous bacteria already present whithin the
human body (13, 26-28). In spite of this, few species of S. pyogenes are known to
express bacteriocins, and none have been shown to express Class IIb, or make use of a
bacteriocin to promote in vivo survival (18-25).

Bacteriocins and their use against

pathogens is an increasing area of research due to its potential as an antibiotic alternative
(29). Yet, their use by the pathogens themselves as another virulence factor for gaining
access to its ideal niche does not appear to be an area of active research. Deciphering
how S. pyogenes may make use of bacteriocins for niche adaptation is a fascinating area
of potential research and could have impacts on our knowledge of other human
pathogens.

Since we are still at the beginning stages, many questions still remain

concerning regulation, immunity, and secretion of blpMNH during the colonization
process of S. pyogenes.

Continued research will ultimately increase our overall
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knowledge of how S. pyogenes, and possibly other pathogens, interact with the
microbiota of the human body when attempting to colonize and cause infection.
4.2.1 Future Work
A necessary part of the bacteriocin system is an immunity protein. Recent work from our
group using functional experiments has identified an immunity phenotype within a
fragment containing both spyM18_0546 and spyM18_0547. Similar experiments can be
repeated with smaller portions of this fragment to identify the coding region responsible
for immunity function. The immunity protein, along with blpMNH, likely makes up the
entire operon regulated by the promoter identified by IVI156 with the RIVET system.
Further work is also critical in determining the method of secretion for BlpMNH. It is
first necessary to determine if the present silE, silD, and spyM18_0541 are responsible for
the secretion of BlpMNH. It may be possible to express both bacteriocin and transporter
from a plasmid under the control of an inducible promoter (such as pMSP3535) within a
heterologous host such as L. lactis. One possibility is that the truncated silD is not
required, as the secondary transport protein has been shown to be unnecessary for at least
one Class IIb bacteriocin, and possibly others (30). Should silE not be the transporter,
further searching through the use of bioinformatics may be used to identify a potential
source for further testing.
Finally, the lack of induction via SilCR would suggest regulation through a different
system. However, attempting to decipher how blpMNH and its immunity protein are
regulated may be difficult. Should regulation occur by the binding of a protein to the
DNA region upstream of blpMNH, whether as part of a two-component system or another
regulatory system, pull down assays with in vivo grown MGAS8232 cell lysates, for
example, could be performed using the known DNA sequence attached to beads as bait.
Mass spectrometry could then be used to identify any separated proteins. Identification of
this regulator would be necessary to determine the activation process of blpMNH within
the nasopharynx.
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4.3 Overall Conclusions
Utilizing the RIVET method in order to identity promoters involved with the colonization
process by S. pyogenes has laid the foundation for numerous areas of research to pursue.
Adjustments to the RIVET system used with S. pyogenes could improve its efficiency and
applicability for analysis in other environments such as human blood or saliva, or in
models of necrotizing fasciitis or other invasive diseases.

A fascinating potential

colonization-promoting mechanism used by S. pyogenes identified via RIVET is through
the use of bacteriocins. Interest in bacteriocins has increased significantly in the past ten
years, especially in LAB, due to the potential use of bacteriocins as an antibiotic
alternative in both clinical and food industry settings (31). However, the bacteriocins of
pathogens, used as virulence factors, have not yet received much attention. The few
studies represented have demonstrated the importance of bacteriocins with S. pneumoniae
(32) and S. mutans (33) in order to colonize their preferred niche, validating their
importance. Identifying the activation of bacteriocins, through this work, by S. pyogenes
during colonization also contributes to this idea. Ascertaining when these bacteriocins
are expressed, along with the bacteria they target, may provide important information as
to how pathogens such as S. pyogenes cause disease and may aid in identifying improved
ways to inhibit or prevent their colonization and reduce the global burden.

171
4.4 References
1.
2.

3.
4.
5.

6.
7.

8.

9.
10.
11.
12.
13.
14.
15.
16.

Cunningham MW. 2000. Pathogenesis of group A streptococcal infections. Clin
Microbiol Rev 13:470.
Walker MJ, Barnett TC, McArthur JD, Cole JN, Gillen CM, Henningham A,
Sriprakash KS, Sanderson-Smith ML, Nizet V. 2014. Disease manifestations
and pathogenic mechanisms of group a Streptococcus. Clin Microbiol Rev 27:264–
301.
Thomason MK, Storz G. 2010. Bacterial antisense RNAs: how many are there,
and what are they doing? Annu Rev Genet 44:167–188.
Silby MW, Rainey PB, Levy SB. 2004. IVET experiments in Pseudomonas
fluorescens reveal cryptic promoters at loci associated with recognizable
overlapping genes. Microbiology (Reading, Engl) 150:518–520.
Holt JF, Kiedrowski MR, Frank KL, Du J, Guan C, Broderick NA, Dunny
GM, Handelsman J. 2014. Enterococcus faecalis 6-phosphogluconolactonase is
required for both commensal and pathogenic interactions with Manduca sexta.
Infection and Immunity.
Kreikemeyer B, McIver KS, Podbielski A. 2003. Virulence factor regulation and
regulatory networks in Streptococcus pyogenes and their impact on pathogen–host
interactions. Trends in Microbiology 11:224–232.
Virtaneva K, Porcella SF, Graham MR, Ireland RM, Johnson CA, Ricklefs
SM, Babar I, Parkins LD, Romero RA, Corn GJ, Gardner DJ, Bailey JR,
Parnell MJ, Musser JM. 2005. Longitudinal analysis of the group A
Streptococcus transcriptome in experimental pharyngitis in cynomolgus macaques.
Proc Natl Acad Sci USA 102:9014–9019.
Yamamoto Y, Sato Y, Takahashi-Abbe S, Takahashi N, Kizaki H. 2000.
Characterization of the Streptococcus mutans pyruvate formate-lyase (PFL)activating enzyme gene by complementary reconstitution of the in vitro PFLreactivating system. Infection and Immunity 68:4773–4777.
Hu Z, Patel IR, Mukherjee A. 2013. Genetic analysis of the roles of agaA, agaI,
and agaS genes in the N-acetyl-D-galactosamine and D-galactosamine catabolic
pathways in Escherichia coli strains O157:H7 and C. BMC Microbiol 13:94.
Lei B, Liu M, Chesney GL, Musser JM. 2004. Identification of new candidate
vaccine antigens made by Streptococcus pyogenes: purification and
characterization of 16 putative extracellular lipoproteins. J Infect Dis 189:79–89.
Livezey J, Perez L, Suciu D, Yu X, Robinson B, Bush D, Merrill G. 2011.
Analysis of group A Streptococcus gene expression in humans with pharyngitis
using a microarray. Journal of Medical Microbiology 60:1725–1733.
Wilson M. 2008. Bacteriology of humans: an ecological perspective. John Wiley
& Sons.
Wilson M. 2005. Microbial inhabitants of humans. Cambridge University Press.
Sawicki JA, Monks B, Morris RJ. 1998. Cell-specific ecdysone-inducible
expression of FLP recombinase in mammalian cells. Biotech 25:868–70– 872–5.
Gersbach CA, Gaj T, Gordley RM, Barbas CF. 2010. Directed evolution of
recombinase specificity by split gene reassembly. Nucleic Acids Research
38:4198–4206.
McIver KS, Myles RL. 2002. Two DNA-binding domains of Mga are required for

172

17.
18.
19.
20.

21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.

virulence gene activation in the group A Streptococcus. Molecular Microbiology
43:1591–1601.
Reyrat JM, Pelicic V, Gicquel B, Rappuoli R. 1998. Counterselectable markers:
untapped tools for bacterial genetics and pathogenesis. Infection and Immunity
66:4011.
Sherwood NP, Russell BE, Jay AR, Bowman K. 1949. Studies on streptococci.
III. New antibiotic substances produced by beta hemolytic streptococci. J Infect
Dis 84:88–91.
Tagg JR, Wannamaker LW. 1976. Genetic basis of streptococcin A-FF22
production. Antimicrobial Agents and Chemotherapy 10:299–306.
Hynes WL, Ferretti JJ, Tagg JR. 1993. Cloning of the gene encoding
streptococcin A-FF22, a novel lantibiotic produced by Streptococcus pyogenes,
and determination of its nucleotide sequence. Applied and Environmental
Microbiology 59:1969–1971.
Tagg JR, Read RS, McGiven AR. 1973. Bacteriocin of a group A Streptococcus:
partial purification and properties. Antimicrobial Agents and Chemotherapy
4:214–221.
Hynes WL, Friend VL, Ferretti JJ. 1994. Duplication of the lantibiotic structural
gene in M-type 49 group A Streptococcus strains producing streptococcin A-M49.
Applied and Environmental Microbiology 60:4207–4209.
Hynes WL, Tagg JR. 1985. Production of broad-spectrum bacteriocin-like
activity by group A streptococci of particular M-types. Zentralbl Bakteriol
Mikrobiol Hyg A 259:155–164.
Wescombe PA, Tagg JR. 2003. Purification and characterization of streptin, a
type A1 lantibiotic produced by Streptococcus pyogenes. Applied and
Environmental Microbiology 69:2737–2747.
Simpson WJ, Tagg JR. 1983. M-type 57 group A Streptococcus bacteriocin. Can
J Microbiol 29:1445–1451.
Lemon KP, Klepac-Ceraj V, Schiffer HK, Brodie EL, Lynch SV, Kolter R.
2010. Comparative analyses of the bacterial microbiota of the human nostril and
oropharynx. MBio 1:1–9.
Gao Z, Kang Y, Yu J, Ren L. 2014. Human pharyngeal microbiome may play a
protective role in respiratory tract infections. Genomics, Proteomics &
Bioinformatics 12:144–150.
Aas JA, Paster BJ, Stokes LN, Olsen I, Dewhirst FE. 2005. Defining the normal
bacterial flora of the oral cavity. J Clin Microbiol 43:5721–5732.
Cavera VL, Arthur TD, Kashtanov D, Chikindas ML. 2015. Bacteriocins and
their position in the next wave of conventional antibiotics. Int J Antimicrob
Agents.
Vaughan A, Eijsink VGH, van Sinderen D. 2003. Functional characterization of
a composite bacteriocin locus from malt isolate Lactobacillus sakei 5. Applied and
Environmental Microbiology 69:7194–7203.
Perez RH, Zendo T, Sonomoto K. 2014. Novel bacteriocins from lactic acid
bacteria (LAB): various structures and applications. Microb Cell Fact 13 Suppl
1:S3.
Dawid S, Roche AM, Weiser JN. 2007. The blp bacteriocins of Streptococcus
pneumoniae mediate intraspecies competition both in vitro and in vivo. Infection

173
33.

and Immunity 75:443–451.
Hillman JD, Dzuback AL, Andrews SW. 1987. Colonization of the human oral
cavity by a Streptococcus mutans mutant producing increased bacteriocin. J Dent
Res 66:1092–1094.

174
APPENDICES
Appendix 1: Animal ethics approval

175
Appendix 2: Clones recovered using RIVET
Clone

Designation

IVI1

Size
(bp)
96

IVI3

129

cryptic

IVI4

244

cryptic

IVI7a

214

cryptic

IVI7b

178

antisense

IVI11

71

antisense

IVI14a

853

antisense

IVI14b

108

cryptic

IVI14c

57

cryptic

IVI15

64

cryptic

IVI16

113

intergenic

antisense

Region in
Genome
1741745 to
1741840
1713341 to
1713213
570003 to
570246
912892 to
912679
1152397 to
1152574
214459 to
214389
640829 to
639977
873659 to
873766
147131 to
147075
1725608 to
1725671
751419 to
751307

Gene
designation
spyM18_2077

Features

spyM18_2050

spyM18_1380

putative PTS system, enzyme II,
A component
putative ATP-dependent DNA
helicase
putative thiamine biosynthesis
lipoprotein precursor
putative uridine kinase

spyM18_0239

hypothetical protein

spyM18_0802

SagC, hypothetical protein

spyM18_1051
spyM18_0155

putative D,D-carboxypeptidase,
penicillin-binding protein
hypothetical protein

spyM18_2064

mitogenic exotoxin Z precursor

spyM18_0916

546 bp at 5' side: putative
peptidoglycan hydrolase
655 bp at 3' side: N-terminal
fragment of Sib38 homolgue
hypothetical protein

spyM18_0710
spyM18_1098

spyM18_0921
IVI17a

312

antisense

IVI17b

162

antisense

IVI19

232

antisense

IVI22

320

cryptic

IVI23a

151

cryptic

IVI23b

44

cryptic

IVI24

514

cryptic

IVI26a

296

cryptic

IVI26b

298

cryptic

IVI27

417

antisense

IVI28a

107

antisense

IVI28b

78

cryptic

IVI29a

107

antisense

positive regulatory protein Mga

1546687 to
1546998
678000 to
677839
1491691 to
1491460
1271790
to 1271471

spyM18_1868

1601103 to
1601253
1010750 to
1010707
136555 to
137068
1073889 to
1073594
1482683 to
1482388
721697 to
721281
677377 to
677271
986273 to
986197
591092 to
590986

spyM18_1926

putative undecaprenyl-PPMurNAc-pentapeptideUDPGlcNAc GlcNAc
conserved hypothetical protein

spyM18_1202

conserved hypothetical protein

spyM18_0144

V-type Na+ -ATPase subunit I

spyM18_1498

hypothetical phage protein

spyM18_1793

hypothetical phage protein

spyM18_0890

putative pyrimidine regulatory
protein
putative ATP-dependent
exonuclease, subunit A
putative sugar ABC transporter
(permease protein)
hypothetical phage protein

spyM18_0836
spyM18_1806
spyM18_1541

spyM18_0836
spyM18_1177
spyM18_0742

putative ATP-dependent
exonuclease, subunit A
hypothetical phage protein

176
IVI29b

105

antisense

IVI29c

38

cryptic

IVI30

161

intergenic

1231877 to
1231981
539410 to
539447
1640515 to
1640355

spyM18_1488

hypothetical phage protein

spyM18_0676

putative cell division protein

spyM18_1973

spyM18_1763

73 bp at 5' side: conserved
hypothetical protein
117 bp at 3' side: putative type I
site-specific deoxyribonuclease
73 bp at 5' side: conserved
hypothetical protein
117 bp at 3' side: putative type I
site-specific deoxyribonuclease
putative PTS system, enzyme II,
A component
hypothetical phage protein

spyM18_2133

putative transposase

spyM18_0789

conserved hypothetical protein

spyM18_0486

spyM18_1974
IVI34a

161

intergenic

1640515 to
1640355

spyM18_1973
spyM18_1974

IVI34b

51

cryptic

IVI35

78

cryptic

IVI37

107

antisense

IVI38

89

intergenic

IVI41

203

cryptic

IVI43

49

antisense

IVI46

210

antisense

IVI48

310

antisense

IVI49

1029

promoter

IVI52

249

cryptic

IVI53

481

promoter

IVI55

54

antisense

IVI57a

185

antisense

IVI57b

83

antisense

IVI59

296

cryptic

IVI60

959

promoter

IVI62

163

cryptic

IVI65a

257

antisense

IVI65a

257

antisense

IVI65a

257

antisense

IVI65a

257

antisense

1714518 to
1714568
1464307 to
1464230
1781199 to
1781093
626749 to
626661
396484 to
396686

spyM18_2050

1871198 to
1871246
1835539 to
1835748
913289 to
913598
1893418 to
1894446
1448278 to
1448030
1027534 to
1027054

spyM18_2232

putative UDP-Nacetylglucosamine
pyrophosphorylase
hypothetical protein

spyM18_2185

conserved hypothetical protein

spyM18_1098

putative thiamine biosynthesis
lipoprotein precursor
putative chromosome segregation
protein
putative transcription regulator

971714 to
971767
146737 to
146921
841031 to
841113
1482683 to
1482388
182746 to
183704
1146888 to
1146726
21654 to
21398
27655 to
27399
84557 to
84301
262614 to
262358

spyM18_1163

putative amino acid ABC
transporter, periplasmic amino
acid-binding protein
hypothetical protein

spyM18_0155

hypothetical protein

spyM18_1014

extracellular hyaluronate lyase

spyM18_1793

hypothetical phage protein

spyM18_0197

hypothetical protein

spyM18_1373

putative internalin A precursor

spyM18_r02

rRNA-23S ribosomal RNA

spyM18_r04

rRNA-23S ribosomal RNA

spyM18_r06

rRNA-23S ribosomal RNA

spyM18_r08

rRNA-23S ribosomal RNA

spyM18_2257
spyM18_1741
spyM18_1223

177
IVI65a

257

antisense

IVI65a

257

cryptic

IVI65b

54

cryptic

IVI69a

193

antisense

IVI69b

51

cryptic

IVI70

203

cryptic

IVI72

600

promoter

IVI78

92

antisense

IVI81

145

cryptic

IVI82a

682

antisense

IVI82b

348

cryptic

IVI84

842

promoter

IVI87

1001

promoter

IVI91

210

cryptic

IVI92

151

antisense

IVI93a

325

cryptic

IVI93b

131

antisense

IVI94

237

antisense

IVI95a

132

antisense

IVI95b

78

intergenic

1344577 to
1344833
1634201 to
1634457
1603230 to
1603177
186190 to
185998
1611161 to
1611111
566923 to
567125
622769 to
623367
641030 to
640939
1248054 to
1247910
466442 to
467123
850043 to
850390
1669042 to
1668201
1587104 to
1588104
988364 to
988155
1500024 to
1500174
752667 to
752343
863452 to
863322
396966 to
396730

spyM18_r09

rRNA-23S ribosomal RNA

spyM18_r11

rRNA-23S ribosomal RNA

spyM18_1929

conserved hypothetical protein

spyM18_0204

glucose-6-phosphate isomerase

spyM18_1939

glycoprotein endopeptidase

spyM18_0707

cell-division protein

spyM18_0784

transcriptional regulator

spyM18_0802

hypothetical protein

spyM18_1515

hemolysin

spyM18_0583
spyM18_1022

DhaKLM operon coactivator
DhaQ
coproporphyrinogen III oxidase

spyM18_2004

hypothetical protein

spyM18_1912

pyruvate formate-lyase

spyM18_1179

sugar ABC transporter ATPbinding protein
acetyl-CoA carboxylase subunit
alpha
hypothetical protein

1139356 to
1139487
1391342 to
1391419

spyM18_1367

spyM18_1815
spyM18_0921
spyM18_1041
spyM18_0486

spyM18_1669

succinic semialdehyde
dehydrogenase
bifunctional Nacetylglucosamine-1-phosphate
uridyltransferase/glucosamine-1phosphate acetyltransferase
hypothetical protein

IVI97a

191

cryptic

571500 to
571689

spyM18_0710

IVI97b

115

antisense

spyM18_0282

IVI100

97

promoter

spyM18_0771

hypothetical protein

IVI101

111

antisense

spyM18_1656

hypothetical protein

IVI106

248

antisense

spyM18_0494

IVI112

107

antisense

252617 to
252503
612261 to
612357
1377561 to
1377671
401018 to
400771
591092 to

7 bp at 5' side: amino acid ABC
transporter permease
20 bp at 3' side: ATP-dependent
RNA helicase
bifunctional ATP-dependent
DNA helicase/DNA polymerase
III subunit epsilon
oligopeptide permease

metal binding protein of ABC
transporter (lipoprotein)
hypothetical protein

spyM18_1670

spyM18_0742

178
590986
IVI115

431

cryptic

IVI116

155

cryptic

IVI118a

724

antisense

IVI118b

252

antisense

IVI119a

198

antisense

IVI119b

183

cryptic

IVI125

103

antisense

IVI129

170

cryptic

IVI132

251

antisense

IVI135

288

cryptic

IVI138a

468

cryptic

IVI138b

295

antisense

IVI138c

103

antisense

IVI138d

84

cryptic

IVI140

327

antisense

IVI142

184

intergenic

1690774 to
1690344
1601101 to
1601255
6604 to
5881
1407068 to
1407319
1391644 to
1391841
1725606 to
1725788
1017508 to
1017610
1220056 to
1219887
416432 to
416182
1073881 to
1073594
1067947 to
1067480
1027614 to
1027908
441923 to
441821
1721939 to
1722022
968624 to
968950
562668 to
562851

spyM18_2030

prolyl-tRNA synthetase

spyM18_1926

hypothetical protein

spyM18_0007
spyM18_1692

transcription-repair coupling
factor
trans-acting positive regulator

spyM18_1670

ATP-dependent RNA helicase

spyM18_2064

mitogenic exotoxin Z

spyM18_1213

hypothetical protein

spyM18_1463

hypothetical protein

spyM18_0513
spyM18_1286

phosphate starvation-induced
protein
hypothetical protein

spyM18_1276

phage protein

spyM18_1224

amino acid ABC transporter
ATP-binding protein
dephospho-CoA kinase

spyM18_0556
spyM18_2057
spyM18_1160
spyM18_0703

spyM18_2110

2 bp at 5' side: conserved
hypothetical protein
510 bp at 3' side: conserved
hypothetical protein
glyceraldehyde-3-phosphate
dehydrogenase, plasmin receptor
putative acetyl-CoA carboxylase
alpha subunit
putative pyruvate formate-lyase 2

spyM18_0562

putative exoribonuclease R

spyM18_1429
spyM18_0544

putative D-Ala-D-Ala adding
enzyme
putative BlpM homologue

spyM18_0111

acetate kinase

spyM18_1893

putative divalent cation transport

spyM18_2256

putative serine protease

spyM18_0014

putative cell division protein

spyM18_0704
IVI143

168

cryptic

IVI146

77

antisense

IVI148

1016

antisense

IVI152

1029

antisense

IVI154

185

cryptic

IVI156

985

promoter

IVI157a

148

antisense

IVI157b

105

cryptic

IVI157c

65

antisense

IVI157d

35

cryptic

233754 to
233921
1500543 to
1500619
1760729 to
1761744
446733 to
445706
1196279 to
1196095
433733 to
434717
107943 to
107796
1571714 to
1571818
1893419 to
1893355
14043 to
14077

anthranilate synthase component
II
pyridoxamine kinase

spyM18_0261
spyM18_1815

179
IVI159

63

antisense

IVI163

88

antisense

IVI164

245

cryptic

IVI165

84

cryptic

IVI167a

327

cryptic

IVI167b

133

antisense

IVI167c

126

antisense

IVI173

91

cryptic

IVI176

42

promoter

IVI177

113

cryptic

IVI178

50

antisense

IVI181a

773

antisense

IVI181b

186

antisense

IVI185

309

antisense

1184631 to
1184693
332105 to
332192
367319 to
367563
13964 to
14047
1220838 to
1220512
1455118 to
1455250
616307 to
616182
484019 to
484109
344746 to
344787
1530798 to
1530686
1207032 to
1206983
983703 to
982931
677648 to
677463
1546690 to
1546998

spyM18_1416

putative competence protein

spyM18_0393

exotoxin type A precursor

spyM18_0446

putative ATP-dependent protease
proteolytic subunit
putative cell division protein

spyM18_0014
spyM18_1464
spyM18_1750

conserved hypothetical phage
protein
hypothetical phage protein

spyM18_0777

hypothetical phage protein

spyM18_0600

putative shikimate 5dehydrogenase
hypothetical protein

spyM18_0414
spyM18_1856
spyM18_1446
spyM18_1174
spyM18_0836
spyM18_1868

ABC transporter ATP-binding
protein
MF3
phosphopantothenoylcysteine
decarboxylase
ATP-dependent exonuclease
subunit A
hypothetical protein
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